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ABSTRACT 
Epigenetic transcriptional gene silencing plays a fundamental role in cancer development 
and has been considered as a target for cancer therapy in the last few years, mainly due to 
its reversibility by small molecules. Among the several methylated genes investigated, 
glutathione-S-transferase (GST) PI, a protein belonging to cellular detoxification systems, 
has been shown to be extensively promoter-methylated in prostate cancer. My study 
therefore describes a new therapeutic approach against prostate cancer, based on the 
combination of demethylating agents and brostallicin, a DNA minor groove binding drug, 
which is activated in the cell by binding to glutathione, a reaction catalyzed by GST. 
Among the demethylating molecules tested on the prostatic cancer cell line LNCaP in in 
vitro combinations with brostallicin, zebularine was able to increase brostallicin activity 
with little toxicity compared to the other tested demethylating drugs. 
These in vitro results prompted the in vivo testing of zebularine with brostallicin on LNCaP 
cells transplanted in mice. Prolonged treatment with zebularine was able to significantly 
improve brostallicin antitumour activity compared to both drugs administrated as single 
agents. When GSTPl expression was investigated in treated samples versus untreated 
controls, no protein re-expression was found and this was related to the unchanged levels 
of GSTPl promoter methylation. In contrast, the demethylating effect of zebularine was 
clearly evident in the promoter of GSTMl gene, which is also silenced by methylation in 
LNCaP cells. GSTMl codes for a class of GST enzymes that has recently been found to be 
more active on brostallicin than GSTPl. 
This indicates that the activation of brostallicin cytotoxicity in LNCaP cells by zebularine 
likely depends on enzymatic activation by GSTMl rather than GSTPl and strengthens the 
feasibility of this combination as a treatment for prostate cancer in the clinic, and as model 
for the therapy of other solid tumours. 
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1.1 THE EPIGENETIC CODE 
The primary sequence of the four nucleotides in DNA represents the first layer of the 
information stored in the nuclei of cells. These 2-3 billion bases of DNA, encoding about 
30000 genes, form, with the histone proteins, the nucleosomes. In these uniformly 
distributed units, a 146bp stretch of DNA is wrapped around a core particle of two 
heterodimers, H2A-H2B and H3-H4 (Khorasanizadeh, 2004). Transcription and translation 
are the means by which cells read the genetic instructions in the DNA sequence. These 
processes are strictly regulated through the binding of sequence-specific DNA binding 
proteins to regulatory promoters and enhancers. Recently, it has been discovered that non-
coding RNA molecules can recognize complementary sequences of DNA or RNA in order 
to transcriptionally inactivate them, before that other DNA modifications occur: in fact it 
seems that once RNAi binds DNA, this is set to stop transmission of genetic information. 
This is a common event in Saccharomices pombe and in Drosophila, but also in plants and 
mammals (Bird, 2002). 
Superimposed upon this "primary structure" is a layer of heritable modifications of the 
chromatin components that we have only just begun to analyse and appreciate. This 
epigenetic information is mainly stored as chemical modifications to cytosine bases and to 
the proteins that package the genome (Lande-Diner and Cedar, 2005; Berger, 2007). 
By regulating chromatin structure and DNA accessibility, these chemical changes 
influence how the genome is made manifest across the diverse array of developmental 
stages, tissue types and disease states. However one critical function of chromatin 
modifications is to distinguish euchromatin, where DNA is kept accessible for 
transcription, and heterochromatin, where chromatin is "inaccessible"; but unlike we 
thought few years ago, this is not "junk" DNA. 
Heterochromatin has a fundamental role in the maintenance of functional chromosome 
structure such as centromeres and telomeres, thus allowing the proper sister chromatid 
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cohesion and chromosome segregation; it also stabilizes repetitive DNA sequences by 
inhibiting recombination between homologous repeats. 
A DNA modification can be defined as "epigenetic" if it does not change DNA sequence 
and it is, at the same time, heritable through subsequent cell generations. The heritability is 
a fundamental aspect of epigenetics (besides its effects on gene expression), which allows 
us to not confuse it with transcriptional regulation, which are transient changes occurring 
during a cell life (Bird, 2002). 
Epigenetic modifications are not a common event In unicellular organisms, but they 
involve the animal genome in any particular cell type: this phenomenon depends on 
different mechanisms, working independently or together to ensure the maintenance of the 
transcriptionally competent chromatin or its proper structure through cell generations. In 
many species, these non-genetic alterations of the DNA sequence are represented by 
covalent modifications of histone proteins and by DNA methylation (Li, 2002). 
1.1.2 DNA methylation 
DNA methylation is a common event in eukaryotes, especially in mammals, but it does not 
occur in yeast or in C.elegans. 
In general, among the four DNA bases, C and A can be further modified by a post-
replicative chemical addition of a methyl group, by specific DNA methyltransferases 
(DNMTs), which use S-adenosylmethionine as the methyl group donor. 
~-methyladenine is usually found in plants, and it is a very specific DNA modification in 
their mitocondrion genome, where there is no cytosine methylation. 
Up to now we have no strong insights about the role of adenine methylation in higher 
eukaryotes. Certainly, plants are characterized by a more differentiated set of DNA 
methyltransferases, and this could justify the experimental data showing that knock out of 
the plant enzyme homologous to animal dnmt 1 is not lethal for plants. 
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In bacteria, methylation has both a regulatory and a protective role; in fact, restriction-
modification systems contain a DNA methylase that protects self DNA sequences from 
digestion with its cognate restriction endonuclease which, conversely, digest unmodified 
foreign DNA, such as viral DNA (Vanyushin, 2005). 
eytosines targeted to be methylated by DNMTs belong to a CG dinucleotide. This 
dinucleotide is generally underrepresented in the genome, because mC can be a mutagenic 
modification, due to the spontaneous oxidative deamination of me to T. In fact, the human 
genome shows the strongest suppression of CpG. thus resulting to be the most infrequent 
dinucleotide in the genome. Methylation occurs globally in the genome, bu not in CpG 
"islands" (Bernstein et aI., 2007), which are DNA regions of >500bp, having a high CpG 
density (CpG observed/CpG expected ratio >0.6) (Gardiner-Garden and Frommer, 1987; 
Takai and Jones, 2002), usually localized upstream of about half of mammalian genes. 
Those CpG dinucleotides residing outside the CpG islands are usually localized within 
repetitive elements, where they are heavily methylated in somatic tissues. 
Methylation was already known for its role in setting up the chromatin structure m 
imprinted regions or the X chromosome (Jaenisch and Bird, 2003). 
The first insights linking methylation and gene silencing come from analysis of 
pericentromeric heterochromatin. Transcriptionally competent regions of DNA, which 
constitute the euchromatin of the genome, show a more variegated picture as regard 
methylation: that's why they must ensure that the proper level of gene expression can be 
stably maintained in the daughter cells in a heritable way. 
Promoters can be differentiated regarding their CpG content: those containing CpG islands 
(about 50%) usually are methylation free and the nucleosomes are associated with highly 
acetylated histones. 
In these promoters, methylation does not normally participate in regulating the 
transcription of downstream genes. whether such genes are being actively transcribed or 
not. However it is necessary to emphasize that methylation is not a transcriptional 
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regulatory mechanism, and these promoters are kept free of methylation, irrespective of 
gene expression levels; this usually depends on the associations of "negative" or "positive" 
factors. 
The role of DNA methylation in CpG-poor promoters is not clear; so it is not known for 
how many of them CpG methylation might have a modulator role in their transcription. 
Some studies show that individual CpG sites in such promoters can determine the 
transcriptional status of a gene by blocking the access of certain transcription factors that 
are sensitive to the methylation of CpG in their sequence. Alternatively, the methylation of 
sites in these regions might also silence genes by helping to recruit protein complexes that 
repress transcription (Jones and Baylin, 2002). 
In both cases described above, we cannot forget that mechanisms involving histone 
modification are as important as DNA methylation in setting up the proper conformation of 
chromatin (Berger, 2007; Kouzarides, 2007). 
In proliferating primordial germ cells there is a general erasure of methylation, also 
involving the parental imprinted regions and the X chromosome in females. Once the 
parental imprints have been erased, new imprints must be re-established according to the 
gender. This re-establishment occurs only after gender-determination has been initiated 
and male and female germ cell development diverges to give rise to sperm or oocytes, 
respectively (Sasaki and Matsui, 2008). Methylation time is different in males and in 
females, because it occurs before meiosis in males, in prenatal prospermatogonia (diploid 
stage), whereas methylation is acquired postmeiotically in the female germ line, in 
particular in growing oocytes that are arrested at the diplotene stage of meiosis 1. The early 
methylation trigger in males accounts for deeper effects that this modification has on the 
entire male genome. In fact, because cytosine methylation results in an increased C-+ T 
mutation rate (Momparler and Bovenzi, 2000) and spermatogonia maintain methylation 
patterns for a large and variable number of mitotic divisions before entering into meiosis, 
the mutational pressure has led to a low density of CpG dinucleotides in paternally 
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methylated differentially methylated regions (DMRs) relative to maternal DMRs. Errors in 
the establishment or maintenance of germ cell methylation patterns can cause human 
diseases (Schaefer et al., 2007). 
Moreover, DNA methylation patterns are physiologically set during the first steps of 
development, when they are erased in the morula and established de novo during 
implantation. Target sequences for de novo methylation are transposons, clustered repeats 
(primarly, pericentric satellite DNA) and, to a lesser extent, single-copy gene sequences 
(Reik,2007). 
Single copy genes and their promoters are usually protected from methylation, but they can 
become aberrantly modified in the developing early stages of human cancers, thus causing 
the silencing of genes, such as tumour suppressor. 
That all chromatin is not compacted into a "closed" form (an event only occurring in the 
mammalian female X chromosome) and that euchromatin and transcriptional active 
regions are not involved in silencing, is related to the presence of some specialized DNA 
elements known as boundary elements, which apparently serve as barriers against the 
propagation of the inactive form of chromatin (Grewal and Moazed, 2003). 
In summary, methylation patterns are set in two different periods in the mammal cells: 
germ cell development and early embryogenesis, in both cases after its erasure in the total 
genome (Li, 2002). This ensures that transcriptionally silenced regions can be stabilized 
and transmitted to the next generations. Thus, from a physiological point of view, 
methylation seems not to be a simple regulatory mechanism of the genome, but rather a 
system of cellular memory, which propagates the silent state. 
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1.1.3 DNA methyltrans/erases and Methyl Binding Proteins 
DNA methylation is mediated by the enzymatic activity of a family of proteins, named 
DNA methyltransferases (DNMTs). At the moment, DNMTs from 1 to 3b have been 
described (Goll and Bestor, 2005). 
Typically, DNMTl is responsible to complete DNA methylation during replication, when 
the new synthesized "daughter" DNA strand needs to be methylated using the parent strand 
as template. In this way, methylation is maintained through subsequent generations. This 
role justifies the name of "maintenance" methyltransferase for DNMTl; it exerts its 
function during the S phase of the cell cycle and, for this reason, it moves from a diffuse 
nucleoplasmic distribution to sites of DNA synthesis (replication foci). DNMTI ensures 
that methylation of both DNA strands is maintained during replication by a semi-
conservative mechanism. DNMTl expresses at least two splice variants, named DNMTo 
and DNMTp: DNMTo is specific to oocytes and to preimplantation embryos, while 
DNMTp has been found in pachytene spermatocytes (Robertson, 2002). 
DNMT2 does not show any methyl-transfer activity, even though it is the most highly 
conserved among all DNMTs across species; in fact DNMT2 homologues have been found 
in plants, yeast, flies, mice and humans (Dong et aI., 2001). Human DNMT2 protein is 
primarly localized to the cytoplasm, in contrast to the exclusively nuclear localization of 
DNMTl and DNMT3. This is because the DNMT2 target is a C in the anticodon loop of 
tRNA Asp, which is strictly conserved in all genomes encoding DNMT2. The exact role of 
this modification is still unknown (Goll et aI., 2006). 
DNMT3s are generally referred as de novo methyltransferases, because they are 
responsible for initiating the methylation pattern in the genome, both at the genn cell level 
and in the embryo. Different enzymes belong to this family. De novo methylation is 
established by DNMT3aJb enzymes, which generally reside in pericentromeric 
heterochromatin (Weisenberger et al., 2004). 
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DNMT3a activity is not strictly associated with a specific phase of the cell cycle and can 
be found at discrete nuclear foci throughout the cell cycle; it is required in male germ cells 
for the establishment of methylation imprints at DMRs and to ensure the proper 
methylation pattern on trasposons and pericentric repeats. 
DNMT3b appears to be specialized for the establishment andlor maintenance of DNA 
methylation of the minor satellite repeats (satellites 2 and 3 on human chromosomes 1, 9 
and 16). It has several isoforms, resulting from alternative splicing, and their expression is 
tissue-specific; among them, DNMT3b4 and DNMT3b5 are expressed predominantly in 
the testis (Robertson, 2002). 
DNMT3L is unique, because it regulates the DNMT3A and 3B function in their 
establishing methylation in prospermatogonia (Li, 2002; Sasaki and Matsui, 2008). 
Further insights into DNMTs functions come from experiments involving KO mice (Goll 
and Bestor, 2005; Robertson, 2002). Thus the Dnmtl-/- genotype is lethal and knock out 
embryos failed to develop beyond mid-gestation. KO fibroblasts are characterized by a 
severe demethylation, also affecting imprinted regions. ES cells lacking Dnmtl grow 
normally in the undifferentiated state, but die by apoptosis when induced to differentiate in 
vitro and in vivo. 
The fact that Dnmt2 is not involved in maintenance or in setting methylation is underlined 
by the normal phenotype of Dnmt2-/- murine ES cells, thus suggesting that this enzyme is 
required for neither maintenance nor de novo methylation. 
The Dnmt3a-/- mouse phenotype appears to be normal at birth, but by 4 weeks of age, all 
the mice die. In contrast, Dnmt3b -1- mice die at birth. Dnmt3a and 3b -/- ES cells exhibit 
comparable degrees of demethylation, although for Dnmt3b-/- cells, a decrease in 
methylation level at minor satellite repeats in the pericentromeric region has been reported. 
The double Dnmt3a-/-Dnmt3b -/- genotype is lethal for mouse embryos and ES double 
mutant cells show a dramatic reduction of the global level of methylation compared to the 
single Dnmt3 KO. 
19 
DNMTs are able to bind many proteins with different functions: among them, histone 
deacetylases (HDAC) and methyl binding proteins (MBDs) are also involved in epigenetic 
modifications. 
MBD proteins read the methylation "language"on DNA, because they specifically bind the 
methylated CpGs. A family of five methyl-CpG-binding proteins has been characterized, 
and each of them contains a region closely related to the methyl-CpG-binding domain 
(MBD) of MeCP2 protein, the founding member of this family, whose important role in 
maintaining gene silencing through the binding to mC is underlined by a severe 
neurological disease, the Rett syndrome, which specifically depends on MeCP2 gene 
mutations. In addition to MeCP2, MBD I, MBD2 and MBD3 have been implicated in 
methylation-dependent repression of transcription. MBP I seems to exert its function 
during S phase of the cell cycle and it is also able to interact with the histone3lysine9 
(H3K9) methyltransferase enzyme, SETDB 1, so coupling recognition of DNA methylation 
to modification of the surrounding chromatin by histone methylation (Klose and Bird, 
2006). 
1.1.4 Histone Code 
There is cross-talk between signals modifying DNA and those modifying histones, and the 
result is the transcriptional state of the genome. While DNA methylation has a repressive 
meaning for transcription, histone proteins can be modified in a more variegated way, both 
for the kinds of modifications and for their consequences, i.e. activating or repressive. All 
modifications occurring on the histones set up the so-called "histone code" (Kouzarides, 
2007). 
Chemical modifications targeting histones occur especially at N-terminal unstructured 
tails, which extend out from the globular regions, that are associated with DNA in 
nucleosomes (Berger, 2007). This regulatory mechanism is strongly conserved, because is 
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common to very different eukaryotes, from Drosophila to yeast and mammals 
(Khorasanizadeh,2004). 
The covalent modifications that take place on histones include the acetylation, 
ubiquitination and sumolation of lysines, mono-, di-, tri-methylation of lysines and 
arginines, the phosphorylation of serines and threonines, and the ADP-ribosylation of 
glutamic acids. All of these modifications, except for methylation, appear to be reversible. 
There has been much effort in the last few years to identify the enzymes responsible for 
these modifications. At the moment better characterized are the methyltransferases and 
kinases, which are also targeted by many signalling pathways. These modifications is 
affect the contacts between different histones in adjacent nucleosomes or the interaction of 
histones with DNA, generally by the alteration in the histone charge, which in turn has 
structural consequences for the chromatin architecture. For example, acetylation has the 
strongest potential to unfold chromatin, since it neutralizes the basic positive charges of the 
lysines, and hence the ionic bond to the negatively charged phosphate groups in DNA. 
Many different kinds of modifications occur on lysine residues and these need a strong 
regulation of the enzymes involved in setting them. Generally, heterochromatic domains 
are associated with low levels of histone lysine acetylation and high levels of certain lysine 
methylation sites, typically H3K9, H3K27, H4K20, while euchromatin has high levels of 
acetylation and is trimethylated at H3K4, H3K36 and H3K79. 
The functional consequences of histone post-translational modifications (PTMs) can be 
direct, causing structural changes to chromatin, or indirect, acting through the recruitment 
of effector proteins. For example, H3K4met recruits protein complexes containing 
bromodomains, which are responsible for acetylation; moreover H3K4met effects could 
also depend on different external circumstances (for example, physiological or damaged 
state) or on a different step (active transcription or a silenced state) of the cell cycle Surely, 
different meanings associated to the same modification could be more flexible than only a 
kind of information during activities occurring at dynamic transcribed regions. 
21 
It is important to note that many kinds of modifications could not be simply classified as 
activating or repressing, but they have the potential to activate or repress gene expression 
under different conditions. 
It is matter of debate whether histone modifications are epigenetic or not, because many of 
them are removable; undoubtedly they have been implicated in a number of epigenetic 
phenomena. I have already pointed out that a chemical modification of chromatin is 
epigenetic only if heritable through subsequent generations: at the moment such a 
mechanism has been proposed only for H3K9 in the transmission of the heterochromatin 
(Khorasanizadeh,2004). 
Together DNA methylation and histone modifications represent a second layer of the 
information carried by the genome, which is not encoded by the nucleotide sequence. 
1.1.5 Nucleosome Remodeling 
ATP-dependent chromatin remodelling complexes, called SWIISNF2 represent an upper 
level of chromatin modifications: they operate at the nucleosome level by using the energy 
of ATP-hydrolysis to introduce superhelical torsion into nucleosomal DNA with the main 
consequence to expose DNA bulges or loops, which modify the accessibility of chromatin 
to different proteins controlling transcription, DNA replication, recombination and other 
biological processes. The fundamental role of this function is underlined by the fact that 
ATPase is the most conserved subunit, among numerous others, which at the moment are 
not well characterized (Li, 2002). 
The chromatin remodelling complexes are involved in at least three types of activities: 
octamer sliding, DNA looping and histone substitution, in general occurring when, 
following replication, the bulk of new synthesized histones needs to be deposited on the 
nucleosome. 
To conclude, epigenetic modifications set up a pattern of different level of expression in 
specific cellular phenomena, including tissue-specific gene expression, cell differentiation, 
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genome imprinting, X chromosome inactivation, regulation of chromatin structure, aging~ 
their deregulation are involved in many diseases, above all cancer (Jaenisch and Bird, 
2003). 
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1.2 EPIGENETICS AND HUMAN DISEASES 
In the last decade much effort has been focused on understanding the heritable causes of 
human diseases besides genetic mutations or chromosomal aberrations. 
The potential disease detenninant of epigenetics depends on its heritability during cell 
division in a given cell lineage; another important factor characterizing epigenetic 
regulatory patterns is its "sensitivity" to environmental factors, acting over time (Bjornsson 
et aI., 2004; Feinberg, 2007). As a consequence, epigenetic modifications of DNA have to 
be heritable and stable through cell generations, but flexible enough to undergo changes 
when necessary, mainly during cellular differentiation and in response to modified 
environmental stimuli. 
It is questionable whether the concept of heritability could be applied only to subsequent 
cell generations in only an organism or also to transmission of characters from parents to 
the offspring, because, as I mentioned in the previous part of this introduction, during early 
embryogenesis, there is an extensive erasure of the parental pattern of genome methylation, 
except for imprinted regions. 
1.2.1 Imprinting disorders 
Imprinting disorders derive from specific defects involving those chromosome regions 
differentially expressed between paternal and maternal alleles. The control of gene 
expression within imprinted domains is exerted by imprinting control regions (lCR), often 
acting over large distances: differential methylation in ICRs is generally established in 
genn cells and maintained throughout development. Loss of imprinting (LOI) is the 
disruption of imprinted epigenetic marks through gain or loss of DNA methylation, or 
simply the loss of nonnal allele-specific gene expression. 
The aberrant imprinted loci, identified up to now, are located on chromosomes 11 15 20 , , 
and are responsible for many different disorders. 
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The Beckwith-Wiedemann syndrome (BWS) comprises deregulation on two neighbouring 
subdomains on Ilp15: one is H19/l0F2 (imprinted, maternally expressed, untranslated 
mRNAI insulin-like growth factor (IOF) 2), which is regulated by a differentially 
methylated region (DMR), methylated on the paternal, but not on the maternal allele. Some 
BWS patients show loss of imprinting of IOF2, which leads to a double dose of this 
autocrine factor, resulting in tissue overgrowth and in an increased cancer risk. The other 
subdomain is regulated by another DMR, which is methylated on the maternal but not on 
the paternal allele; among the genes in this deregulated region is p57kip2, a cyclin-
dependent kinase inhibitor. 
The Prader-Willi Syndrome (PWS) and Angelman Syndrome (AS) affect the same 
imprinted locus at 15qll-q13 that contains both paternally and maternally expressed genes. 
While PWS arises from loss of the paternally expressed genes, the loss of maternally 
expressed genes determines AS. 
Another pair of human disorders caused by opposite alterations at the same locus is 
Albright hereditary osteodystrophy (AHO) and pseUdohypoparathyroidism (PHPIA). 
These diseases are related, because both arise from the deregulation of the same imprinted 
locus on chromosome 20q13, called ONAS, which encodes the a subunit (Osa) of the 
heterotrimeric OTP-binding protein Os. The two disorders are differentially inherited: 
while AHO is paternally transmitted, PHPla shows a maternal transmission. Both diseases 
display mental retardation and subcutaneous ossification, but PHA 1 A patients also show 
resistance to the peripheral action of several hormones involved in activating pathways 
coupled to Os. 
It is important to note that the bulk of CpO dinucleotides, outside the CpO islands, resides 
in the intergenic and intronic regions of DNA, particularly within repeat sequences and 
transposable elements: these cytosines carry a strong methylation (about 70-90% of CpO 
dinucleotides are methylated), which ensures the proper structure to heterochromatin and 
silencing of repeat sequences and transposable elements. Chromosome instability could 
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result from expansion of trinucleotide repeats during gametogenesis. Depending on the 
nucleotide sequence in the repeats, these triplets can be methylable, as in the case of CGG 
repeats, or not: in the first case, an increased level of methylation results in an aberrant 
silencing and leads, among the other possible diseases, to the Fragile X Syndrome 
(FRAXA). This X-linked disorder causes mental retardation in about 1 in 4000 males. It is 
characterized by an extensive increase of the CGG repeats (from 6-52 copies in a normal 
situation to more than 200 copies in the pathological status) within the 5' -untranslated 
region of FMRl gene which encodes an RNA-binding protein expressed in many foetal 
and adult tissues. In contrast to hypermethylation due to increased numbers of CGG 
triplets, other epigenetic disorders come from the contraction of repeats, thus causing 
hypomethylation: An example is represented by the Facioscapulo-humeral muscular 
dystrophy, with the loss of copies of the polymorphic 3.3kb D4Z4 repeats (Robertson, 
2005). 
In summary, diseases could depend either on DNA hypermethylation, which leads to an 
aberrant silencing, or hypomethylation, which could make the affected loci more fragile 
and unstable or allow an aberrant overexpression of specific genes. 
Other disorders arise from defects in the molecular machinery regulating the setting or the 
control of methylation. For example, in systemic lupus erythematosus (SLE), reduced 
levels of DNMTl result in a global hypomethylation of T cell genomes (Richardson, 
2003). Similarly, a heterozygous mutation in the DNMT3b gene is associated with the 
decondensation of pericentromeric heterochromatin on chromosomes 1 and 16 in ICF 
(Immudeficiency, Centromeric region instability and Facial anomalies) patients. 
However, in addition to intrinsic cell factors whose defects lead to a deregulated 
overall/gene-specific methylation, extrinsic factors, such as environmental toxins like 
heavy metals, can disrupt cellular DNA methylation patterns in the cells (Hatchwell and 
Greally, 2007; Feinberg, 2007). 
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Recently great interest has been generated by the consequences of assisted reproductive 
technologies (ART) on the epigenetic programming of the embryo; in fact it has been 
demonstrated that children born through ART have an increased frequency of developing 
BWS and AS (Wilson et aI., 2007; Robertson, 2005). 
1.2.2 Epigenetics and Cancer 
The first sign of an epigenetic origin of neoplasia derived from abnormalities in gene 
imprinting found in cancer. In particular a double dose of the IGF2 growth factor has been 
found in apparently normal colonic epithelium of patients with colorectal cancer and this 
appears to result from loss of imprinting of the region regulating IGF2 expression. The 
relationship between double doses of IGF2 and cancer risk was further supported by data 
from mice engineered for Igf2 biallelic expression, which show a higher proportion of 
undifferentiated cells (Feinberg and Tycko, 2004). 
Gene silencing by methylation fits well with Knudson's two hit model (Knudson, 2000): 
when one of two alleles is mutated in the germ line of a patient with a familial form of 
cancer, and the resultant tumour retains both alleles of the gene, hypermethylation is 
commonly seen as the second inactivating change (Herman and Baylin, 2003). 
While the earlier efforts in cancer epigenetics were focused on understanding the 
involvement of changes in DNA methylation with respect to both aberrant 
hypermethylation of epG in gene promoters and hypomethylation, it is now clear that 
abnormalities comprising a multitude of aberrations in virtually every component of 
chromatin can be involved in carcinogenesis. The mechanism of epigenetic heredity seems 
to share the same characteristics with genetic alterations, mainly because they are 
transmitted faithfully during mitosis, thus undergoing the same selective process in the 
development of cancer and collaborating together in its evolution. Nevertheless, epigenetic 
events can potentially occur at an increased rate compared to mutations in somatic cells. 
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DNA methylation patterns are profoundly modified in tumours. Not only are there 
increased levels of methylation in the promoters of genes involved in carcinogenesis, but it 
is now emerging that alterations are genome-wide. Also we have to think of a general 
change in 5-methylcytosine distribution rather than an overall increase in the total amount 
of methylation (Jones and Baylin, 2007). 
However there is an emerging idea that some tumours can be characterized by the 
concordant methylation of a specific set of genes, arising from the so-called "CpG island 
methylator phenotype" (CIMP) (lssa, 2004). 
The first epigenetic abnonnality discovered in tumours was hypomethylation, occurring 
both in heterochromatin and euchromatin. In the latter case, the main consequence is the 
activation of genes conferring a growth advantage to tumours. For example, 
hypomethylation of the MDRl promoter was linked to its overexpression and acquirement 
of multi drug resistance in acute myelogenous leukaemia. Alternatively, ifhypomethylation 
occurs at pericentromeric satellite sequences, it might predispose to their breakage, 
aberrant recombination and, in general, to genomic instability (Gaudet et aI., 2003), that is 
a hallmark of cancer (Hanahan and Weinberg, 2000). 
Although hypomethylation was the first epigenetic modification discovered, researchers' 
attention was initially concentrated on hypennethylation of CpG islands in the promoter 
region of genes involved in cancer development. The list of genes that are inactivated by 
hypermethylation is becoming more and more extensive and involves genes belonging to 
different pathways and responsible for the onset of different kind of tumours. 
Like for genetic changes, researchers analyzed the timing of epigenetic changes and it was 
concluded that these play a seminal role in the earliest steps of cancer initiation and the so 
called "epigenetic gatekeepers" were identified. For example, the tumour suppressor p16 is 
one of the most common and earliest epigenetically mediated losses in human cancer. Its 
silencing occurs in a subset of preinvasive stages of breast, colon, lung and other cancers. 
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Undoubtedly, whatever is the modification, i.e. genetic or epigenetic, it must push the early 
aberrant clonal expansion of cells (Feinberg et al., 2006). 
If both genetic and epigenetic modifications can result in aberrant gene function, thus 
allowing the survival and clonal expansion of transformed cells, how do they differ? The 
first answer could be that gene mutations in a single tumour are seldom multiple in a given 
pathway, since selection for one hit appears sufficient to produce full pathway disruption, 
while multiple epigenetic events may frequently affect a single-cell pathway. If these 
events occur in a cancer stem cell, together with the deregulation of the polycomb complex 
of protein (PcG) system and histone modifications, they provide an advantage for cell 
growth and hence tumour expansion. There is not always a direct cause and effect role in 
gene silencing, but it is becoming clear that whole groups of genes may be inactivated as a 
part of an abnormal program (Jones and Baylin, 2007). 
There is an emerging relationship between the already known mutations, including 
chromosomal aberrations that occurr in tumours, and epigenetic modifications, above all 
because studies performed until now have highlighted that the latter are not sporadic 
events, but alterations affecting more or less each pathway associated with tumour 
initiation and progression in every kind of tumour. By this mechanism of silencing, the 
expression of tumour suppressor genes in the cells can be reduced or eliminated and it 
constitutes an alternative mechanism for transformation to gene mutations. This might 
imply that genes that are inactivated by mutations are not, at the same time, the target for 
methylation. However aberrant epigenetic modification can progressively affect gene 
expression as result of the prolonged exposure to dangerous molecules, such as 
carcinogens, or of a particular diet (for example, dietary supplements with folate or 
vitamins can exert marked effects on the incidence of colon cancer) (Jaenisch and Bird, 
2003). 
Genome wide methylation analysis allowed researchers to identify genes that are silenced 
in different stages of tumour progression or in a specific kind of tumour, thus giving a 
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biomarker for tumour type, or for risk assessment or indicators of susceptibility or response 
to therapy. But researchers' interest has also been focused on the assessment of the role of 
epigenetics in malignant transformation. In fact, the idea of a seminal role of epigenetics in 
acquiring an aberrant phenotype, which is then followed by genetic changes and clonal 
expansion, has begun to be generally accepted (Feinberg et aI., 2006). 
Our view of cancer progression is often anchored to the sequential genetic changes 
described by Vogelstein (Kinzler and Vogelstein, 1996) for colorectal tumourigenesis and 
characterized by a continued clonal selection that gives rise to tumour proliferation, 
invasion, metastasis and drug resistance. In this model of cancer onset, epigenetic changes 
are viewed as surrogate alterations for genetic changes, by simply mimicking their effects 
on gene expression. 
From the epigenetic point of view, the tumour genome is characterized by an extensive and 
general hypomethylation and by the hypermethylation of gene promoters (mainly tumour 
suppressors), which can be tumour-specific (Clark and Melki, 2002). The former arises 
first and is strongly linked to chromosomal instability and loss of imprinting, while the 
latter is restricted to promoters. 
Increasing numbers of genes are normally found to be methylated at promoters, but 
hypomethylated and activated in the corresponding tumours, as in the case of melanoma 
antigen family A, 1 (MAGE1) in melanoma (Ohman and Nordqvist, 2001). 
In the last few years, studies on epigenetic alterations have highlighted that they are very 
early events in tumour aetiology initially affecting pre-cancerous tissues. So it has been 
proposed that the first step in cancer development could involve the epigenetic disruption 
of stem/progenitor cells, which might perturb the normal balance between undifferentiated 
progenitor cells and differentiated committed cells within a given compartment. 
Epigenetic deregulation affects the tumour progenitor genes, which regulate "sternness" 
itself, mainly its pluripotency and unlimited self-renewal and define the balance towards 
stem cell renewal and proliferation over normal differentiation within a given tissue. The 
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disruption of tumour-progenitor genes could be a consequence of the microenvironment, 
and this influence is a mark of the plasticity of the "epigenetics" on DNA. 
The first modifications does not alter the normal phenotype of the cells in which they 
occur; the tumour transformation depends on a second hit, generally an initiating mutation 
(but also an epigenetic activation of an oncogene or silencing of a tumour suppressor) 
within the subpopulation of epigenetically disrupted progenitor cells: this mutation is 
specific for the tumour type. 
The transformation process itself comes to an end when cells become able to evolve their 
transformed phenotype, through further genetic or epigenetic events, such as telomere 
erosion, chromosomal rearrangements etc. 
The epigenetic progenitor model of cancer mainly explains phenomena such as 
environmental influence and the common occurrence of late metastatic disease. It also 
strongly supports the use of epigenetic therapies, which exploit the reversibility of 
epigenetic modifications. 
Examples of early epigenetic modifications include the loss of p 16 expression in pre-
invasive lung and breast tumours or GSTPl in the first stages of prostate cancer. These 
early epigenetic alterations predispose cells to the genetic abnormalities that advance the 
neoplastic process, but they also act over the entire period of tumourigenesis. 
Colon cancer offers a model for tumour progression by epigenetic mechanisms and to 
understand how both genetic changes and epigenetic gene silencing combine to determine 
the phenotype of a tumour cell. It has been demonstrated that both alleles of the same gene 
can be silenced by these two different mechanisms, but that they do not ever occur 
simultaneously on the same allele (Baylin and Ohm, 2006). The deregulation of Wnt 
pathway (and its antagonist SFRPs) is one of the mechanisms characterizing the 
progression from normal epithelial cells to invasive cancer; epigenetic silencing of SFRPs 
determines a constitutive expression of Wnt, which, in turn, inactivates the well known 
tumour suppressor adenomatosis polyposis coli (APC) in colon tissues. 
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Wnt constitutive activation characterizes the early stages, pre-invasive colon lesions, even 
before the appearance of mutations in the pathway. The fundamental role of SFRPs in 
detennining clonal expansion is demonstrated by experimental data in which deletions of 
genes that encode DNMTs lead to SFRP promoter demethylation and expression. This 
results in the downregulation of Wnt signalling and induction of apoptosis, despite the 
presence of mutations in downstream genes of the pathway (Baylin and Ohm, 2006). 
However, the analysis of colorectal cancer has allowed not only the sequence of epigenetic 
and genetic modifications in carcinogenesis to be defined, but also to appreciate the 
mechanistic differences between them, using a genome wide approach. Results published 
by Frigola et al. (Frigola et aI., 2006) demonstrated for the first time that epigenetic gene 
silencing in cancer can encompass a large chromosomal region, and not only a specific 
CpG island. In fact, samples from patients and colon cancer cell lines (namely HCT 116 
and SW 48) demonstrate a contiguous hypennethylation of an entire 4Mb band of 
chromosome 2q.14.2, containing both regions corresponding to CpG island criteria (as 
defined by Gardiner and Frommer, 1987) and regions which do not meet the standard 
definition of a CpG islands. All genes in this region show a significant re-expression after 
treatment with the demethylating agent 5-aza-deoxycytidine (5-aza-dC) and the 
de acetylase inhibitor tricostatin A (TSA), whether or not they have a CpG island in the 
promoter. 
Long range epigenetic silencing (LRES) through methylation seems to be specific for 
cancer cells; in nonnal cells, X inactivation and imprinting, which also involve a long 
range silencing, mainly depend on non coding RNA or microRNA transcripts (Baylin and 
Ohm,2006). 
Another example of the relationship between epigenetic and genetic gatekeeper steps in 
cancer progression comes from the Hypennethylated In Cancer (HIC1) and p53 genes. 
HICl is a target of the active pS3 and becomes hypennethylated in cancer from early, pre-
invasive stage breast and colon tumours. Hicl +/- Trp53+/- mice develop osteosarcomas, 
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breast and ovarian tumours and show deletion of the wild type allele of Trp53. During the 
early stages of tumour progression, loss of Hie 1 expression through methylation results in 
partial loss of pS3 function. Cells that acquire more powerful inactivating mutations in pS3 
are selected for and contribute to rapid tumour growth and progression (Baylin and Ohm, 
2006). 
I have generally referred to epigenetic modifications without offering more insights in the 
kind of modifications that affect the early stages of tumour development. Firstly it seems 
that histone methylation, mainly H3K9, occurs during the initial phases of gene silencing 
in cancer and that DNA methylation later spreads over the promoter to "lock in" the 
transcriptional activity. Actually we know more about the maintenance than the initiation 
of tumour-suppressor gene methylation (Bachman et aI., 2003; Espada et aI., 2004). 
The fact that epigenetic modifications occur in the early stages of tumour development 
undoubtedly represents a real potential for drug targeting, as silenced genes can be induced 
to express again. 
I have previously described the molecular machinery supporting the epigenetic 
modification of chromatin. It is also important to understand if there is a deregulation of 
this machinery during cancer initiation and progression. Undoubtedly the picture is quite 
complicated: cancer is characterized by both hypomethylation and hypermethylation of the 
genome even though, in recent years, many studies have mainly focused on 
hypermethylation analysis of the promoters of cancer-related genes. However alterations in 
DNMTs activity and its role in the modification of methylation pattern in cancer are not 
well understood. Elevated levels and activities of DNMT proteins occur in various cancer 
types, including gastric, bladder, leukaemia, colon and lung. However the clearly distinct 
roles of maintenance methylation for DNMTl and de novo methylation for DNMT3a and 
3b do not seem to be strictly respected in cancer. In fact, both genetic depletion and RNA 
interference against DNMTl in human colon and other cancer cells resulted only in lower 
decrease in overall DNA methylation (Ting et aI., 2004), minimal loss of promoter 
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hypermethylation and undetectable re-expression of silenced tumour suppressor genes. But 
these data are not supported by other studies performed on different cancer models, so the 
conclusion could be that the threshold requirements for DNMTl differ in different cancers 
(Robert et aI., 2003~ Ting et aI., 2006). No significant changes were also detected in 
DNMT3b -/- clones, which contain about 97% of wild type genomic 5-methylcytosine 
content. 
Instead extensive demethylation was observed in double knock out (KO) cells for DNMTl 
and DNMT3b (corresponding to a roughly 95% reduction in mC content): the lack of these 
two enzymes affects the methylation level of each kind of "methylatable" target: satellite2 
sequences, Alu repeats, but also single copy genes and the imprinted gene Insulin Growth 
Factor (IGF) 2. In particular, single copy genes have an expression level comparable to the 
one we can obtain with 5-aza-dC treatment (see later). 
The complete erasure of methylation in the double KOs compared to the weak decrease in 
the single DNMT KO supports the idea that DNMTl and DNMT3b cooperatively maintain 
all methylation in the HTl16 cell line, both at repeat sequences and at single copy genes. 
The resulting idea is that there is, at least in part, a functional redundancy among the 
enzymes responsible for genome methylation and that we cannot clearly distinguish a 
maintenance DNMT from de novo DNMT (Rhee et aI., 2002; Leu et aI., 2003). 
There is little doubt that the complete re-expression of tumour suppressor genes in double 
KO cells clearly demonstrates that methylation is a silencing mechanism involved in 
tumourigenesis. 
It is well established that tumours have a decreased level of the global 5-methy1cytosine 
level, about 20-60% less than their normal counterpart, that mainly affects the body of the 
genes involved (the coding regions and introns) and the repetitive DNA sequences, which 
account for 20-30% of the human genome. The mechanism responsible for genome 
hypomethylation in cancer is unclear. Several possibilities have been proposed, including 
insufficient dietary folate or genetic lesions in the folate metabolic pathway, since the liver 
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of rats, fed with folate deficient diets, exhibits genome hypomethylation and also increased 
DNA strand breaks and typically develops cancer. 
In addition, it is also possible that hypomethylation is a result of the deregulation of the 
putative demethylase enzymes or conversely due to dysfunctions of the DNA 
methyltransferases enzymes. 
In contrast to the global hypomethylation, gene promoters containing the so-called CpG 
islands can be hypennethylated and this modification is correlated with transcriptional 
silencing. Although the most significant proportion of any CpG islands is located in the 
5'untranslated region and the first exons of the genes, certain CpG islands can be 
occasionally be found within the body of the gene, or even in the 3 'region: CpG islands in 
these atypical locations are more prone to methylation. Exceptionally, certain small genes 
can be considered in their totality as a whole CpG island. 
CpG islands (not all, but those ensuring an advantage to tumour progression) will become 
progressively hypennethylated and this process could be age-related or influenced by 
environmental stimuli. As I have previously described, DNA methylation occurs by 
covalent addition of a methyl-group at the carbon 5 of the cytosine ring, resulting in 5-
methylcytosine; but the methyl-groups cause gene silencing and a closed chromatin 
confonnation only if they project into the major groove of DNA. 
There is a controversial question about the hit necessary to initiate the aberrant methylation 
in cancer; the problem is related to its very early occurrence, before transfonnation of a 
healthy cell: thus, we "see" only the final outcome of this process. 
The list of genes involved in tumourigenesis and silenced by methylation is becoming 
more and more extended. The actual field of research is addressed on defining a specific 
pattern of methylated genes for specific kind of tumours, the mentioned CIMP; this 
fundamentally implies that methylation is a non-random process, but also that methylation 
has a cause that should be searched for and identified. Actually our knowledge is still 
focused on the analysis ofthe final process that is the methylation status of genes; this kind 
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of approach has been improved with more and more sophisticated techniques, which allow 
to assess patterns of epigenetic modification in a gene-specific or genome-wide manner. 
In normal cells, the active transcription of genes represents a hard obstacle to methylation 
setting in promoters; however these regions contain the molecular apparatus of the open 
configuration of the chromatin that is acetylated histones, transcription factors and 
coactivators. It is important to note that the regions flanking a promoter could have a 
closed and methylated structure without interfering with gene transcription. It is thought 
that unmethylated CpG islands are protected from the spreading of the surrounding 
methylation by the presence of not well characterized barriers. In a cancer cell, there could 
be a breakdown of these barriers with methylation then spreading into the CpG islands of 
promoter regions, that set up the closed and transcriptionally inactive configuration (lones 
and Baylin, 2002). 
In sporadic forms of cancer, methylation could affect the promoters of both alle1es of a 
gene, while in the familial forms methylation always represents the second, not inherited, 
hit that leads to the complete silencing of the affected gene. 
The number of epigenetically silenced cancer-related genes equals or exceeds the number 
of those inactivated by mutations. Thus, promoter hypermethylation affects genes involved 
in cell cycle (p16, pIS, Rb, pI4), DNA repair (BRCAI, hMLHI, MGMT) (Teodoridis et 
aI., 2005), carcinogen-metabolism (GSTpi), cell-adherence (CDHl, CDH13), apoptosis 
(DAPK, TMSl) and many others (Esteller, 2002; Esteller, 2007). 
Results obtained using different approaches indicate that there IS a range of 100-400 
promoter hypennethylated CpG islands in a given tumour and that this methylation profile 
differs among different tumour types. In particular, methylation of p16, p14 and 0-6-
methylguanine DNA methyltransferase (MGMT) was found in colorectal adenomas, while 
aberrant methylation of MLHl is typical of endometrial hyperplasia. In contrast, the 
MAGE gene family has an opposite pattern of expression, because these genes are 
normally silenced through methylation in the healthy adult tissues and expressed only in 
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the testis. In many tumours, including lung, sarcomas, mammary and colon carcinomas, 
MAGEs are aberrantly demethylated and transcriptionally active, thus suggesting the 
potential use of this antigen as a target for cancer immunotherapy (Karpf and Jones, 2002; 
Ohman and Nordqvist, 2001). 
Besides DNA methylation, epigenetic silencing of chromatin is related to the proteins 
involved in histone modifications and in chromatin structure, so we could speculate a 
deregulation also in these systems (Lund and van Lohuizen, 2004; Roberts and Orkin, 
2004). There is a tight interdependence between DNA methylation and chromatin 
modification for DNA packaging: HDACs form a complex with both DNMTs and MBPs 
and deacetylated histones determine a more closed chromatin configuration. This implies a 
problem of hierarchy between DNA methylation and histone deacetylation, even though 
data obtained by treating cancer cells with 5-aza-dC seem to support the dominant role of 
methylation with respect to deacetylation induced by HDAC I and 11 (Jones and Baylin, 
2002). Histone methylation makes the epigenetic regulation more complicated, because its 
impact depends on the specific Lys modified and on the number of residues bound. The 
hypermethylated promoters of cancer genes are enriched for enzymes known to catalyze 
Lys methylations. Subsequently di- and trimethylated H3K9 are recognized by 
chromodomain proteins, like HP1, which set the chromatin in a closed configuration. In 
human cells loss of DNMTl results in a decreased level of H3K9me2 and H3K9me3, 
typical marks of silencing in heterochromatin and in euchromatin respectively (Fahrner et 
al.,2002). 
Genes specifically silenced in a specific tumour could represent a biomarker: later I will 
discuss the first approaches to use GSTpi methylation detection in biological fluids and 
biopsies as a marker for detecting prostate cancer (Laird, 2003). 
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1.3 PROSTATE CANCER 
The main function of the prostate is to produce seminal fluid. The prostate is made up of a 
fibromuscular stroma and epithelial glands, in which the adenocarcinoma occurs and which 
is composed of three kinds of cells: basal, luminal secretory and neuroendocrine. There are 
a few basal cells that secrete components of the basement membrane and a subset of these 
might also be the stem cells for the luminal epithelial cells. 
The luminal cells express the androgen receptor and secrete in an androgen-dependent 
manner components of the prostatic fluid, including the prostate specific antigen (PSA). 
PSA is a serine protease of the kallikrein gene family, which is almost exclusively a 
product of the prostate cells and thus an exceptionally useful tumour marker for diagnosis 
of prostate cancer and for monitoring the effectiveness of a treatment. The stroma is 
composed of fibroblasts, smooth muscle cells, dentritic cells, nerves and some infiltrating 
cells, such as mast cells and lymphocytes. Some stroma cells are androgen-responsive and 
produce growth factors that act in a paracrine fashion on the epithelial cells. This stromal-
epithelial crosstalk is an important regulator of the growth, development and honnonal 
responses of the prostate. The well-organized secretory glandular structure in the nonnal 
prostate becomes disrupted in prostate cancer. 
Prostate cancer is one of the most frequent kinds of tumour among male popUlation of the 
western world and accounts for 29% of all male deaths. Its development depends on 
numerous factors such as age, race, dietary and environmental factors, steroid honnones, 
family history etc., but undoubtedly, the most prominent risk factor is aging. In fact, 
approximately 75% of the clinically detectable prostate cancers are diagnosed in men 
between 50-70 years of age (Karan et aI., 2003). 
Another fonn of prostate disease is benign prostatic hyperplasia (BPH). This is due to the 
synthesis of a more potent fonn of testosterone, which stimulates the proliferation of 
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stromal and glandular elements. BPH is not a precursor or a premalignant lesion of prostate 
cancer (PCa), even though both require androgens for growth. 
Prostate cancer develops in a stepwise manner going from normal prostate epithelium to 
androgen-independent cancer, across proliferative inflammatory atrophy (PIA), prostatic 
intraepithelial neoplasia (PIN), localized cancer and finally metastatic cancer (Feldman and 
Feldman, 2001). 
The occurrence of an inflammatory process is an initial and common event in the disease's 
evolution and the factors typically associated with inflammation have been found to be 
involved in the development of prostate cancer. These include cell and genome damage, 
increased cellular proliferation a a tissue microenvironment rich in cytokines and growth 
factors (Palapattu et al., 2005). 
The region characterized by inflammation is the peripheral zone of the prostate, containing 
proliferative epithelial cells (De Marzo et al., 2004). The inflammation could be considered 
the normal response of epithelial cells when infections, ischemia, or 
endogenous/exogenous toxins affect prostate tissue. The first reaction is the creation of a 
tissue microenvironment that promotes the recognition and repair of the cellular damage as 
well as the eradication of foreign particles, infected cells and irreparably damaged cells. 
Generally, two molecular events mark this phase: the synthesis of reactive oxygen and 
nitrogen oxide species by inflammatory cells (typically lymphocytes and macrophages), 
which can alter protein structure and function and cause lipid peroxidation, and the 
increased expression of carcinogen-detoxification enzymes, such as GSTa, Cox-2 and 
GSTpi. GSTpi is normally expressed in basal cells, but not in luminal cells. When damage 
occurs, these cells produce high levels of GSTpi presumably in order to sustain the 
elimination of the dangerous species. GSTpi silencing exposes cells to genomic damage 
mediated by carcinogens and marks the transition between PIA and PIN or PCa (Figure 
1.3.1). 
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1.3.1 Prostate Cancer: general characteristics 
Although prostate cancer usually arises in the peripheral zone of the gland, it is generally 
multifocal and characterized by a marked molecular heterogeneity. A well recognized 
precursor of prostate cancer is the high-grade prostatic intraepithelial neoplasia (HGPIN), 
which consists of architecturally benign prostatic acini lined by cells that seem to be 
malignant. 
PIN and PCa share some of the molecular changes conferring a growth or survival 
advantage. Similar to other types of epithelial cancer, PCa contains many somatic genomic 
alterations, including point mutations, deletions, amplifications, chromosomal 
rearrangements and changes in DNA methylation. But, unlike some carcinomas, for 
example colorectal and pancreatic, where specific oncogenes such as k-ras and pS3 are 
usually mutated, PCa does show a high heterogeneity from case to case or even from lesion 
to lesion in a single case (DeMarzo et aI., 2003). 
The most famous tumour suppressor, p53, is rarely mutated in primary prostate tumours 
(10-20%) and this percentage increases in metastatic lesions. Similarly, inactivation of 
retinoblastoma (RB)1 and cyclin-dependent kinase inhibitor 2A (CDKN2A) genes is not so 
frequent in the early steps of tumourigenesis, but occurs at higher frequencies in metastatic 
and hormone refractory lesions. In contrast, alterations in NKX3.1 gene and Phosphatase 
and Tensin (PTEN) homologue gene are more widespread in prostatic tumours (Karan et 
al.,2003). 
NKX3.1 encodes a prostate-specific homeobox gene that is essential for normal prostate 
development. NKX3.1 protein binds PSA promoter and represses the expression of the 
PSA gene and its expression decreases as cancer develops and evolves from a localized to 
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Dietary carcinogens and oxidant carcinogens, elaborated by inflammatory cells, can be detoxified in basal 
epithelial cells and in cells undergoing proliferative inflammatory atrophy by GSTpi (shown in its dimeric 
catalytically active form). Cells in the PIN zone, which are devoid of GSTpi, undergo genomic damage 
mediated by such carcinogens (MSRl , Macrophage Scavenger Receptor). (From (Nelson et aI. , 2003), 
modified) 
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PTEN is a tumour suppressor, because it is responsible for dephosphorylation and 
inactivation of phosphatidylinositol-3,4,5-trisphosphate (PIP3) protein, which, in its active 
fonn, induces cell proliferation. PTEN mutations have been found in up to a third of 
honnone refractory pea samples. Nevertheless homozygous deletions are a frequent 
characteristic of a subset of primary cancers. Loss of PTEN function also has consequences 
on the levels of the cyclin-kinase inhibitor p27: the expression of this protein is in fact 
suppressed by PIP3/Akt pathway. Thus, when PTEN no longer functions, p27 levels 
decrease and this is usually related to a poorer prognosis in prostate cancer. 
The androgen receptor (AR) gene has been extensively studied, above all its therapeutic 
implications. When prostate cancer is still androgen-dependent for its growth, this receptor 
can be the target for androgen suppression by honnone therapy. Despite initial responses, 
progression to an androgen independent and metastatic fonn is inevitable, mainly because 
of AR modifications, such as gene amplification or mutations. 
In summary, in prostate cancer, genetic modifications do not show, at the moment, 
unifonn picture, even though studies at the chromosome level have shown that gains at 7p, 
7q, 8q and Xq, and losses at 8p, 10q, 3q and 16q are very common, together with telomere 
shortening, which could also be evident in PIN lesions (Nelson et al., 2003). 
1.3.2 Prostate Cancer and Epigenetic Modification 
Prostate cancer is one of the most investigated tumours for methylation modifications 
acquired during its evolution. An aberrant epigenetic pattern has been found both in the 
early and late stages of the disease, but also in a significant fraction of high-grade PIN 
(Yegnasubramanian et al., 2004). 
The growing list of papers published in the last few years on the epigenetics of prostate 
cancer underlined that this kind of tumour might be classified by a panel of methylation 
markers, including not only the hypennethylation in the promoter regions of several genes 
belonging to different pathways, but also a global hypomethylation (Yamanaka et al., 
42 
2003; Li et aI., 2005; Perry et aI., 2006). As in other cancers, the role of global 
hypomethlation is relevant and in particular it affects the abundant repetitive sequences 
(such as the Long Interspersed Nuclear Element-I, LINE-I, retrotransposons) that are 
densely methylated in normal cells. Demethylation increases chromosomal instability, 
which is a mark of the advanced stage of this (and other) tumour types and their 
metastases. In addition, selected single copy genes become hypomethylated. Amongst 
these, is the gene encoding an urokinase plasminogen activator (PLAU) involved in 
tumour invasion and metastases. This shows extensive hypomethylation in hormone-
independent cancer cells, together with the Cancer Associate Gene (CAGE, a novel 
cancer/testis antigen gene) and heparanase, an end-p-D-glucuronidase, which becomes 
highly expressed in cancer tissues compared to normal tissues. 
In addition to this, more than 30 genes undergo aberrant hypermethylation in prostate 
cancer. These genes include classic and putative tumour-suppressors and genes involved in 
different cellular pathways, such as hormonal responses, tumour-cell invasion and/or 
tumour architecture, cell cycle control and DNA damage repair. For many of these genes, 
promoter hypermethylation is often the main mechanism determining their functional loss 
in prostate cancer. Inappropriate silencing of these genes can contribute to cancer 
initiation, progression, invasion and metastases (Figure 1.3.2 and Figure 1.3.3). 
In general, it has been found, through clinical studies, that this "epigenetic catastrophe" 
usually involves the early stages of prostate cancer progression and confers an advantage 
to the clonal growth of the transformed cells. Genes usually methylated in the early stages 
of tumour development/aetiology belong to DNA damage repair and to transcriptional 
regulation pathways. Undoubtedly the most extensively studied gene in these classes is 
GSTPl (Lin et aI., 2001b), which is silenced through methylation in 90% of primary 
prostate tumour samples and in about 70% of PIN samples examined. 
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Figure 1.3.2 Cellular pathways affected by methylation and involved in prostate 
cancer development. 
From (Perry et al., 2006), modified. 
sme indicates silencing mediated by methylated cytosine in the promoter of the corresponding gene. 
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Very recently, methylation of the GSTIl isoform has been found in about 54% of tissue 
samples collected in a clinical study, thus further increasing the percentage of tumours with 
a global inactivation of GST genes (Dobosy et aI., 2007; Lodygin et aI., 2005). 
Data regarding 0-6-methylguanine DNA methylatransferase (M GMT) gene are not so 
clear and univocal, because it has been found methylated in some studies, but not in others 
and further analysis need to clearly determine the role of methylation in silencing of this 
gene. 
Methylation does not seem to affect classic tumour suppressors, such as Rb 1, TP53 and the 
VHL gene. An emerging role is that of the RASSFIA gene, encoding a protein similar to 
the RAS effector protein and probably involved in cell cycle arrest. Its methylation is 
observed in 54%-94% of tumour samples examined, but also in PIN. In spite the few data 
available, RASSFIA methylation occurs in early prostate cancer development and 
increases as cancer progresses. 
Genes involved in cell cycle progression are not usually silenced by epigenetic 
mechanisms, except for CDKN2A, which, surprisingly, is methylated not in the promoter, 
but in exon 2. Although this modification does not affect its expression, it is unique for 
prostate cancer tissue and could be useful as a marker (Li et aI., 2004). 
Late stages of prostate tumours, characterized by androgen-independent growth and by the 
metastatic process, depend on the inactivation of genes belonging to the adhesion system. 
Thus E-cadherin is usually methylated in cell lines and in high-grade prostate cancer, 
together with CD44, whose function is related to matrix adhesion and signal transduction. 
In the androgen-independent stage of prostate cancer, the androgen-receptor (AR) gene 
becomes inactivated or deregulated in its function and it could be not expressed because of 
methylation of its promoter. The incidence of methylation-mediated AR silencing ranged 
from 0% to 20% in primary prostate cancers and from 13% to 28% in androgen-
independent cancers. In contrast, methylation is the leading cause of the absence of the 
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estrogen receptors (ERa and ER~) and retinoic acid receptor ~ in the advanced stages of 
prostate cancer. 
Although DNA methylation has been the most extensively studied epigenetic modification 
in prostate cancer, other chromatin changes can contribute to tumour transformation. Thus, 
histone modifications have a relevant role in allowing, or not, gene transcription, not only 
via their direct action on chromatin conformation, but also via the interaction with other 
regulating proteins and with DNMTs. 
Histone acetyltransferases (HATs) affect a wide range of cellular processes by increasing 
transcriptional activity, for example that of the androgen receptor leading to an increased 
activity of this receptor, without the androgen stimuli. Conversely, HDACs, which are up-
regulated 2-3 fold in PC a, especially androgen-independent PCa, are responsible for a 
closer structure of chromatin and seem to be involved in the decreased transcriptional 
activity of the vitamin D receptor. This prevents 1,25-(OH)2-vitamin D3 exerting its cell 
cycle regulatory antiproliferative effects. 
Another significant histone modification in prostate cancer is methylation: the EZH2 
protein is responsible for Lys27 methylation on histone H3, which is a mark of 
transcriptional activation. EZH2 upregulated, especially in metastatic PCa (Schulz and 
Hatina, 2006). 
The fundamental role of the epigenetic modifications, in particular DNA methylation, in 
prostate cancer initiation and progression has prompted investigators to use the most 
frequently methylated genes as markers for tumour detection. To be fit for this purpose, 
gene methylation detection methods need to be specific and sensitive and, at the same time, 
readily applicable to clinical specimens obtained through minimally invasive procedures. 
Among all genes methylated in prostate cancer, GSTPl shows the highest frequency and 
this occurs very early in tumour induction (Harden et aL, 2003; Song et aI., 2002). 
Recently, analyses on different kinds of male bodily fluids have highlighted that GSTPl 
hypermethylation may be useful for the early detection and diagnosis of PCa (Henrique 
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and Jeronimo, 2004; Hopkins et aI., 2007). Sensitive and quantitative methods of detection 
help to establish this gene as tumour marker, while using very little tumour material for 
diagnosis. They can also detect tumour foci in apparently benign areas, especially because 
GSTPl methylation is a positive signal surrounded by widely negative signals in each 
contaminant of the sample used. 
Clinical studies have involved detections of GSTpi methylation in PIN, PCa tissues and 
metastases and, very rarely, in BPH (Nakayama et aI., 2003), but also in blood, ejaculates 
and urine of the PCa patients (Gonzalgo et aI., 2003). The possibility of finding GSTPl 
methylation in these latter fluids could make it an instrument of diagnosis for PCa and for 
monitoring residual disease after curative surgery and therapy, instead of serum PSA, 
which lacks specificity because it does not distinguish BPH from PCa. 
When we consider promoter methylation in body fluids as a cancer biomarker, the 
detection of a specific kind of tumour is extremely important. Specific prostate cancer 
detection could be compromised, because in males both liver and kidney tumours could 
show GSTPl methylation, even if at much lesser extent than prostate cancer. As a 
consequence, the combination of the most frequently methylated genes in PCa should be 
considered as a tumour "fingerprint", in order to improve PCa specificity and provide 
better diagnostic and prognostic information. Thus evaluation of various combinations of 
CpG island hypermethylation at GSTPl, APC, PTGS2, MDRl (multi drug resistance 1) 
and RASSF1A promoters allows 100% sensitivity and >92% specificity (Tokumaru et aI., 
2004). 
In summary, prostate cancer is undoubtedly characterized by widely distributed epigenetic 
modifications, which surely confer a growth advantage to the tumour. 
The epigenetic causes of cancer in contrast to genetic causes allow the specific adoption of 
epigenetic therapies, in order to revert the aberrant modifications on DNA. For prostate 
cancer, this could be particularly suitable, because this kind of therapy could act 
simultaneously on androgen receptor function, cell adhesion and migration, cell cycle 
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control and genome damage and repair pathways, blocking tumour development at 
different steps and hence increasing the chances of success. 
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1.4 GLUTATHIONE-S-TRANSFERASE 
Glutathione-S-Transferases (GST) represent a class of abundant detoxifying enzymes in 
both prokaryotic and eukaryotic cells. These proteins catalyze the attachment of the 
nucleofilic reduced peptide GSH to non-polar compounds containing an electrophilic 
carbon, nitrogen or sulphur atom. In general, we can summarize the reaction catalyzed as 
follows: 
OSH + R-X -. OSR + HX 
where R-X is the electrophilic substrate (Armstrong, 1997). 
We can broadly distinguish soluble and membrane-associated enzymes. Among the former 
are the cytosolic and mitochondrial OSTs, sharing some similarities in three-dimensional 
folding. Microsomal OSTs, also referred membrane associated proteins in eicosanoid and 
glutathione metabolism (MAPEG) do not show any structural similarities to the other 
classes. 
From a physiological point of view, OST enzymes confer protection to the cells against 
oxidative stresses, especially those resulting from oxygen radical attacks on membranes, 
nucleotides and fatty acid chains (in general, to biological macromolecules). However, 
OSTs exert their function also to protect against damage by exogenous electrophiles, such 
as environmental pollutants, industrial intermediates, pesticides and herbicid~s. 
Much interest has arisen from the capability of OST to detoxify cancer cells from cytotoxic 
drugs and the link between OST activity/expression and anticancer drug resistance has 
been extensively investigated. 
1.4.1 GSTen(J'mes 
Cytosolic OST enzymes fall into different classes, named alpha, mu, pi, theta, omega and 
zeta. They are 199-244aa in length. These different classes have a common evolutionary 
precursor gene, identified as the theta gene. During evolution, the alpha, mu, pi genes arose 
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by duplication of this gene and the most pronounced structural differences occurred in the 
catalytic region. 
The enzymes form dimers of subunits belonging to the same class. This characteristic 
allows different homo- or heterodimeric isoenzymes and this widens the substrate 
spectrum of the catalyzed reactions. Allelic variants of each isoenzyme have also been 
described, and these can explain differences in the efficiency of the reactions. 
In each class, mouse and human protein primary structures share about 40% identity, while 
no more of 25% identity has been found among different classes within a species. 
GSTs have strong binding properties. In fact, besides catalyzing conjugation, reduction and 
isomerization reactions, cytosolic GSTs also bind, covalently and not covalently, 
hydrophobic non-substrate ligands. This contributes to intracellular transport, sequestration 
and disposition of xenobiotics and hormones. 
1.4.1.1 Enzyme structures 
GST structure consists of N-terminal and C-terminal domains, which totally differ for the 
secondary/tertiary structure. The N-terminal domain usually folds in four strands ~-sheets 
and specifically binds GSH through electrostatic and hydrogen bonding interactions, while 
the C-terminal domain is constituted by a-helices and is particularly involved in the 
xenobiotic species recognition. To allow reaction catalysis, the xenobiotics lie in the 
crevice between the N-terminal and the C-terminal domains. This is the general structure 
of the soluble form of GSTs, and, although there are similar topologies, the structures 
differ in many details accounting for the specificity of each class. For example, mu and 
alpha class enzymes have a more constricted actives site than pi, sigma and theta classes 
(Hayes et aI., 2005). 
I have previously mentioned that the functional form of GST enzymes is a dimer. This 
structure results from the interaction of two distinct subunits through a ball-and-socket 
model in alpha, pi and mu classes; in this model the side chain of a phenylalanine residue 
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(the ball) of the first subunit protrudes in the socket between the a4 and a5 helices of the 
second subunit. Up to now, catalytically active monomers have not been observed in 
mammals, but they have been described in non-mammalian species. 
In order to activate the sulphur for nucleophilic attack, GST -GSH binding, occuring 
through hydrogen-bonding interaction on the dimer surface of the enzyme and the core ppa 
motif recognizing the y-glutamyl portion of GSH, is the most conserved in all cytosolic 
enzymes. In contrast, the differences among the GSH binding sites of the various enzyme 
classes involve the interaction of the GST protein with the sulphur of the GSH peptide. 
This common tridimensional structure does ensure catalysis of many different reactions, 
including, for example, nucleophilic aromatic substitutions, epoxide ring openmg, 
reversible Michael additions, isomerizations, and peroxidase reactions. The substrate 
bonding occurs on the C-terminal domain II of the GST enzyme. This domain is typically 
characterized by differences in its architecture among the different GST classes. 
Nevertheless all GST enzymes share the capability of catalyzing the addition of GSH to 1-
chloro-2,4-ditrobenzene (CDNB), and this reaction is widely used as kinetic enzymatic 
assay to test the GST functionality. It is important to note that it does not discriminate the 
different GST classes (Habig and Jakoby, 1981). 
GST alpha class is mainly expressed in the liver and is encoded by a gene cluster localized 
on chromosome 6p12. This cluster contains 5 genes, encoding for the 5 isoenzymes of the 
class (GSTAI-GSTA5). In turn, each isoenzyme is generally characterized by genetic 
polymorphisms, involved in transcriptional modulation of the genes. Among the different 
isoenzymes, AI, A2 and A4 are widely expressed in human tissues. GSTAI is particularly 
active towards several carcinogens, including polycyclic aromatic hydrocarbons and 
epoxides, while the A3 isoenzyme is selectively expressed in steroidogenic tissues and 
plays, a role .in .steroid hormone biosynthesis. In general, members of the alpha class 
possess high glutathione peroxidase activity and play an important role in protecting cells 
against the genotoxic effects of reactive oxygen species and the products of peroxidation. 
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Homozygous null GSTA4 mice have been characterized: they show an apparent normal 
phenotype, but are more susceptible to bacterial infections. Liver and brain contain 
increased mRNA levels for other GST classes (in particular, GSTA1I2, A3 and GSTMl) 
and for other enzymes involved in ROS detoxification. 
Omega class. Two different isoenzymes characterize this not well-characterized GST, 
which do not catalyze the reactions typical of the other GSTs, except that for CDNB. They 
are abundantly distributed in the liver, macrophages, glial and endocrine cells. 
Zeta class is particularly expressed in hepatocytes and renal proximal tubule cells and is 
mainly involved in the GSH-dependent transformation of a-alogenate acids. At the 
moment, the unique isoform of this class, GSTZI, has been characterized as 
maleylacetoacetate isomerase (MAAI), which is in the catabolic pathway of phenylalanine 
and tyrosine. GSTZI null mice are prone to renal injury following phenylalanine and 
tyrosine overload and die if provided with drinking water containing phenylalanine. 
Theta and sigma classes. GSTTl gene is located on chromosome 22q 11.2. One of the 
reactions catalyzed by this class is the conjugation of halomethanes in human erythrocytes, 
but GSTTI substrates also include industrial and environmental chemicals. Recent studies 
have found GSTTI expressed particularly in prostatic tissue, but there is little insight on 
the consequences of this overexpression. 
GST sigma encodes the hematopoietic, GSH-dependent, prostaglandin D2 synthase. The 
phenotype of the KO mice is related to allergic reactions, which are weaker than in WT 
mice. 
GST mu class is characterized by 5 different isoforms (GSTMl -. GSTM5), which, in 
turn, contain different polymorphisms. GSTM genes are located in tandem on chromosome 
1, but they can be differentially expressed in human tissues. In particular, GSTMl has been 
found in liver, stomach and brain, while isoforms GSTM2-GSTM5 have uniquely an 
extrahepatic expression. GSTMl is involved in detoxification of numerous electrophilic 
substances including carcinogens, and, probably, of lipid peroxydation products. GSTM2 
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and M3 have brain localization. GSTM2 has been identified as prostaglandin E: in the 
brain it binds GSH to redox cycling products of dopamine, thus allowing their 
detoxification: in an unbound form, these products can contribute to the processes involved 
in neurodegenerative diseases, such as Parkinson's disease and schizophrenia. Therefore 
the main role of GSTM2, especially of its B allelic form, could be protection against 
neurodegeneration. KO mice for GSTM5 have been generated, but, at the moment, no 
clear phenotype has been described. 
GSTpi class has been the most extensively studied, in particular for its well-recognized 
role in carcinogenesis. From a physiological point of view, GSTpi was first identified as 
placental isoform but was subsequently found in many tissues at variable levels. It is the 
most ubiquitous and highly expressed GST class in mammals. Its expression is inducible 
by exogenous agents including chemotherapeutic agents and the overexpressed protein is a 
mechanism of resistance to anticancer therapy of a wide range of human tumours. 
GSTP gene is located on chromosome 11 as single unit, but it is highly polymorphic and 
the different alleles have different efficiencies in catalytic activity. 
KO mice for GSTP isoforms 1 and 2 do not have an aberrant phenotype or an increased 
incidence of any kind of tumours; but when treated with TPA or 7,12-
dimethylbenzanthracene (DMBA), a significantly higher number of skin papillomas were 
induced than in wild type mice (Gate et al., 2005). Similarly, treatment with tobacco smoke 
components increased the number of lung adenomas formed. This peculiar sensitivity of 
lung and skin to GSTpi absence could relate to the fact that GSTpi is the most abundant 
GST form in lung and skin of the humans (Henderson and Wolf, 2005; Hayes et al., 2005). 
1.4.1.2 GSTpi hypermethylation 
As I described before, an aberrant DNA methylation could be now considered a hallmark 
of cancer, together with those previously analyzed by Hanahan D, and Weinberg R.A.in 
Cell (Hanahan and Weipberg, 2000). 
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There have been numerous attemps to try to associate a specific marker of methylation to a 
specific kind of tumour. In this regard, hypermethylation of the human GSTPl gene 
represents a useful and specific tool to particularly identify prostate cancer cells, because 
the 5' -region of GSTP 1 gene contains a CpG island that is the target of an aberrant 
hypermethylation during tumourigenesis. This event occurs very early in tumour 
development and this made it difficult to evaluate the kinetics of the silencing process, 
particularly when a cell line is used for such analyses. 
Nevertheless, studies on prostate tissues highlight that there is a clear difference in 
methylation status between benign tissues and tumours, and that GSTPl methylation is 
involved in a more general "epigenetic catastrophe" that targets many kind of genes. Both 
alleles of the gene are affected, resulting in the complete absence of the protein in the cells. 
We can consider GSTPI a "caretaker" gene, because loss of the protein renders prostate 
cells vulnerable to genome damage (generally associated with chronic prostate 
inflammation) via repeated exposure to carcinogens, which, in turn, promotes 
transformation to high-grade PIN and prostate cancer. 
GSTPl in an autosomal gene located on chromosome llq13; it spans about 4kb and 
comprises 7 exons and 6 introns, encoding for a 715b mRNA transcript. The GSTPl 
promoter is located in a 1.5kb CpG island (from -400bp upstream to 800bp downstream of 
the transcription start site), that also spans exons 1-3: its core region contains two Spl 
sites, a consensus AP-I site and a TATAA box (Rushmore and Pickett, 1993). Detailed 
methylation analysis of the entire gene showed that, in normal prostate tissues, the CpG 
island is completely unmethylated; however, beyond the CpG island region, from intron 4 
to the 3' end of the gene, there is extensive methylation in both normal and prostate cancer 
tissue, even though this does not affect gene expression (Lee et al., 1994). In contrast, in 
prostate cancer tissues, adjacent promoter CpG dinuc1eotides are fully methylated and this 
correlates with the loss of GSTpi enzyme expression. Hypermethylation was found in both 
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the top and the bottom strands of DNA, while no mutations affecting GSTpi expression 
have so far been reported (Millar et aI., 1999; Esteller et aI., 1998). 
The GSTPl gene modification by methylation is a step by step process, which starts with 
the transcriptional silencing of the gene. Genes encoding GSTs are characteristically 
expressed at very low levels in many tissues, until induced via increased transcriptional 
activity, by exposure to oxidants and electrophiles. In the absence of an inducing exposure, 
low levels of GSTPl transcription might render its CpG island vulnerable to de novo DNA 
hypermethylation. In fact we actually have to think of methylation setting as a consequence 
of a broken balance between methylated and unmethylated status, regulated by the 
transcriptional level of the gene. 
Probably when transcriptional activity becomes lower, de novo methylation is favoured 
and begins to spread across the promoter. The transcriptional silenced gene is targeted by 
the methyl binding protein MBD2 at methylated cytosines, which contributes to the 
assembly of a protein complex involving histone deacetylases and DNA 
methyltransferases. This establishes a closed chromatin conformation, that may be 
responsible, together with methylation of H3K9, for the maintenance and persistance of the 
silenced state in the subsequent tumour cell generations, (Stirzaker et aI., 2004). 
The methylation spreads across a boundary element at the 5' end of the CpG island. This 
region is marked by a repeated AT AAA sequence, which in turn is adjacent to an Alu 
repeat in 3'; such sequence boundary has not been found at the 3'end of the GSTPI island. 
In normal prostate tissue, methylation is confined to the Alu repeats and no modification 
occurs both in the AT AAA repeat and in the CpG island. It is not clear whether the 
AT AAA repeat is itself the boundary element or whether it is fortuitously located 5' or 3' 
to the actual barrier sequence, which protects the CpG island from methylation. However it 
does not .appear, to contain ,binding sites for proteins, which could represent a physical 
obstacle to the moving of methylation and also the Spl binding site does not seem to be 
involved in protection against de novo methylation. 
56 
In prostate cancer cells, this marked methylation boundary is disrupted or bypassed as the 
entire CpG island, on both alleles, is methylated, following the transcriptional silencing of 
the gene (Millar et aI., 2000). 
Undoubtedly, reduced expression of the GSTPl gene likely plays the main role in its 
silencing and could represent the starting point for the chemical modifications of DNA and 
histones in its promoter which "lock" the chromatin in this region. 
1.4.1.3 Besides the GSH transfer catalysis: regulatoryfunctions ofGSTmu and pi 
Earlier I described the GST catalysis of GSH ligation to endogenous and exogenous 
electrophiles, presumably in order to allow their detoxification. Although the catalytic 
efficiencies for many of the substrates are low, GSTs have, as we have seen before, 
pleiotropic substrate specificity. The fundamental role of the GST family in cell defences is 
further widened by data showing its involvement in a regulatory (and non catalytic) 
binding activity to the stress-activated kinases, such as the c-Jun-N-terminal kinase (JNK), 
which links stress stimuli to apoptotic response. At the moment this function has been 
demonstrated for GSTmu and GSTpi, the latter being typically overexpressed in many 
kinds of tumours, but not in prostate cancer (McIlwain et aI., 2006). 
GSTpi and mu exert their regulatory function as monomers, in contrast to their dimeric 
structure, by which they catalyze the conjugation of GSH to electrophiles. 
Based on this regulatory activity, GSTpi and mu have been often referred as "ligandins". 
JNK is a member of the mitogen activated stress kinase family (MAPK), which also 
includes the extracellular signal regulated kinase (ERK) and p38-MAPK. JNK was initially 
identified as a protein involved in the cellular response to environmental stresses (UV 
light, H202, osmotic shock and withdrawal of growth factors), pro-inflammatory cytokines 
and interleukins. JNK regulates c-jun (which belongs to the transcription factor complex 
AP-l), by binding to c-jun N-terminus and phosphorylating it at Ser-63 or Ser-73. 
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In non-stressed cells, GSTpi binds the NH2-tenninal region of JNK and so it prevents JNK 
being phosphorylated and hence catalytically active. Under conditions of oxidative or 
chemical stress, GSTpi releases JNK and the two unbound proteins exert their specific and 
catalytic functions. GSTpi will fonn a dimer to detoxify the dangerous molecules, while 
JNK, in its phosphorylated fonn, will, in turn, phosphorylate c-jun, which acts as 
transcription factor in the apoptotic pathways, if a prolonged or high level exposure to 
stress signals occurs (Wang et aI., 2001). 
A similar pattern applies to GSTmu, which exerts its regulatory function by binding the 
apoptosis signal-regulating kinase 1 (ASKI) to fonn a GSTmu:ASKI complex. In 
conditions of oxidative stress, or, more specifically, of heat shock, GSTmu oligomerizes, 
allowing the release of ASKI and the subsequent induction of apoptosis, generally through 
the activation of downstream kinases (Cho et aI., 2001). It is important to underline that the 
fate of the cell (Le. either proliferation or apoptosis) after the activation of these stress-
induced pathways, will be dependent upon the concentration and exposure time of the 
stress. In some cases, transient or low level exposure can induce cell proliferation, while 
prolonged or high level exposure can induce apoptosis (Gate et aI., 2004). 
To complete the description of GSTpi activity, it should also be considered that the GSTpi 
catalytic property can be associated with its regulatory function. In fact GSTpi plays an 
important role in the glutathionylation of the oxidized and inactive fonn of l-cys-
peroxiredoxin (l-cys Prx). The GSH binding to the catalytic cysteine of l-cys-Prx leads to 
restoration of its peroxidase activity, thus enabling it again to respond to oxidative or 
nitrosative stresses. 
1.4.1.4 Mitochondrial and MAPEG enzymes 
Glutathione-S-Transferases;. K.is widely and unifonnly expressed in human tissues and is 
the only GST enzyme found in mitocondria. New data show that it is also located in 
peroxisomes, suggesting that it might specifically be involved in p-oxidation of fatty acids, 
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either through its catalytic activity or via interaction with a membrane pore. As with the 
other soluble members of the GST family, GSTK has a high activity for CDNB. 
Considerably less is known about the structure and the mechanism of the microsomal GSH 
transferases that are involved in xenobiotic metabolism. In contrast, there is more insight 
into their role in the production of eicosanoids. Six human MAPEGs have been identified 
and, based on their primary structure, they fall in four subgroups. These enzymes are 
characterized by a trimeric structure, each subunit consists of five membrane-spanning 
regions, at least two of which are likely to be a-helices perpendicular to the membrane 
surface. The N-terminus of the enzyme appears to be located on the luminal side of the 
endoplasmatic reticulum, while the C-terminus and the active site face the cytosol. 
Three MAPEG enzymes are involved in eicosanoid synthetic pathway, and are identified 
as leukotriene C4 synthase (L TC4S), 5-lipoxygenase activating protein (FLAP) and as 
prostaglandin E2 synthase 1 (PGES 1). There is no evidence of their involvement in 
oxidative stress responses (Hayes et aI., 2005). 
1.4.2 GSH 
Glutathione (GSH) is a water-soluble tripeptide composed of the aminoacids glutamine, 
cysteine and glycine. It serves to maintain a reducing cellular environment and this 
function is so important that GSH is widespread in plants, mammals, fungi and some 
prokaryotic organisms. In some human tissues, it attains millimolar concentrations, 
especially where it exerts a detoxifying role, such as in the liver and brain. 
This tripeptide can exist intracellularly in either an oxidazed (GSSG) or reduced (GSH) 
state. Maintaining an optimal GSH:GSSG ratio in the cell is critical to survival, hence there 
is tight regulation . .of the system. When alterations in the redox balance occur by exposure 
to ROS, dose-dependent changes in GSH:GSSG ratios can potentially influence a number 
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of target proteins, by causmg oxidation and disulfide exchange reactions at specific 
cysteine residues. 
GSH deficiency puts the cell at risk for oxidative damage; furthermore, many different 
pathologies show an imbalance of the GSH levels. 
GSH synthesis is inhibited by the phosphorylation of y-glutamylcysteine synthase (y-
GCS). However GSH itself suppresses its own synthesis when high levels are reached in 
the cell (Townsend et al., 2003). 
1.4.3 GST and CANCER 
The role of GST polymorphisms in cancer susceptibility and the increased GST levels in 
determining anticancer drug resistance have been recently described (Townsend and Tew, 
2003; Waxman, 1990). 
In general, absent GST enzymes may result in a poorer elimination of the electrophilic 
carcinogens, which increase the risk of somatic tumourigenic mutations on DNA. 
A null genotype for GSTMl or GSTTl classes can be found in humans and, in particular, 
GSTTlnull is related to a higher risk of acute or chronic myelogenous leukaemia, while 
the GSTMI null genotype was associated with an increased risk of prostate cancer (Katoh 
et aI., 2008; Rebbeck et aI., 1999). 
The GSTpi picture is undoubtedly more diverse: as with other GST enzymes, GSTpi is 
overexpressed in a wide variety of tumours, including ovarian, non-small cell lung cancer 
(NSCLC), breast, colon, pancreas and lymphoma, usually as a response to chemotherapy. 
Among the different GSTP polymorphisms, GSTPIA has been reported to play a role in 
the acquisition of resistance to cisplatin via the formation of platinum-GSH conjugates. 
Patients homozygous for the GSTPIB allele have a reduced capacity to detoxify platinum -
based anticancer agents, thus.making this phenotype favourable in terms of response rate. 
Individuals positive for the GSTPIC allele seem to have a lower incidence of breast 
cancer. Except for prostate cancer, an elevated GSTP expression is generally associated 
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with a more aggressive tumour, a poorer prognosis and resistance to chemotherapy 
(McIlwain et aI., 2006; Dang et aI., 2005). 
When we consider these increased levels of GST activity in cancer, we think not only of an 
increased capacity to detoxify drugs, but also of the regulatory roles ofGSTs as monomers, 
especially GSTpi and mu. This non-enzymatic role of GSTpi also has a direct relevance in 
drug-resistant tumours. In fact, as an endogenous switch for the control of the signalling 
cascade pathway, elevated expression of GSTpi can alter the balance of the regulation of 
kinase pathways during treatment, thereby conferring a potential selective growth 
advantage. 
There is much data on the effects of anticancer drugs on GST levels in cancer cells. Some 
drugs (chlorambucil, melphalan, nitrogen mustard, acrolein, ethacrynic acid) are direct 
substrates of GSTs and resistance strictly depends on increased levels of GST, in particular 
GSTpi. In general, a common characteristic of these drugs is the electrophilic nature of 
their active cytotoxic moieties, so they can be directly inactivated through catalytic 
conjugation to GST through a thioether bond formation. Other common anticancer drugs 
have not been characterized as GST substrates, even though the corresponding resistant 
cell lines show increased levels of this detoxifying protein. Typically the drugs include 
antimetabolites, antimicrotubule drugs, topoisomerase I and II inhibitors, mitomycin C, 
adriamycin, cisplatin and carboplatin (Tew, 1994). Many of these drugs induce apoptosis 
via activation of the MAP kinase pathways, specifically JNK and p38. Due to the fact that 
GST also acts as an inhibitor of the MAP kinase pathway, elevated GST levels could in 
turn determine an increased resistance to apoptosis. Cisplatin is an example of a drug 
whereby JNK activity is required for maximal cytotoxicity: inhibition of the JNK 
signalling pathway leads to a decrease in cisplatin-induced apoptosis, while c-jun 
overexpression increases cell sensitivity to this drug (Townsend and Tew, 2003). Thus, 
increasing GST levels is a generalized means of cell defence against anticancer drugs and, 
as a consequence, GST could represent a target to design new molecules that could 
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specifically kill tumour cells, instead of exerting a non-specific cytotoxic effect on all 
tissues, including the normal tissues, which usually determines the toxicity of the classic 
therapeutic regiments. 
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1.5 ANTICANCER THERAPY 
The history of anticancer drug therapy covers the past century and offers many insights to 
develop new and more specific drugs to eliminate cancer cells. The first molecules were 
discovered quite serendipitously from their cytotoxic effects hematopoietic cells. Only 
later were the efforts applied to solid tumours. In general, the mechanism of action of these 
drugs was unknown and usually only identified and more extensively studied after testing 
their efficacy on patients. The first example was a mustard gas compound, which alkylates 
purine bases in DNA, leading to crosslinking of the strands and then apoptosis. This was 
followed by the discovery of the antifolates, such as methotrexate, purine analogs and 
other alkylating agents. 
The first drug combination treatment took into account the use of the known cytotoxic 
drugs in order to circumvent cancer resistance and relapse after the treatment with a single 
agent. Another significant problem arisen during clinical trials was the acute and long-term 
toxicity of chemotherapy, which affected almost every organ of the body. 
As molecular and genetic studies tried to understand the biology of tumour cells compared 
to normal cells, the possibility of a targeted therapy against deregulated markers arose. The 
targets included growth factors, signalling molecules, cell cycle proteins, modulators of 
apoptosis and molecules promoting angiogenesis. The first successful drug developed 
inhentionally against a molecular marker was Imatinib, as inhibitor of the BCR-Abl kinase, 
which is relevant in chronic myeloid leukaemia. 
Another target is the epidermal growth factor receptor (EGFR) both at its ATP-binding 
moiety level (using Gefitinib or Erlotinib) and at the extracellular domain level (using 
Cetuximab ). 
The central role of angiogenesis in allowing tumour proliferation and metastasis has made 
antiangiogenic therapy an attractive field for anticancer strategies. 
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Since then, new molecules have been synthesized against the vascular endothelial growth 
factor (VEGF) receptor, and, despite some clinical failures of this approach, new strategies 
are exploring the combination of antiangiogenic drugs and established cytotoxic 
molecules. 
Thus, the perspectives of combination therapy have changed: from being an empirical set 
of cytotoxic drugs, to a more effective strategy based on the discovered molecular markers 
for particular kinds of tumours (Dancey and Chen, 2006). In addition, more clinical trials 
are now designed with the aim of identifying subsets of patients that are more likely to 
respond to certain drugs, thereby avoiding the needless cost and toxicity of an ineffective 
treatment. 
1.5.1 Systemic Treatment for Prostate Cancer 
As already outlined, prostate cancer (PCa) is the most common non-cutaneous cancer in 
the western world. Its incidence increases with age and it is also related to dietary and 
environmental factors. The early detection of transformed prostate cells benefitted from the 
advent of serum prostate specific antigen (PSA) testing, which has enabled a more 
extensive screening of the male popUlation. 
Many prostate cancers initially require the presence of circulating androgens that influence 
the proliferation and maintenance of the secretory prostate epithelium. Because cell 
turnover in the prostate is relatively slow, the multi step evolution from a restricted form to 
epithelial cells to invasive cancer is estimated to span decades. In the localized disease 
stage, patients are treated with radiation therapies and radical prostatectomy, which 
certainly allows a full pathological assessment of the tumour, but, at the same time, can 
have significant side-effects, such as impotence and urinary incontinence. Even now, the 
optimal therapy for early stage prostate cancer is not clear, especially because of the need 
for a long follow-up after randomized clinical trials. 
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In contrast, considerable efforts have addressed the advanced stages of prostate cancer. The 
most widespread therapeutic approach is androgen withdrawal, which usually results in 
tumour responses in 80-90% of patients. Androgen ablation therapy is very effective in 
androgen-dependent cancer and nowadays, instead of orchiectomy, this kind of therapy is 
performed through pharmacological methods, using a combination of androgen receptor 
antagonists with a gonadotropin-releasing hormone (GnRH) inhibitor. AR antagonists also 
prevent androgens produced by the adrenal glands from binding to AR in the prostate 
(Horwich,2006). 
Androgen ablation therapy fails because of the development of the androgen-independent 
stage of disease: intermittent administration was used in attemps to slow down this disease 
progression, but these trials did not produce clear results. Resistant tumours accumulate 
stepwise changes in DNA structure and gene expression, that provide a selective survival 
and growth advantage to the cells, which then no longer need hormone for growth 
(Feldman and Feldman, 2001). 
In the last few years different therapeutic options for hormone refractory prostate cancer 
have been investigated. 
Chemotherapy is being explored and the first survival benefit has come from treatment 
with docetaxel as first line therapy. More encouraging results have since been obtained by 
combination treatment, for example with prednisolone (causing adrenal suppression). 
Among other cytotoxic drugs, platinum derivatives, such as satraplatin, showed promising 
preclinical results against taxane-resistant cells, thus supporting subsequent clinical 
applications. Actually, the newest approach, as already mentioned, is to target those 
molecular markers which specifically distinguish cancer cells from normal cells and 
generally this is in association with cytotoxic chemotherapy. 
Antiangiogenic therapy seems to have potential, because plasma levels of VEGF increase 
from healthy controls to patients with localized or metastatic prostate cancer. 
Bevacizumab, a VEGFR inhibitor, has been enrolled in combination with docetaxel against 
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metastatic hormone refractory prostate cancer (HRPC), leading to a substantial 
prolongation of life compared to administration as a single agent. 
Small molecule inhibitors have been specifically designed to target those proteins which 
contribute to tumour growth and progression in prostate cancer. Thus atrasentan is an 
antagonist of the endothelin-A (ET-A) receptor, while imatinib is an agent that inhibits the 
tyrosine kinase activity of the platelet-derived growth factor receptor (PDGF), which is 
abundant in metastatic prostate cancer. Both atrasentan and imatinib have been used in 
clinical trials in combination with docetaxel. 
A new approach comes from nucleotide-based targeted therapy, based on the use of 
anti sense oligonucleotides (ASOs) that are complementary to a selected gene's mRNA. 
These targeted RNAs show an increasing level in transformed prostate cells and are 
usually related to cancer progression and aggressiveness, but also to the acquisition of drug 
resistance. At the moment, genes targeted for silencing are clusterin (which suppresses 
apoptotic cell death in response to androgen withdrawal and whose levels increase with the 
Gleason score), ribonucleotide reductase (RNR, an important enzyme for cell division and 
tumour growth, whose R2 subunit is often overexpressed in tumours, thus promoting drug 
resistance), but, above all, HSP27, a heat shock protein that is strongly induced under 
conditions of cell stress. The levels of HSP27 increase as prostate cancer becomes more 
and more aggressive and metastatic. HSP27 may serve as therapeutic "hyper-node", a 
target situated at the centre of many pathways involved in regulating cellular responses to 
treatment-induced stress, so its inhibition would silence multiple survival pathways at 
once. At the moment, ASOs against the proteins described above are in phase IIII clinical 
trials, usually in combination with docetaxel (Hadaschik and Gleave, 2007). 
From a therapeutic point of view, of great potential, but still poorly investigated in prostate 
cancer, is aberrant DNA methylation which is characteristic of the disease initiation and 
progression and affects many different pathways (Li et aI., 2005). To date, clinical trials of 
agents reverting genomic DNA methylation have obtained satisfying results only in 
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haematological malignancies. Actually, one such agent, decitabine, has undergone a phase 
II clinical trial for the treatment of hormone refractory metastatic prostate cancer, but 
serious side effects, including myelosuppression and the promotion of malignant 
transformation of genes, through induction of global DNA hypomethylation, have 
compromised its further development as a single agent. New approaches should consider 
the combination of methylation-modifying drugs with histone deacetylase (HDAC) 
inhibitors and conventional chemotherapeutic agents. To this purpose, GSTpi, whose 
epigenetic inactivation marks one of the earliest steps of carcinogenesis of the prostate, 
could represent a good target for reverting-therapies, in order to restore GSTpi-mediated 
detoxification processes and hence to attenuate genome-damaging stresses. 
1.5.2 GSTas a target/or anticancer therapies 
The first consideration when we think of GST as target for anticancer therapy is its 
overexpression in tumours, which supports the idea of a greater specificity of a possible 
treatment against tumour than normal cells. Considering the multiple roles of GST in cells, 
different approaches could target GST in its detoxifying activity, or in its modulatory role 
of the stress kinases or in its GSH binding activity. As I described earlier, increased GSTpi 
levels develop as a mechanism of resistance, especially after treatment with cytotoxic 
drugs that are GST substrates. Using a specific inhibitor of GST, the resistant phenotype 
should be reverted. For this purpose, the first inhibitor designed to lower GST levels in 
tumour cells was ethacrynic acid (EA), which acts as a non-competitive inhibitor of GSH 
for GST binding as well as depleting the GSH cofactor by forming an EA-GSH conjugate. 
Binding to both GSH and GST serves to inhibit enzyme activity. EA has been reported to 
potentiate the cytotoxic effects of chlorambucil and melphalan, but the lack of specificity 
against a .particular class of GST (EA inhibits GST Cl, 11, n) and its side effects (EA has 
diuretic properties) have reduced its therapeutic value (Townsend and Tew, 2003). 
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Another GST inhibitor, specific for class pi, is TLKI99. This drug has been demonstrated 
to improve the sensitivity of different tumour models to anticancer drugs (Townsend et aI., 
2005). However treatment with TLK 199 causes a myeloproliferative effect in mice and 
this could be explained as a consequence of the disruption of the interactions between GST 
and JNK: the increased levels of free JNK could lead to an increased cellular proliferation 
in the bone marrow. 
As regards the synthesis of prodrugs that can be activated, hopefully in a specific way, in 
the tumour cells, GST PI-l represents a promising target, because its expression is 
enhanced in many tumours that have a poor prognosis or are resistant to classic cytotoxic 
drugs. The lead compound of this class has been TLK286, which is cleaved in the cell into 
a GSH analogue and nitrogen mustard, that then alkylates cellular nucleophiles. Clinical 
trials of TLK286 have shown limited adverse side-effects but significant antitumour 
activity and/or disease stabilization in patients with various advanced malignancies that 
were usually resistant to platinum and irinotecan. This supports its further development in 
the late stages of clinical experimentation (Townsend and Tew, 2003; Townsend et aI., 
2005). 
New prodrugs have been designed in order to release NO after a GSTpi catalyzed reaction; 
they also induce apoptosis, after activation of p38, JNK and ERK proteins (McIlwain et aI., 
2006). 
Many tumours overexpress GSTpi and prostate cancer is thus unique in that it lacks the 
GSTpi detoxifying activity, which could make this tumour particularly susceptible to drugs 
that are inactivated by GSH binding. However, as I hinted above, treatment with these 
drugs has no significant clinical effect on hormone refractory PCa and this could open the 
path to new therapeutic strategies. 
The methylated GSTPI gene represents an early and well recognized marker of malignant 
transformation of the prostate. Thus its re-expression could be an advantage both for cell 
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protection against stress and for the possibility of using prodrugs, that are activated 
intracellularly by GSTpi. 
1.5.3 Molecules Reverting Epigenetic Modifications of DNA 
Gene silencing through epigenetic mechanisms represents a reversible biological 
modification, which can be targeted for treatment of human cancer (Issa, 2007). This is 
undoubtedly an advantage compared to gene inactivation through mutations or deletions 
and, in the last years, there has been an increasing interest in developing therapeutic 
strategies capable to reactivate epigenetically silenced genes. At the moment, targets of 
epigenetic therapies are DNA methylation and histone modification, in particular histone 
deacetylation, that, as I have described previously, means transcriptional silencing. 
The first specific inhibitors of DNA methylation were the nucleoside analogs 5-azacytidine 
(5-aza-CR) and its deoxy- derivative, 5-aza-2' -deoxycytidine (5-aza-dC); initially they 
were classified as differentiating agents rather than demethylating molecules. They are still 
extensively used and were recently approved by the Food and Drug Administration (FDA) 
for use in haematological malignancies. More recently, the use of anti sense 
oligonucleotids, directed against the DNMTI mRNA, was investigated, aimed to 
specifically inhibit DNMT and to avoid the toxic effects of nucleoside analogs. 
Some demethylating properties were serendipitously discovered for drugs already used for 
different purposes in clinic: among them, procainamide and procaine, respectively an anti-
arrhythmic drug and a local anaesthetic were shown to be able to revert promoter gene 
methylation. 
Epigenetic silencing is almost universally associated with histone deacetylation, which is 
catalyzed by at least three classes of HDACs in human cells. The HDACs are partly 
redundant in function and a growing series of small molecules has been designed to inhibit 
their activities either globally or more specifically. Because it has been demonstrated that 
DNA methyltransferases and histone deacetylases can interact each other, a variety of trials 
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are now combining HDAC and DNMT inhibitors, in order to reduce some of the side-
effects associated to DNA methylation inhibition, while still achieving an effective level of 
gene reactivation (Lyko and Brown, 2005). 
Treatment with "epigenetic" drugs may have consequences that are not only uniquely 
related to the reactivation of genes associated with tumour transformation, such as tumour 
suppressors. In fact the first epigenetic strategies were based on the simplified concept that 
reactivation of these genes would surely lead to tumour growth arrest. In this respect, the 
regulation (Le. demehylation) of the p 16 promoter provides an example of this approach; 
but this causal relationship has not been always demonstrated (Karpf and lones, 2002). 
An important consideration for strategies that seek to reactivate gene expression is the 
phenomenon of re-silencing: both nucleosides analogs and non nucleoside inhibitors do not 
block DNMTl synthesis, but trap it on DNA, thus implying that continuous and effective 
re-expression could be achieved only with prolonged treatment. 
In addition to gene expression changes that occur as a direct consequence of reversing 
promoter methylation status in a specific gene, indirect gene expression changes in other 
genes may also result. This can depend on the relationship existing among different 
proteins, especially if belonging to the same signal transduction pathway. An example is 
given by the activation of the interferon signal transduction after treatment of colon cancer 
with 5-aza-dC: the data demonstrated that interferon pathway genes are not each 
individually regulated by methylation. 
So therapeutic strategies should consider not only the re-activation of the target methylated 
genes, but also more general consequences on the pattern of gene expression, in order to 
understand the global effects obtained after treatment with these demethylating molecules. 
Examination of gene expression changes in a bladder cancer cell line compared to normal 
fibroblasts showed that approximately 60% of the genes induced by 5-aza-dC did not 
contain promoter CpG islands, thus supporting the notion that 5-aza-dC treatment regulates 
the expression of many genes indirectly. At the same time, not every promter-methylated 
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gene is re-activated after treatment with demethylating agents. Approaches aimed at 
evaluating the global genomic changes in methylation demonstrated that about 600 CpG 
islands (out of 45000 in the human genome) may be aberrantly methylated in individual 
human tumours and that 5-aza-dC treatment led to gene reactivation of about 40% of them. 
This could depend on different factors: first of all, a gene becomes re-expressed following 
promoter hypomethylation, only if the treated cells have transcription factors competent for 
the binding and activation of the unmethylated gene promoter. However it is also possible 
that the majority of genes are not activated by 5-aza-dC treatment because chromatin 
structural alterations are dominant over methylation for silencing (Karpf and lones, 2002). 
This supports the need to combine demethylating drugs with molecules reverting histone 
modifications. But the use of histone demethylase inhibitors in epigenetic therapy is not 
ideal, because the methyl groups on histones can result in either transcriptional activation 
or silencing, whereas histone deacetylation always means silencing. In the last few years, 
there has been much interest in the development of molecules targeting HDACs (Y 00 and 
Jones, 2006). 
The main problem of the demethylating therapy is its lack of specificity against a particular 
set of genes, which results in a global DNA hypomethylation, linked in turn to genomic 
instability, elevated rates of mutations and the activation of transposable elements. 
Moreover, the combination with HDAC inhibitors does not resolve this problem and the 
therapy still affects the global genome. Neverthless, because epimutations rarely appear in 
healthy tissues and because epigenetic drugs act on actively dividing cells, epigenetic 
therapies could more efficiently affect tumour cells rather than normal cells. This makes 
feasible the use of these drugs for anticancer therapy and opens a window for their 
combination with new or classic cytotoxic molecules, which could take advantage from the 
altered expression state of the genome, to exert their killing effects (Plimack et al., 2007). 
DNA methylation inhibitors fall into three classes: 
• nucleodides inhibitors, 
71 
• non nucleoside inhibitors, 
• rationally designed inhibitors. 
1.5.3.1 Nucleoside inhibitors 
The prototype molecule of this class is 
5-azacytidine (5-aza-CR, higher panel): 
it was discovered as cytodifferentiating agent by Jones et al. 
in the early 1980s (Jones and Taylor, 1980): in experimental 
conditions, 5-azacytidine allowed myogenic conversion of 
cultured mouse embryo cells, and this phenomenon was 
related to inhibition of methylation. This drug, together with 
its deoxy- analog, 5-aza-2' -deoxycytidine (5-aza-dC, lower 
panel), has a modified cytosine ring. They are incorporated 
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Before this step, they are metabolized by kinases that convert the nucleosides into 
nucleotides for incorporation into DNA and/or RNA (Momparler, 1985). In fact 
ribonucleotides, such as 5-aza-CR and zebularine (which I will describe later) are 
phosphorylated by uridine/cytidine kinase and other kinases to generate the corresponding 
mono-, di-, and triphosphates, which ultimately end up in RNA. The effects of their 
incorporation into RNA have not yet been well studied, although some data suggest that 
this results in ribosomal disassembly, defective tRNA function and inhibited protein 
production. If the ribonucleotide diphosphates are reduced by ribonucleotide reductase into 
a deoxy-diphosphates, they will be incorporated into DNA. 5-aza-dC is a more potent 
demethylating agent than 5-azaCR, because it is only incorporated into DNA. Normally, 
when a cytosine is methylated by DNMTs, the DNMTs flip out the eytosines from the 
double helix to form an intermediate complex in which S-adenosylmethionine (Ado-met: 
the methyl group donor) is incorporated. This allows methyl group transfer from Ado-Met 
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to the C5 of cytosine and the release of the enzyme in a p-elimination reaction. On the 
other hand, if a cytosine analog is incorporated into DNA a complex is formed but the 
nitrogen atom in the position 5 of the ring prevents the release of the enzyme and results in 
the formation of a covalent complex. Thus DNMTs no longer methylate DNA, and 
subsequent DNA replication cycles will lead to a progressive demethylation (Figure 
l.5.3.1). 
As I described in the first chapter of this introduction, DNMTl interacts with a number of 
proteins linking the enzyme to the nuclear matrix and targeting it to replication foci and 
repair sites. In addition, it contains sites for binding of HDACs and other proteins involved 
in transcriptional repression. 5-azaCR and 5-aza-dC can cause conformational changes in 
DNMTl, thus altering its interaction with other proteins; in particular, this could result in 
the inhibition of methylation and dissociation of HDACs, leading to rapid remodelling of 
chromatin and restoration of gene expression. 
The mechanism of action of cytidine analogs has been studied for DNMTl. There have 
been no reports describing effects on the catalytic activity ofDNMT3a or 3b, but given the 
conservation of the mechanism of cytosine DNA methylation, we could suppose that they 
are similar to DNMTl, which is the most abundant DNA methyltransferase in cancer cells 
(Christman, 2002). 
5-azaCR and 5-aza-dC are highly toxic in cultured cells and animals. Indeed, the first 
therapeutic application of 5-azaCR was cytotoxic in the treatment of myelodisplastic 
syndromes and acute myeloid leukaemia. It is very difficult to distinguish whether the 
consequences of the treatment depend on the re-expression of particular genes, such as 
tumour suppressors, or on particular defects occurring in DNA, that set in motion the 
complex machinary of cellular responses to DNA damage. Studies performed on mutant 
cell lines expressing lower levels of DNMTI demonstrated that these cells were 
substantially more resistant to the toxic effects of the demethylating drug 5-aza-dC than the 
heterozygous or wild type cells with normal DNA methylation levels. This could be 
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explained by the covalent binding of the enzyme to DNA, rather than the DNA 
methylation, being the key mediator of the drug induced cytotoxicity (Juttermann et aI. , 
1994). 
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Figure 1.5.3.1 Kinetic of DNA demethylation induced by 5-aza-dC 
From (lssa, 2007), modified 
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5-aza-dC has been shown to be very effective in inducing apoptosis in p53-null cells in a 
dose-related way. The relationship with the p53 deficiency is very high, but, if we consider 
its demethylating properties rather than the apoptotic ones, these are not dependent on p53 
status. 
Very importantly, 5-aza-dC is able to induce a significant demethylation at concentrations 
that do not to induce apoptosis. 
The explanation of the above data is probably the fact that treatment with 5-aza-dC leads to 
the formation of covalent protein-DNA adducts with the DNMTs. As a result, cells are 
subjected to a severe DNA damage, which, in p53 proficient cells triggers a p53-dependent 
G21M checkpoint, preventing further proliferation of the damaged cells. In the case ofp53-
deficient cells, two factors aggravate the consequences of the DNA damage induced by 5-
aza-dC: on one hand, p53 deficient cells are known to be ineffective in various aspects of 
DNA repair; on the other hand, they fail to execute the G21M checkpoint, so they are 
subjected to multiple levels of genomic damage and, by failing to arrest their proliferation, 
enter into a mitotic catastrophe (Nieto et aI., 2004). 
5-aza-dC has been shown to be highly mutagenic, and these mutations mainly occur at the 
CpG dinucleotides; when 5-aza-dC-DNMT adducts form on DNA, the cytidine ring could 
open through the disruption of the N l-C6 bond and the subsequent hydrolysis, leading to 
the inactivation of the enzyme and to dangerous breaks on DNA. The opened rmg 
represents a pre-mutagenic lesion that can induce C:G-+G:C transversions, but also 
C:G-+T:A transitions and C:G-+A:T transversions (Jackson-Grusby et aI., 1997). 
In order to overcome the toxicity related to the covalent complexes of DNMT/5-aza-dC on 
DNA, new schedules of treatment have been adopted, by which the demethylating 
properties could prevail over toxicity. To this aim, in vitro experiments have shown that 
optimal methylation inhibition occurred at low doses (Nieto et al., 2004). These data have 
been further confirmed by clinical trials, showing that low-dose exposures leads to greater 
responses, also in terms of DNA methylation, and are associated with less toxicity 
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(Appleton et aI. , 2007; Issa et aI., 2004). This is a very important concept, because this 
therapeutic approach is more feasible for combination schedule of treatment, above all in 
solid tumours, where the demethylating drugs alone do not seem to be successful to date. 
However, combination therapy also allows overcoming another limit of the cytidine analog 
treatment, that is the rapid DNA re-methylation within few days after stopping 
demethylating drug administration. 
The two DNA methyltransferase inhibitors, azacytidine and decitabine represent the most 
active agents for the treatment of myelodysplastic syndrome (MDS) patients. The therapy 
induces complete responses, lasting months to years in some patients, even though 
resistance seems to develop in the majority of them with an unknown mechanism (Goffin 
and Eisenhauer, 2002). These drugs have recently obtained the FDA approval in this kind 
of disease. 
Among the other azacytidine derivatives, we have to consider the dihydro-5-azacytidine 
(DHAC) and the 5-F-CdR. DHAC is hydrolytically more stable and less cytotoxic than 5-
aza-CR and it has been shown to inhibit methylation in human lymphoid and leukaemia 
cell lines, as well as in tumour bearing mice. 
5-F-CdR has a complicated metabolic activity in mammalian cells and this could prevent 
its further development in clinical trials. 
1.5.3.2 Zebularine 
A disadvantage of the azanucleosides is their instability in aqueous solutions, which could 
complicate their use in the clinical setting. Zebularine is 
cytidine analogue containing a 2-(lH) -pyrimidinone ring 
(Driscoll et al., 1991) that was originally developed as a 
cytidine deaminase inhibitor because it lacks an amino group 
at position 4 of the pyrimidine ring. 
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In addition, unlike azanucleosides, zebularine is stable in aqueous solution up to a pH of 
12. It retains similarities to mechanism of DNMT inhibition of 5-aza-dC (see above), but 
its chemical characteristics result in differences in potency as a demethylating agent. When 
zebularine is inserted into DNA as cytidine analog, it becomes the target for DMNTI 
enzymatic activity: during methylation reaction, the targeted zebularine is rotated out of 
the helix into the catalytic pocket of the enzyme, (while the dG on the complementary 
strand remains stacked within the DNA helix), and it determines the covalent attachment of 
the enzyme to DNA, which will be in turn depleted from the cellular pool and preventing 
its methylating activity. 
The main chemical difference with 5-aza-dC, besides the loss of -NH2 in position 4, is that 
zebularine lacks nitrogen in position 5, so why is the bond with DNMT permanent? And 
why does ~ elimination not occur? The reason is that the C5 of zebularine is not active, 
because the C6 chemistry resembles that of a cytidine deaminase inhibitor, rather than that 
of a DNMT inhibitor; therefore reaction with Ado Met does not take place (Zhou et aI., 
2002). Before being incorporated into DNA (at the GCGC target site), zebularine needs to 
be first phosphorylated and then converted to a deoxynuc1eotide: this represents the rate-
limiting step of the reaction. However its ribose moiety determines its incorporation into 
RNA as well as into DNA. This characteristic, together with its peCUliarity as cytidine 
deaminase inhibitor, probably lowers the effective availability of zebularine as a 
demethylating agent. Unfortunately a more direct route as deoxyribonucleotide is not 
currently available, since 2' -deoxyzebularine is not active, probably because it is not 
phosphorylated (Marquez et aI., 2005; Ben Kasus et aI., 2005). Neverthless zebularine is 
able to induce and to substain DNA demethylation over time. 
The first studies showing the demethylating properties of zebularine resembled those of 5-
aza-CR in the early 1980s by Jones et aI., that is, the capability of zebularine to induce 
muscle cell formation in 10T1I2 cells (mouse embryonic cell line). The muscle phenotype 
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has been reported to be induced by inhibitors of cytosine methylation, suggesting that 
zebularine inhibits DNA methylation in these cells. 
Undoubtedly one of the most valuable characteristic of zebularine is its stability in both 
acid and neutral solutions. This allows its administration via the oral route and, together 
with minimal in vivo toxicity, this makes it a promising clinical candidate for reversing 
DNA methylation and to be used as drug for cancer chemotherapy, chemoprevention and, 
in general, epigenetic therapy. 
Demethylating properties of zebularine have been further appreciated because it has also 
been shown to be more specific for cancer cells thus reducing toxic effects in normal cells. 
This advantageous effect seems to depend on differential metabolism between cancer and 
normal cells, mainly related to lower levels of the uridine/cytidine kinase in normal cells 
compared to cancer cells. This could account for a decreased zebularine incorporation into 
both RNA and DNA of normal fibroblasts (Cheng et aI., 2004b). However, cancer cells 
exhibited a greater growth inhibition, probably as a direct result of the incorporation of the 
drug into DNA. At this purpose zebularine, at the concentrations inducing DNA 
demethylation, results to be effective in inducing apoptosis in p53-deficient cells (usually 
tumour cells), even though this effect is not as marked as in the case of 5-aza-dC (it is 
roughly 50% of that of 5-aza-dC). The demethylating properties of zebularine are further 
supported by the depletion of DNMT enzymes following treatment: cancer cells show a 
complete depletion of DNMTl and partial depletion of DNMT3a and DNMT3b2/3. This 
apparent specificity of the 2-(lH)-pyrimidinone ring for DNMTl is unexpected, since all 
known DNMTs appear to utilize the same mechanism of action. Perhaps zebularine 
exhibits a greater enzymatic binding affinity for DNMTl than for other DNMTs (Cheng et 
aI., 2004a); among them, DNMT3b has per se a reduced catalytic activity, while DNMT3a 
is expressed throughout the cell cycle, as opposed to DNMTl and DNMT3b, which are 
cell cycle regulated. The depletion of DNMT3a can therefore only occur during the S 
phase, in which the 2-(lH)-pyrimidinone ring is incorporated into DNA. Following oral 
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administration, zebularine has been shown to reactivate the methylated p 16 gene and to 
elicit tumour suppression of human T24 bladder cancer cells in mouse xenografts, without 
significant toxicity (Cheng et aI., 2003). 
Another appreciable characteristic of zebularine is its activity as a cytidine deaminase 
inhibitor. Cytidine deaminase is a key enzyme in the catabolism of 5-aza-dC, which is 
converted to 5-aza-2'deoxyuridine, a completely inactive product. This represents a 
potential obstacle for curative therapy with 5-aza-dC, mainly because of the very high 
levels of cytidine deaminase in human liver and spleen. Moreover, resistance to 5-aza-dC 
can be mediated by increased levels of cytidine deaminase in tumours. In contrast, 
zebularine is not degraded by this enzyme, even though it is characterized by a longer 
metabolic process before being inserted into DNA. 
All these factors support firstly the practicability of zebularine as demethylating agent in 
vivo and then the possible use of a combination of zebularine with 5-aza-dC. Actually this 
kind of approach has just been tested in the murine leukaemia cell line L1210, where it 
produced a greater inhibition than either of the two agents administrated alone (Lemaire et 
al.,2005). 
1.5.3.3 Non nucleoside analog inhibitors o/methylation 
The limitations of the cytidine analogs, mainly related to toxicity both in vitro and in vivo, 
have prompted investigators to explore new strategies that could revert aberrant 
methylation in cancer cells. Actually, the data obtained up to now by testing non-
nucleoside analogs as DNA methylation inhibitors, are still controversial and the re-
activation of epigenetically silenced genes likely depends on the particular locus and the 
cell line being considered. 
Procainamide was approved by FDA as a specific agent for the treatment of cardiac 
arrhythmias and only later were its demethylating properties discovered (Lin et aI., 2001 a; 
Segura-Pacheco et aI., 2003). Procainamide is able to bind CG-rich DNA sequences and 
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this has supported the idea that it might be a demethylating agent. However it has also been 
shown to specifically target DNMTl. In fact procainamide failed to reduce genomic m5dC 
content in HCT116 colon cancer cells where DNMTI was genetically deleted, but it 
significantly reduced global methylation in parental HCT cells and HCT cells with no 
expression of DNMT3b. This demonstrated that de novo methyltransferases were indeed 
not sensitive to procainamide inhibition. During methylation of the hemimethylated strands 
of the DNA, procainamide acts by reducing the affinity of DNMTl for both DNA and 
AdoMet (methyl donor) and, as a consequence, the DNMT I processive mechanism of 
action is compromised. However procainamide is a partial inhibitor of DNMTI and the 
velocity of the reaction does not reach zero even at very high concentrations (Lee et aI., 
2005). 
Procainamide has a good safety profile with none of the major disadvantages of nucleoside 
analogs, and although only a few genes and cell lines have been analyzed, it seems to 
reactivate genes silenced by methylation. 
Procaine (PCA) is a drug approved by the FDA for use as a local anesthetic. Its ability to 
bind CpG-rich DNA has suggested that it could also be a demethylating agent. This has 
been supported by experimental data, showing a global genomic methylation decrease after 
treatment of the MCF-7 breast cancer cell line with increasing concentration of PCA and 
the demethylation and re-expression of a CpG island associated gene (RAR ~2) (Villar-
Garea et aI., 2003). PCA increased the antitumour activity of several conventional 
anticancer drugs, such as cisplatin, mitomycin C, doxorubicin, but how this property could 
be related to the hypomethylation is a matter of debate and, up to now, no relationship 
between the re-expression of a particular gene by PCA and sensitization to chemotherapy 
has been demonstrated. 
Other strategies to revert aberrant methylation in cancer have been tested, but they still are 
at preclinical level of evaluation. Among them is methioninase, which depletes methionine 
(the methyl donor in methylation reaction) (Machover et aI., 2002) and (-)-
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epigallocatachin-3-gallate (EGCG, green tea extract), whose demethylating properties were 
demonstrated in a human esophageal cancer cell line, where it reverted silencing of p 16, 
RAR~, MGMT and hMLHl genes. A suggestion of its possible involvement in 
demethylation comes from molecular modelling studies showing that EGCG is well 
accommodated in a hydrophilic pocket ofDNMTl (Fang et aI., 2003). 
Other examples of demethylating agents include arsenic and phenethyl isothiocyanate: the 
latter, in particular, has been used to reactivate GSTPl expression. The lack of further 
preclinical and clinical development does not corroborate, at the moment, the potential of 
these drugs as clinical demethylating molecules (Wang et aI., 2007). 
To overcome the limits of the classic molecules used until now, rational design studies of 
the target to be silenced have helped the synthesis of new molecules, which, hopefully, 
could have activity both in vitro and in vivo. 
RG 108 is the first DNMT inhibitor produced by a rational drug design: it was selected for 
its ability to block the active site of the human DNMTl enzyme in an in silico model. 
Experiments performed in vitro confirmed that RG 1 08 was able to reactivate several 
epigenetically silenced tumour suppressor genes. At the same time, the compound did not 
seem to alter the methylation status of centromeric repeats and this implies that RG 108 
treatment should not affect chromosome stability (Brueckner et aI., 2005). 
SIlO, a 5'-aza-pG-3-dinucleotide contains 5-aza-dC and operates via similar mechanism of 
action to the parent compound to inhibit DNA methylation, induce expression of the p 16 
tumour suppressor gene and inhibit tumour cell growth, but it is resistant to deamination by 
cytidine deaminase, which rapidly depleted the plasma levels of 5-aza-CdR (Y 00 et aI., 
2007). 
In summary, the data available until now suggest that, despite their considerable 
cytotoxicity, azanucleoside inhibitors show the strongest demethylation effects (Chuang et 
aI., 2005). The epigenetic changes induced by non-nucleoside inhibitors seem to be more 
controversial and their action could be gene-specific or cell line-specific; however the 
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concentrations used in experimental conditions showing demethylation were very high and 
this could make their application in clinical trials very difficult (Stresemann et aI., 2006). 
1.5.3.4 HDAC inhibitors 
Among the modifications affecting histone proteins, acetylationJdeacetylation is the most 
feasible target for an epigenetic therapy in cancer cells, because histone acetylation is only 
related to transcriptional activation and deacetylation is only related to transcriptional 
silencing. As a consequence, treatment with molecules that specifically inhibit histone 
deacetylation could lead to re-expression of genes that are important in tumour 
suppression. 
In the last few years, many molecules with this specific target have been synthesized and 
tested in different cellular systems, in preclinical studies and in phase IIII of clinical trials, 
even though many concepts need to be clarified about their mechanism of action. 
Although histone deacetylation has a general and fundamental role in regulating gene 
expression, HDACi seem to directly affect transcription of only a relative small number of 
genes. Recent analysis using microarrays estimate that about 10% of genes are affected by 
this kind of treatment. The reason why this happens is not clear, but we have to consider 
that histone tails are targets of many other covalent modifications that can also affect gene 
expression. In particular, histone methylation, which proceeds after deacetylation of 
histone tails, can induce heterochromatin and euchromatin gene silencing. In these 
instances, addition of HDACi would not be sufficient to reactivate the silenced genes. 
A relatively wide range of compounds have been identified that are able to inhibit the 
activity of class 1, class 2 and class 4 HDACs. They derive from both natural sources 
(depsipeptide, apicidin, trichostatin A, sodium butyrate) and from synthetic routes (for 
example, hydroxamic acid derivatives). Crystallographic studies using trichostatin A 
(TSA) and suberoylanilide hydroxamic acid (SAHA) indicate that these compounds inhibit 
HDAC activity by interacting with their catalytic site, thereby blocking substrate access. 
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These inhibitors target, with more or less the same efficiency, every class of HDACs. Only 
a few molecules are emerging as preferential inhibitors of class 1 versus class 2 HDACs, 
and even fewer (that is tubacin for HDAC 6) are able to discriminate efficiently among 
HDACs that belong to the same class. If we consider HDACi as molecules inducing gene 
expression, different HDACi activate a common set of genes, and this indicates that that 
certain loci are more susceptible to these compounds than others. 
HDACi show specificity for tumour cells rather than normal cells, and this makes them, 
despite their quite unknown effects on cellular pathways, appropriate molecules for clinical 
development. 
The research developed until now on these molecules have highlighted that their efficiency 
is rarely associated to the re-expression of a particular gene, such as tumour suppressors in 
cancer; their anticancer potential stems from their ability to affect several cellular 
processes that are deregulated in neoplastic cells: cell-cycle arrest, differentiation, 
apoptosis and, in addition, activation of host immune response and inhibition of 
angiogenesis. So HDACi could also work through non-transcriptional mechanisms, and, as 
a consequence, they might be considered as partial epigenetic drugs. In leukemias, HDACi 
have demonstrated differentiating properties, inhibiting cell cycle and blocking 
proliferations of cancer cells. It also been shown that HDACi-induced growth arrest is 
tightly linked to the induction of the cdk inhibitor p21, and in some cases this arrest seems 
to be irreversible and to resemble the phenomenon of replicative senescence (Minucci and 
Pelicci, 2006). 
HDACi are also involved in apoptosis, by the upregulation of the pro-apoptotic BCL2 
family members and the downregulation of the anti-apoptotic proteins of the same family; 
this is associated with the subsequent activation of the caspases. 
As regard the use of HDACi in cancer therapy, they have shown encouraging results in 
preclinical models, not only in leukemias, but also in solid tumours. Specifically, butyrates 
inhibited the growth of colon, prostate, endometrial and cervical carcinomas; valproic acid 
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(already used for epilepsies) delays the growth of primary breast cancer and inhibits the 
size and number of metastasis found in the lung. 
In general, SAHA, CBHA and TSA markedly suppressed the growth of a range of solid 
tumours xenografts, and inhibited the progression of spontaneous tumours that were 
induced with carcinogens. Their therapeutic effect is usually reached at very high dosage 
(range of concentrations is millimolar); however they exhibit a short half life and are able 
to overcome the multidrug resistance that is mediated by overexpression of P-glycoprotein. 
Phase IIII of clinical trials have begun, with HDACi administrated both as single agents 
and in combination. Generally they have shown low toxicity, which might be at least in 
part the result of the non-specific side-effects of each individual HDACi, rather than the 
consequences of inhibiting HDAC per se (Johnstone, 2002). 
If we strictly consider HDACi as molecules reverting epigenetic modification of the 
chromatin, the most logical therapeutic consequence is to combine them with 
demethylating agents, because methylation and histone deacetylation contribute each other 
to set of a closed conformation of the chromatin. Functional synergy between DNA 
methylation and histone deacetylation has been shown experimentally using 5-aza-dC and 
rSA. rSA alone had no effect on transcription of epigenetically silenced genes and 5-aza-
dC alone weakly induced transcription. However, the combination of both 5-aza-dC and 
rSA resulted in a robust induction of gene expression, which indicates that, although DNA 
methylation and histone deacetylation act in synergy to silence genes, DNA methylation is 
the dominant mechanism in silencing (Cameron et al., 1999). 
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1.5.4 BROSTALLICIN 
Brostallicin (PNU 166196) is a synthetic a-bromoacrylic derivative of distamicin A, 
belonging to the DNA Minor Groove Binder (MGB) class of anticancer drugs. Like 
distamycin A, it is characterized by a four-unit pyrrol carbamoyl backbone (fig.l.5.4,A), 
which enables brostallicin to bind to AT regions present in the minor groove of the DNA 
One of the main derivatives of dystamicin A with anticancer properties has been 
tallimustine, whose excellent antitumour activity in preclinical studies was compromised 
by severe myelotoxicity in clinical trials, preventing the administration of potentially 
therapeutic doses (D'Incalci and Sessa, 1997). While taIlimustine is a nitrogen mustard 
derivative, brostallicin belongs to the a-halogenoacrylic derivatives of dystamicin A, in 
which the halogen-group is represented by bromo. Among these different halogen 
containing molecules synthesized, a-bromo and a-chloroacrylamido-derivatives showed a 
significant cytotoxicity, while the a-fluoroacrylamido and acrylamido derivatives were 
inactive. 
Among the bromo acrylic MGBs, PNU 151807 (fig. 1.5 .4,A) was initially considered 
because of its in vitro cytotoxicity and in vivo antitumour activity significantly higher than 
that of tallimustine. PNU -151807 was able to non-covalently bind TA rich-regions in the 
minor groove of DNA, but was unable to alkylate DNA in classical in vitro assays 
(Broggini et aI., 2004). Its a-bromoacrylic moiety seems to interfere with cell cycle 
progression by so far unknown mechanism. 
Brostallicin per se did not produce any alkylation in any of the selected DNA interacting 
regions; this capability was acquired only in the presence of cellular thiols (particularly 
GSH), whose intracellular concentration is in the millimolar range. These chemical species 
allow brostallicin to perform a first-step Michael-type attack, followed by a further 
reaction leading to a second nucleophilic substitution, resulting in turn in alkylation of 
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Figure 1.5.4 Brostallicin structure and reaction 
(A) Chemical structures of PNU 151807 and brostallicin. The a-bromoacrylic group (blue) and the four-unit 
carbamoyl backbone (red) are highlighted on brostallicin formula. 
(B) Role of the GSHlGST system in the interaction between DNA and the a-bromoacrylic derivatives 
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for the antitumour activity of brostallicin was demonstrated by experimental data showing 
that brostallicin had an increased activity against melphalan-resistant L1210 cells 
(L121O/L-PAM), which are characterized by high levels of glutathione, compared to wild 
type L1210 cells (Broggini et aI., 2004). 
As I described previously high levels of the GSH/GST system restricts the cytotoxicity of a 
substantial number of anticancer agents and, as a consequence, it usually represents a 
mechanism of resistance. In marked contrast to this, in the presence of GSH/GST, 
brostallicin is able to bind covalently to AT -rich regions in DNA, and with a sequence 
specificity that is different to that of its precursor, tallimustine. 
1.5.4.1 In vitro and in vivo brostallicin antitumour activity 
In vitro and in vivo studies strengthen the concept that the antitumour activity of 
brostallicin is increased in tumours with high GSHlGST levels. Among the different GST 
classes, GSTn and GSTJl are more effective than the a-class in catalysing the reaction 
between brostallicin and GSH. This might be important clinically, because GSTn is the 
most prevalent GST class expressed in tumours, and brostallicin could exert its antitumour 
activity if those tumours become resistant to other drugs by its upregulation. 
When human GSTn cDNA was transfected into the human ovarian cancer cell line A2780, 
a 2- to 3- fold increase in the intracellular GSTn levels resulted in a 2- to 3- fold increase in 
the cytotoxic activity of brostallicin. These results were further confirmed in the human 
breast carcinoma cell line, MeF-7, transfected with GSTn: here brostallicin showed a 5.8 
fold increase in cytotoxicity in the transfected cells versus control cells (Geroni et aI., 
2002). 
The in vitro data were further supported by in vivo experimentation using A2780 control 
(wild type, wt) and transfected (A2780/GST) cells transplanted into immunodeficient mice. 
The antitumour activity of brostallicin was clearly increased in tumours overexpressing 
GSTn. In contrast no changes in cisplatin efficacy were observed. This increased tumour 
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antitumour activity of brostallicin was not associated with an increased toxicity in mice 
(Geroni et aI., 2002). 
Another appreciable characteristic of brostallicin is the maintenance of its cytotoxicity in 
cells with defects in DNA mismatch repair system (MMR) (Fedier et aI., 2003). MMR 
proteins recognize mismatched base pairs in the DNA, arisen either spontaneously during 
metabolism or from modified nucleotides provoked by physical and chemical agents, and 
are thought to link DNA damage recognition to an apoptotic pathway, thereby preventing 
mutagenesis, tumourigenesis and tumour progression. Tumours resulting from MMR-
deficiency include the hereditary non polyposis colon cancer and some sporadic 
carcinomas such as mammary, ovarian or endometrial cancer. However loss of MMR 
results in resistance to a variety of widely used anticancer drugs, including the 
topoisomerase I poisons camptothecin and topotecan, the topoisomerase II poisons 
doxorubicin, epirubicin, mitoxantrone and etoposide and some platinum compounds such 
as cisplatin and carboplatin. 
Among the MGB agents, MMR status can affect the antitumour activity of tallimustine, 
but, interestingly, this is not the case for brostallicin. Probably the covalent reaction 
product of brostallicin with DNA is not a substrate for MMR, whereas tallimustine-
alkylated DNA by is recognized by MMR (Fedier et al., 2003). 
In this scenario, brostallicin might be a good candidate for treatment of those tumours 
showing resistance to cisplatin either through deficiencies in MMR or increased levels of 
the GSHlGST system, or, indeed, both. 
1.5.4.2 Brostallicin Combinations 
The above characteristics make brostallicin a good candidate for combination therapy with 
different anticancer agents that can influence the intracellular GSH/GST levels. The 
combined use of anticancer agents is a common strategy in clinical chemotherapy, 
especially in metastatic cancer (Ten Tije et aI., 2003; Leahy et aI., 2007); thus a good 
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rationale for combinations represents a favourable mark for the development of new 
molecules. 
The demonstration that GST1t enzymatic activity increases in tumour cells in response to 
cDDP, DX and CPT-ll treatment, prompted investigators to explore the in vivo 
combination of cDDP and brostallicin. The results supported the starting hypothesis, 
because cDDP administrated before brostallicin clearly had a synergistic antitumour 
activity, compared to the opposite schedule (brostaIlicin before cDDP), in which no 
increased antitumour activity of brostallicin was demonstrated. These results have been 
confirmed using other combinations, including, besides brostallicin, DX, CPT -11, and 
taxotere, but again only when these drugs preceed brostallicin. Interestingly from a 
therapeutic point of view, the increased antitumour activity was not associated with an 
increased toxicity, especially because the use of a well designed drug combination allows 
lowering the concentrations of the single agents involved (Sabatino et aI., 2003). 
An additional attractive therapeutic application is presented by tumours with low GST 
levels due to hypermethylation of the GST gene promoter. This is particularly relevant for 
prostate carcinoma, were more than 90% of tumours are characterized by this epigenetic 
modification, responsible, for GST expression silencing. 
The combination of brostallicin with agents able to revert hypermethylation and allow the 
re-expression of GST1t gene could therefore result in a tumour-selective synergistic 
activity. 
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1.6 PERSPECTIVES ON THE COMBINATIONS OF 
DEMETHYLATING MOLECULES WITH CYTOTOXIC DRUGS 
Tumour treatment with demethylating agents is becoming more and more appreciable as 
new genes are being discovered to be silenced in an "epigenetic way". For this reason the 
search for molecules able to inhibit the mechanism of the epigenetic silencing has been 
strengthened in the last years, but, at the moment, the results obtained with the non 
nucleoside analogs or with rationally designed inhibitors are not as strong as those 
obtained with the "oldest" demethylating nucleoside analog 5-aza-dC. Zebularine has 
demonstrated to be a promising candidate in this kind of therapy and we need to more 
deeply study its demethylating effects on a broader spectrum of genes. What is clear is that 
drugs targeting methylation are more effective on blood tumours than in solid ones. In fact 
data obtained by administrating demethylating agents on solid tumours (actually very few 
if compared to studies on blood) demonstrated not a univoque outcome, especially when 
they are administrated as single drug. Moreover there is an increasing interest in the 
treatment of these tumours with combinations of epigenetic drugs and the classic 
cytotoxics, which are currently used in chemotherapy. The rationale for these combinations 
is further corroborated by the knowledge that tumours might epigenetically silence specific 
genes as mechanism of resistance to therapy, as it has been well demonstrated for 
hMLH Un ovarian cancers after treatment with cisplatin. As a consequence, treatment with 
molecules reverting (hopefully: we have to remember that there is no specificity for a 
particular gene) the silenced target could re-sensitize tumours to chemotherapy; in fact, in 
vivo studies, showed that combination of 5-aza-dC with cisplatin, carboplatin and 
temozolomide on A2780 with methylated hMLHl (A2780/cp70) resulted in an increased 
antitumour activity compared to the drugs administrated alone, because of the re-
expression of hMLHl after treatment with 5-aza-dC (Plumb et aI., 2000). New studies are 
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exploring the feasibility of zebularine in these combinations, because treatment with 5-aza-
de often determines hematologic toxicity (Balch et aI., 2005). 
I have described before that therapy with demethylating agents could allow the re-
expression of genes, which have become methylated during the process of tumour 
transformation, thus resulting in growth inhibition. This has been demonstrated for tumour 
suppressors, like p16 in bladder cancer, whose re-expression determined the growth 
inhibition of tumours in vivo. 
But it is remarkable that methylation affects not only tumour suppressors, but also other 
genes, whose proteins could have an important role in the treatment regiments, like GSTPl 
in prostate cancers. 
Thus the characterization of the epigenome of each kind of tumour could help to more 





The mechanism of action of the minor groove binder brostallicin has been extensively 
studied in our laboratory for many years. Previously I have demonstrated that this new 
anticancer drug can be successfully used in combination with cytotoxic drugs that are able 
to induce the overexpression of the GSTpi enzyme as a mechanism of resistance (Sabatino 
et aI., 2003). In order to widen the spectrum of brostallicin activity, new combination 
strategies have been considered and in this thesis I explore the combination with epigenetic 
therapies, specifically, demethylating agents. Previous studies that have focused on the 
epigenetic modifications of human cancer have shown that prostate cancer is characterized 
by an extensive methylation of the GSTPI promoter. 
For this reason the overall aim of this study has been to combine a demethylating drug with 
brostallicin in a cellular model of prostate cancer (LNCaP cells) which has methylated 
GSTPI, in order to widen the antitumour activity of this new anticancer drug to a tumour 
model with an epigetically silenced GSTpi enzyme. 
This general objective was pursued through the following steps: 
I. firstly, I have verified that LNCaP cells can be sensitized to brostallicin, by 
transfecting them with a GSTPI expressing plasmid construct; 
2. I have assessed several demethylating drug for their ability to increase the 
cytotoxic activity of brostallicin in LNCaP cells through in vitro combinations; 
this step has allowed me to test several schedules of combinations with different 
molecules known to be able to revert DNA methylation; 
3. I have translated the most suitable combination found in vitro to an in vivo system, 
in particular to a xenograft model; 
4. I have analyzed GSTPI expression and GSTPI promoter methylation after 
treatment with the selected demethylating agent; 
5. I have analyzed other genes that might be affected by the demethylating agent 
treatment, due the possible non-specific action of the drugs reverting 
epigenetically silenced genes. 
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These strategies are in line with new therapeutic approaches now in the clinical phases of 
development, especially for solid tumours. 
In the last part of my project, I have evaluated the effects of decitabine on MAGEIA 
methylation levels in normal and tumour samples of patients recruited into a phase I 
clinical trial. The specific aim of this part of the project was to verify that indeed, in the 
clinical setting, demethylating agents can significantly re-induce the expression of silenced 
genes in solid tumours. 
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3. MATERIALS AND METHODS 
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3.1 CELL CULTURE 
Cell culture procedures were carried out aseptically in class II humidified laminar flow 
hoods. Cells were maintained in a Heraeus Auto-Zero C02 incubator at 37°C with 5% C02 
in air and tested for mycoplasma contamination once a month by PCR (Forward primer: 
5' -TGCACCATCTGTCACTCTGTTAACCTC; Reverse primer: 5' -ACTCCT ACGGGAG 
GCAGCAGTA). 
The human cancer cell lines used in my investigations were: the human prostatic cancer 
cell lines LNCaP and Du145 and the human breast cancer cell line, MCF-7. 
LNCaP, Du145 and MCF-7wt cells were obtained from the American Type Culture 
Collection (ATCC, Rockville, MD, USA); MCF-7/neo and the sublines over-expressing 
GST isoforms, MCF-7/GST7t, MCF-7/GSTa, MCF-7/GST).!, were kindly supplied by Dr. 
Jeffrey A. Moscow (Moscow et aI., 1989). 
3.1.1 Culture Conditions 
The LNCaP and Du145 cell lines were maintained in Roswell Park Memorial Institute 
(RPMI)-1640 medium supplemented with 10% fetal calf serum (FCS, Sigma; for Du 145 
cell culture, FCS was previously inactivated at 56°C for 30 minutes ') and 2mM L-
glutamine (BioWhittaker). The LNCaP/GSTpi subline was grown in the same conditions 
with the medium supplemented with G418 500).!glml (Invitrogen (Milan,ltaly): lOOX stock 
solution, 80mglml, in 100mM Hepes pH 7.4 is stored at -20°C until use). The MCF -7 cell 
line was maintained in Dulbecco's Modified Eagle's Medium (D-MEM) supplemented 
with 10% FCS and 2mM L-glutamine and the MCF-7 sublines, over-expressing the 
different GST isoforms, were grown in D-MEM medium, supplemented with 10% FCS, 
2mM L-glutamine and G418 antibiotic, as reported (Moscow et aI., 1989). Media were 
purchased from Sigma and contained supplements necessary for the growth of the cells 
except for the serum (stored at 4°C as 50ml aliquots, when thawed), which was added 
when the media were prepared before use. 
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Cells were passaged twice a week before they reached confluence, to maintain a 
logarithmic growth. The cells were replaced with fresh liquid nitrogen stocks after every 
four to five months of culture. Procedures to detach and subculture were the same for all 
the cell lines used and consisted of two washes with warm sterile phosphate buffer saline 
(PBS, Sigma) and detachment with a ready-to-use solution of trypsin! 
ethylenediaminetetralcetic acid (trypsin!EDTA, Sigma). The trypsin activity was stopped 
by adding FCS-containing medium. 
After centrifugation at 1200rpm for 10 minutes at room temperature, cells were 
resuspended in the appropriate medium, counted (Coulter Counter, ZM) and seeded at the 
required density (LNCaP cells: 10xl04 cells/ml; Dul45 and MCF-7 cells: 5x104 cells/ml). 
3.1.2 Long term storage of cells 
To generate and maintain batches of cells, exponentially growing cells were washed twice 
with PBS, harvested by trypsinization and centrifuged at 1200 rpm for 10 minutes at room 
temperature. The cell pellet was re suspended in culture medium containing 50% v/v of 
cryoprotective agent (Bio-Whittaker, Milan-Italy) and 20% FCS to a density of 5xl06 
cells/ml. Aliquots of Iml of the cell suspension were kept on ice for 30 minutes, cooled 
slowly for 3 hours in liquid nitrogen vapour and then immersed in liquid nitrogen. Cells 
were recovered from the cell bank by rapid thawing to 37°C in a water ba~h, centrifuged at 
1200 rpm for 10 minutes at room temperature, resuspended in 5ml culture medium and 
transferred to a T-25 tissue culture flask; one day later, the medium was removed and new, 
fresh medium was added. 
3.1.3 Cell transfection and clone selection 
To obtain LNCaP cells over-expressing GSTpi protein, LNCaP cells were transfected with 
GSTPlIpcDNA3 plasmid construct, which was kindly provided by Dr. Sergio Marchini 
(Department of Oncology, Mario Negri Institute), using aseptic conditions. 
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JMI09 bacterial cells (stored at -SO°C) containing the construct were scraped from the 2ml 
Nalgene tube and suspended in 10ml LB medium (1 %w/v bacto-tryptone, Sigma, 0.5%w/v 
bacto-yeast extract, Sigma, 1 %w/v NaCI, Sigma, to a final volume of 11 with deionised 
water. The medium was autoclaved for 15 min and ampicillin was added once it had 
cooled to 55°C) containing 50Ilg/ml ampicillin (LB-amp), in a sterile 50ml tube, and 
allowed to grow at 37°C in a shaking incubator at 30rpm. After Sh, lml was mixed with 
100ml of a fresh solution of LB-amp in a 250ml conical flask, and bacterial cells were left 
to grow overnight at 37°C and 30rpm. Bacterial cells were then collected by a 30min 
centrifugation at 1700rpm at 4°C. After removal of LB medium, plasmid DNA was 
purified using a Qiagen Plasmid Midi Kit (Qiagen) according to the manufacturer's 
instructions. The DNA recovered from the midi preparation was quantified using a 
spectrophotomer, by reading the absorbance at 260nm and 2S0nm. The quality of DNA 
prepared was determined by the ratio between 260nm and 2S0nm absorbance (ratio ~ 1.S 
for good quality samples). The amount of DNA was calculated considering that a solution 
of DNA 50Ilg/m1 would give an absorbance of 1.0 at 260nm. 
To transfect DNA into LNCaP cells, Lipofectamine 2000 reagent (Invitrogen) was used 
according to the manufacturer's instructions. Briefly, cells were seeded at high density in a 
T -25 flask one day before trasfection in order to have a 90-95% confluence at the time of 
transfection. Both DNA and Lipofectamine were diluted separately in Opti-MEM I 
Reduced Serum Medium (Invitrogen). After 5 minutes of incubation of Lipofectamine at 
room temperature, the diluted DNA was added (the final ratio was DNA Illg to 
Lipofectamine 2000 31l1) and incubated for 20 minutes at room temperature. The mixture 
was then added to the cells (about 81lg DNA in a T-25 flask) which were incubated at 37°C 
until harvesting. 
Two days later, the medium was removed and the cells detached with trypsinlEDT A 
solution. After counting, the cells were seeded in 15mm plates at density of 5000 cells/ml 
in RPMI medium containing the antibiotic G418 (500llg/ml). 
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A second transfection was performed using the same conditions, except the cells were 
selected with 0418 at 1000 ).!g/ml. 
At these antibiotic concentrations, parental cells are killed and the only cells able to grow 
are likely to be those which have integrated the transfected plasmid into their DNA. The 
plates were then kept at 37°C and the medium renewed every two-three days. Colonies 
were visualized under the microscope and single colonies isolated by using plastic cloning 
rings which were attached to the plate with sterile Vaseline. TrypsinlEDTA solution (20 
).!l) was introduced into the cloning rings and the detached cells were transferred to 6 well 
plates, containing 2ml of medium plus 0418. Each clone was seeded in duplicate in two 
parallel plates: one plate was used to verify the presence of the gene of interest by western 
blotting and the other was used to maintain the clone for further studies and for long term 
storage. 
3.1.4 Growth inhibition assays 
The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay is a very 
simple colorimetric method that allows the determination of the effect of drugs on cell 
growth. The assay is based on the ability of mitochondrial succinate dehydrogenase to 
metabol_ise the tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolio 
bromide) into its formazan (Denizot and Lang, 1986; Mosmann, 1983) .. Briefly, 20).!1 of 
MTT (Sigma, 6mglml in sterile PBS) are added to the cells in 96 well plates and incubated 
for at least 4h at 37°C in the dark. The medium is then removed, and the insoluble 
formazan salts are dissolved with a solution of 0.025N HCI in isopropyl alcohol, and the 
optical density at 550 nm determined (spectrophotometer "Titertek", Dasit Milan-Italy). 
To investigate the effects of drugs on cell growth, LNCaP, Du145 cells and MCF-7 cells 
were seeded in 96 wells plates and allowed to attach for at least 48h. 
The cell concentration used for seeding depended on the cell line and the kind of drug 
treatment performed: when the effect of only a single drug was assesed, LNCaP cells (wild 
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type and the clones overexpressing GSTpi) were seeded at 7000 cells/well, while Du145 
and MCF -7 cells were seeded at 3000 cells/well, due to different kinetics of cell growth 
(LNCaP cells have a doubling time of roughly 64h, while for Du145 and MCF-7 cells this 
is about 28-30h). When combination drug treatments (96h) were performed, LNCaP cells 
were seeded at 3500cells/well. For treatments longer than 96h (8 days, as described in 
Results 4.1.2.4), LNCaP and Du145 cells were pretreated in T-25 flasks, before being 
seeded in 96 wells plates prior to treatment with the second drug, which was added with a 
concentration range into sixtuplicate wells, for 72h; control untreated cells were incubated 
with an equivalent volume of fresh medium. Growth inhibition was calculated as 
percentage of the OD values obtained in drug free control cultures (%Ctrls), or, for the 
combinations, as percentage of the OD values obtained in the demethylating drug alone 
cultures. The mean concentration causing 50% growth inhibition compared to the cells 
(ICso) was determined for each drug from at least three separate experiments and was 
calculated from the linear regression fitting of the growth inhibition curves. 
For experiments involving pretreatment with 5-aza-dC (Results, fig. 4.1.3), LNCaP cells 
were seeded in 6 well plates at 20000 cells/well. They were allowed to attach for 48h, 
before adding 5-aza-dC 0.05JlM. Because 5-aza-dC has a half-life of 12h at 37°C, medium 
was replaced daily with medium containing fresh 5-aza-dC. After two weeks, brostallicin 
at increasing concentrations was added for 72h. The effect of the combination of the two 
drugs was assessed by the crystal violet staining. Iml of crystal violet (commercially 
available solution 1 %w/v in water; BDH, Mila, Italy) was added in each well for 2 minutes 
at room temperature. After extensive washes in water, with the final two washes in distilled 
water, the plates were air dried. 
The MTT assay was used to determine the toxicity of demethylating agents on LNCaP 
cells, by performing treatments at the same concentrations and exposure time used in the 
different combinations with brostallicin. 
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3.1.5 Statistical analysis 
The effects of the drugs, alone or in combination, on cell viability were compared using the 
one-way Analysis of Variance (ANOVA, Statview Statistical Package SAS Institute Inc., 
third edition). Differences among the OD values obtained with the MTT assay were 
considered statistically significant when p < 0.05. 
3.1.6 Drug solutions 
Stock solutions were prepared according to the following table: 
Drug Stock solution concentrations 
5-aza-dC (Sigma) 4.4mM in PBS (stock solution stored at -20°C) 
procaine (Sigma) 3.67mM in PBS, freshly prepared 
procainamide (Sigma) 100mM in PBS, freshly prepared 
zebularine (purchased by 
N erviano Medical 4.4mM in PBS (stock solution stored at -20°C) 
Sciences; Milan, Italy) 
trichostatin A (Sigma) 5mM in ethanol (stock solution stored at -20°C) 
brostallicin (purchased by 
Nerviano Medical 1mglml in DMSOlO% + PBS 90% freshly prepared 
Sciences) 
3.3mM in medium, freshly prepared (kept at 37°C for 
cDDP (Sigma) 
30' before treatment) 
Table 3.1.1 Drug solutions 
The stock solutions were diluted in culture medium to provide the appropriate 
concentrations for cell treatment. 
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3.2 DNA EXTRACTION 
3.2.1 Genomic DNA extraction/rom xenograft tissue samples 
Frozen tissue fragments, excised from LNCaP tumours of mice treated with zebularine 
(SOOmg/kg for two cycles, Results, fig. 4.2.2, A), weighing up to SOmg were used for DNA 
extraction on the Maxwell™ 16 Instrument (Promega), provided with the Maxwell™ DNA 
purification kit (Promega). This instrument purifies uses Magnesil® Paramagnetic 
Particles (PMPs), which provide a mobile solid phase that allows the capture, washing and 
elution of the target material. DNA was quantified using a Nano-Drop ND-I000 
spectrophotometer, according to the manufacturer's manual (Celbio, Italy). 
3.2.2 Genomic DNA extraction/rom human biopsies 
Following written informed consent of patients involved in a phase I study of decitabine, 
receiving epirubicin, cisplatin and infusional S-FU (ECF) for advanced gastric or 
oesophageal cancer, tissue samples were collected, on days + 1 and +11 after decitabine 
administration, from primary tumour sites and normal mucosa of the patients. On the same 
days, blood samples were collected. All samples were immediately frozen in liquid 
nitrogen and stored at -80°C. 
Tissue samples (about 2Smg) were ground in liquid nitrogen to a fine powder. DNA was 
extracted by using the reagents in the BACC2 Nucleon DNA extraction kit (Amersham 
Biosciences), after an overnight digestion at SO°C with the proteinase K solution (IOllgllll) 
of the kit. At the end of the extraction, DNA was precipitated by adding 2 volumes of cold 
absolute ethanol and then washed by adding cold 70% (v/v) ethanol. DNA was air dried 
and re-dissolved in an appropriate volume ofnucIease-free water. 
DNA was quantified using a Nano-Drop ND-I000 spectrophotometer, according to the 
user's manual. 
102 
3.2.3 Genomic DNA extraction from human blood 
DNA extractions were performed by using the reagents in the BACC3 Nucleon DNA 
extraction kit (Amersham Biosciences). 
Blood samples (4-Sml) of the patients involved in the phase I study (see prevIOUS 
paragraph) were thawed at room temperature before extraction, which was performed 
accordingly to the manufacturer's instructions. At the end of the extraction, DNA was 
precipitated by adding 2 volumes of cold absolute ethanol and then washed by adding cold 
70% (v/v) ethanol. DNA was air dried and re-dissolved in appropriate volume of water. 
DNA was quantified with Nano-Drop ND-1000 Spectrophotometer, according to the user's 
manual. 
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3.3 METHYLATION ANALYSIS 
3.3.1 Sodium bisulflte modification of DNA 
The methylation status of a DNA sequence can be determined using sodium bisulfite. 
Incubation of DNA with sodium bisulfite results in conversion of unmethylated cytosine 
residues into uracil, leaving the methylated cytosines unchanged (fig. 3.3.1, A). Therefore, 
bisulfite treatment gives rise to different sequences for methylated and unmethylated DNA 
(fig.3.3.1, B). The most critical step for correct determination of a methylation pattern is 
the complete conversion of unmethylated cytosines. Cytosine forms adducts across the 5-6 
bond with bisulfite; hydrolytic deamination of the resulting cytosine-bisulfite derivative 
gives a uracil-bisulfite derivative, and removal of the sulphonate group by a subsequent 
alkali treatment gives uracil. This reaction does not occur if the cytosine is methylated. 
It is important to note that bisulfite reacts with cytosine either as the free base, the 
nucleoside (ribo- or deoxyribo-), the nucleotide or in oligonucleotides. However the 
reaction is highly single-strand specific (Clark et aI., 1994). 
Genomic DNA (l J,lg) was modified using EpiTect® Bisulfite Kit (Qiagen), according to 
the manufacturer's instructions. After modification, the DNA was eluted into 40J,l1 Tris-
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(3')b--OTUAGTG-------GO----GCm-------OGAAGTU---
1- peR amplification both DNA strands (5' ) a --GAGTTAT-------TG----CG--------GTTTTAG---
(3')a--CTCAATA-------AC----GC--------CAAAATC---
Figure 3.3,1 Sodium bisulfite reaction with cytosine residues 
(A) bisulfite modification of an urunethylated cytosine 
(B) Bisulfite modification in a DNA duplex: the green ring highlights one unmethylated and bisulfite 
converted cytosine and the red ring highlights one methylated and unconverted cytosine. 
From (Clark et al., 1994), modified. 
105 
3.3.2 Amplifications of bisulfite modified genomic DNA by Methylation Specific peR 
Polymerase chain reaction (PCR) is a technique to exponentially amplify in vitro a small 
quantity of a specific nucleotide sequence in the presence of template sequence, two 
oligonucleotides primers that hybridize to opposite strands and flank the region of interest 
in the target DNA, a termostable (taq) DNA polymerase. The reaction is cycled involving 
template denaturation, primer annealing, and the extension of the annealed primers by 
DNA polymerase until enough copies are made for further analysis. 
Methylation-specific PCR (MSP) is able to distinguish methylated and unmethylated 
cytosines in a DNA sequence and was described for the first time by Hermann (Herman et 
aI., 1996). It is based on the amplication of a selected region of DNA, previously modified 
by bisulfite, using two pairs of primers: one anneals a DNA region if this contains 
methylated cytosines in the CpG dinucleotides (as a consequence of which the cytosines 
are not converted by bisulfite), the other anneals the same DNA region if this contains 
unmethylated cytosines (that are converted into uracil, which codes as thymine). 
3.3.2.1 Assessment of bisulfite DNA modification by amplification of the calponin gene 
To verify complete bisulfite modification of DNA, a sequence that contains only cytosines 
not comprised in a CpG island was PCR-amplified after bisulfite modification with primers 
that will only give an amplified product if the cytosines in the template sequence have been 
successfully converted to uracils. For this purpose, a region of the calponin promoter was 
amplified alongside every modified "unknown" DNA sample. 
PCR was done in a total volume of 25p.1, containing Ip.l (100ng) modified template DNA, 
IOp.M of each pnmer (F: 5'-GGAAGGTAGTTGAGGTTGTG; R: 5'-
CCCAAACTCAAAACTCTAACCTAAC), 3mM MgCh, O.2mM deoxynucleotide 
triphosphates (Applied Biosystems, Warrington, United Kingdom), and 1 unit FastStart 
Taq (Roche Diagnostics, Lewes, United Kingdom). PCR amplification involved an initial 
incubation at 95°C for 5 minutes, followed by 35 cycles of: 95°C for 30 seconds, annealing 
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at 63°C for 30 seconds and extension at 72°C for 90 seconds. The annealing temperature 
was about 3-S degrees lower than the melting temperature (Tm) of the primers calculated 
as follow: Tm= 4X (G+C) + 2X (A+T). Following these 3S cyles of amplification, a final 
extension was done at 72°C for 10 minutes. After adding the loading buffer (EDT A 0.1 M, 
sucrose SO%w/v, bromophenol blue solution 0.2S% and xylene cyanol solution 0.2S% to a 
final volume of Sml with pure water) to each sample, PCR products were loaded on 2%w/v 
agarose (Eppendorf, Italy) gel in TAE buffer (Tris base 2M, EDTA pH 8 SOmM, S.1% 
glacial acid acetic to 11 with deionized water), together with Sill of SObp DNA ladder 
(ready-to-use marker O.1mg/ml, Fermentas-MBI, Italy). PCR products (333bp) were 
visualized under UV light after ethidium bromide (Sllg/ml solution in TAE, protected from 
light and stored at 4°C, Sigma. Warning: ethidium bromide is a mutagenic substance and 
should be handled with protective clothing and disposal gloves) staining. 
Samples successfully modified by bisulfite give well defined amplification products. 
3.3.2.2 Methylation Specific peR of GSTP 1 promoter 
Primers for the GSTPI gene promoter were designed described in Results (fig.4.2.6). PCR 
was done in a total volume of2SIlI, containing I III (lOOng) modified template DNA, 10llM 
of each pnmer (F: S'-AGTTGCGCGGCGATTTC;· R: S'-
GCCCCAA TACT AAA TCACGACG), 2mM MgCh, 0.2mM deoxynucleotide 
triphosphates (Applied Biosystems, Warrington, United Kingdom), and I unit FastStart 
Taq (Roche Diagnostics, Lewes, United Kingdom). 
PCR reaction was subjected to initial incubation at 9SoC for S minutes, followed by 3S 
cycles of 9SoC for 30 seconds, annealing at 61°C for 30 seconds and extension at 72°C for 
30 seconds. The annealing temperature was determined as described in the previous 
paragraph. Final extension was done by incubation at 72°C for 10 minutes. The 
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amplification products were l40bp in length and were separated according to the previous 
conditions. 
Because MSP is a sensitive assay for the analysis of DNA methylation, care has to be 
taken to minimize false-positive and false-negative PCR products. For this purpose, 
commercially available DNAs were used as template for setting the PCR conditions with 
the GSTPl primers: In Vitro Methylated (IVM, CpGenome™ Universal Methylated DNA, 
Chernicon) is an enzymatically methylated human male genomic DNA and was used as a 
methylation-positive control (100% methylation); human male genomic DNA (Promega) 
was used as negative control (O%methylation). 
3.3.2.3 Methylation Specific peR of GSTMl promoter 
Primers for the GSTMl gene promoter were designed as described in Results (fig.4.3.5); 
the region was amplified by using the touch down PCR, which allows the use of very high 
annealing temperatures (close to the melting temperature of the primers, calculated as 
described in the paragraph 3.3.2.1) in order to avoid false positives. For GSTMl promoter 
amplification 2 couples of primers were used, specifically annealing methylated or not 
methylated bisulfite treated DNA (see figure 4.3.5) (Lodygin et aI., 2005). The PCR 
conditions are summarized in the following table: 
Table 3.3.1 MSP conditions for GSTMl 
Primer Sequence Product Annealing [Mg++] 
Forward (F)lReverse (R) 5' --+ 3 ' Size(bp) Temp (OC) mM 
on bisulfite modified template sequence 
F(N.Q:GAAGTTGGCGAGGTCGAGTTTC l57(M) Touch Down 
95°C x5min 
F({D:GGGAAGTTGGTGAGGTTGAGTTTT 95°C X 30" 68°C X 30" 2cycles 
n oc X 60" 
GSTMl 
R (N.Q: ACCCGCCACAACCCGAAAAACG 161(U) 95°C x 30" 3 66°C X 30" 2cycles 
R(lD:CAACCCACCACAACCCAAAAAACA n oc X 60" 95°C X 30" 
65°C X 30"36cycles 
n oc x 60" 
n oc x 10' 
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PCR products were separated and visualized accordingly to the conditions described in the 
previous paragraphs. 
3.3.3 Pyrosequencing: general description 
Pyrosequencing (PSQ) is a method that quantitatively monitors the incorporation of 
nuc1eotides through the enzymatic conversion of released pyrophosphate to generate a 
proportional light signal. Analysis of DNA methylation patterns by PSQ measures the 
degree of methylation at all CpGs within the sequenced region, after bisulfite treatment of 
DNA (Tost and Gut, 2007; Agah et aI., 2004; Ahmadian et aI., 2006). 
Step 1 
A sequencing primer is hybridized to a single stranded, PCR amplified, bisulfite treated 
DNA template, and incubate with the enzymes, DNA polymerase, ATP sulfurylase, 
luciferase and apyrase, and the substrates, adenosine 5'phosphosulfate (APS) and luciferin. 
Step 2 
The first of four deoxyribonucletide triphosphates (dNTP) is added to the reaction. DNA 
polymerase catalyzes the incorporation of the deoxyribonucleotide triphosphate into the 
DNA strand, if it is complementary to the base in the template strand. Each incorporation 
event is accompanied by release of pyrophosphate (PPi) in a quantity equimolar to the 
amount of incorporated nucleotide. 
Step 2 
(DNA}n + dNTP Polym raa. • (DNA)llTl + PPi 
Step 3 
ATP sulfurylase quantitatively converts PPi to A TP in the presence of adenosine 5' 
phosphosulfate (APS). This ATP drives the luciferase mediated conversion of luciferin to 
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oxyluciferin that generates visible light in amounts that are proportional to the amount of 
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coupled device camera (CDD) and is seen as peak in a Pyrogram TM. The height of each 
peach (light signal) is proportional to the number of nucleotides incorporated. 
Step 4 
Apyrase, a nucleotide degrading enzyme, continuously degrades ATP and unincorporated 
dNTPs. This switches off the light and regenerates the reaction solution. The next dNTP is 
then added. 
Step 4 
dNTP Apyrue.. dNDP + dNMP + phosphate 
ATP Apyrase.. ADP + AMP + phosphate 
Step 5 
The addition of dNTPs is performed one at a time. It should be noted that deoxyadenosine 
alfa-thio triphosphate (dATPuS) is used as a substitute for the natural deoxyadenosine 
triphosphate (dATP) since it is efficiently used by the DNA polymerase, but not 
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recognized by luciferase. As the process continues, the complementary DNA strand is built 
up and the nucleotide sequence is determined from the signal peaks in the Pyrogram. 
Step 5 
nuc,'Eaotide SE!qu~mce 
GC 11 GGCC T 
\ j~ \. I "-
" 
\. 
G C T 11 G C T 
.. 
nocl'9otide added 
3.3.3 Pyrosequencing: GSTPl and .MAGE1Apromoter methylation analysis 
To generate a sufficient amount of template, DNA was PCR-amplified, with one of the two 
primers labelled with biotin at its 5' -terminus. The primers chosen for this reaction 
amplifies all states irrespective of methylation status, because they anneal regions mainly 
devoid of CpG dinucleotides (fig.4.2.6). PCR was done in a total volume of 50IlI, 
containing 2111 (200ng) of modified template DNA, IOIlM of each primer (GSTPl:F 5'-
GGGGAGGGATTATTTTTATAAG,R biotin 5'-AATTAACCCCATACTAAAAACTCT; 
MAGEIA: F 5' -TTTTTATTTTTATTTAGGTAGGAT, R biotin 5' -
TCT AAAAACAACCCAAACT AAAAC. All primers were purchased by VH Bio Ltd, 
UK), MgCb 2mM for GSTPl and 4mM for MAGEIA, 0.2mM deoxynucleotide 
triphosphate (Applied Biosystems, Warrington, United Kingdom), and 2 units FastStart 
Taq (Roche Diagnostics, Lewes, United Kingdom). 
PCR amplification was subjected to initial incubation at 95°C for 5 minutes, followed by 
49 cycles of 95°C for 30 seconds, annealing at 54°C (GSTPl) or 53°C (MAGEIA) for 30 
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seconds and 72°C for 30 seconds. Final extension was done by incubation at 72°C for 10 
minutes. 
In a 96 well PCR plate, PCR products were dispensed. In each well, containing the 
amplified DNA (40Jll), 3JlI of streptavidin coated beads (which bind the biotinylated 
primer inserted into DNA during the amplification) and 37Jll of binding buffer (Biotage) 
were added. 
The four troughs of the Pyrosequencing Vacuum Prep Workstation (Biotage) were filled 
with 70% Ethanol, denaturating buffer (0.2M NaOH), wash buffer and Milli-Q water. 
PCR plate was vortexed for 5 minutes; then the vacuum tool of the workstation was placed 
in the PCR plate and allowed to aspirate the suspension of DNA-beads; the vacuum tool 
was moved to 70% ethanol, to O.2M NaOH and, at the end, to the wash buffer. 
The described steps allow to prepare the single-stranded DNA template (through the alkali 
treatment) immobilized on streptavidin-coated sepharose beads. 
In a PSQ 96 Low Plate the sequencing mix, consisting of l.5Jll sequencing primer 10JlM 
(GSTP1: GGATTATTTTTATAAGGT; MAGEIA: TGTTGTTAGTTTTGGTTTAT) and 
43.5JlI annealing buffer (Biotage) for each sample, was dispensed. The sequencing primer 
in the PSQ plate was then hybridized to the single-stranded DNA template. 
After a 5 minute incubation at 80°C, the PSQ 96 plate was transferred to the PSQ 96MA 
pyrosequencer (Biotage). 
All the reagents (nucleotides, substrate and enzyme mix) for the pyrosequencing were 
dispensed into the appropriate wells of the PSQ TM96 Reagent Cartridge, according to the 
volume calculation of the software. The pyrosequencer automatically dispensed these 
reagents to the samples in the PSQ plate, when the reaction was allowed to run. 
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3.4 IN VIVO EXPERIMENTS 
3.4.1 Animals 
CBI7/SCID (Severe Combined Immunodeficiency) male mIce (Charles River, Calco, 
Lecco, Italy) were used for LNCaP cell transplantations. Eight week old mice, weighing 
20-25g, were maintained under specific pathogen-free conditions, in cages with paper filter 
covers, and they were provided food and water ad libitum. Procedures involving animals 
and their care were conducted in conformity with the institutional guidelines that are in 
compliance with national (D.L. n.116,G.U., supp1.40, 18 Febbraio 1992, Circolare No. 8, 
G.U., 14 Luglio 1994) and intemationallaws and policies (EEC Council Directive 86/609, 
OJ L 358,1, Dec 12, 1987; Guide for the use of Laboratory Animals, United States 
National Research Council, 1996). 
3.4.2 Tumour model 
For drug testing, LNCaP cells were suspended in saline and BD Matrigel Matrix Basement 
membrane (BD Biosciences) (ratio 1 :1) and implanted subcutaneously into the left flank of 
recipient SCID mice (5xl06cells/mouse). When the tumour was palpable (approximately 
0.2g weight, attained roughly three weeks after transplant), animals were randomly divided 
into test groups each consisting at least of seven mice. 
3.4.3 Drug administration 
Brostallicin was administrated intravenously (iv) and zebularine was administrated 
intraperitoneally (ip) according to the schedule indicated in Results (figA.2.2). The volume 
of administration for both drugs was 10ml/kg of body weight. 
Zebularine was dissolved in saline and 50mg/ml stock solutions were prepared and stored 
at -20°C, while brostallicin was prepared immediately before use: it was dissolved in 
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DMSO 50% in saline at Img/ml and then diluted in saline to the final concentration 
0.04mglml. 
3.4.4 Evaluation of antitumour activity and toxicity 
Beginning on day 0lthe length (L) and width (W) of the solid tumour mass were measured 
using callipers twice weekly and the tumour volume (TV) was calculated as TV = 
(LxW2)/2 (assuming a density of I, the calculated tumour volume corresponds to the 
tumour mass value\ The tumour volume at day n was expressed as relative tumour 
volume (RTV) according to the formula RTV = TVnlTVo, where TVn is the tumour 
volume at day n and TVo is the tumour volume at day O. 
The doubling time (days) of the not treated tumours was calculated as DT = In2/A., where A. 
is the coefficient of the X value in the equation of the exponential curve that was fitted the 
tumour growth curve of each control mouse. 
The percentage of tumour growth inhibition (T/C%) was determined by calculating RTV 
as: T/C% = 100x (mean RTV of treated group)/(mean RTV of control group). According 
to the National Cancer Institute standards, a TIC ~ 42% is the minimum level for a drug to 
be considered active (Geran RI et al.I972). 
Toxicity was evaluated on the basis of weight loss. Body weight was recorded the same 
day of tumour measurement and was taken as a measure of toxicity, together with gross 
autopsy findings. The percentage of weight loss was calculated by the ratio: 
100X (mean Body Weight Treated Groupl mean Body Weight Control Group). 
Antitumour activity was evaluated at the highest non-toxic dosage of the drugs 
administrated as single agents, which is the highest dosage that can be administrated 
without causing death or undue toxicity. A dose producing a weight loss nadir of 20% or 
drug related death was considered as excessively toxic. 
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3.4.5 Statistical analysis 
Tumour volumes of treated and untreated mice were compared by analysis of variance 
(ANOV A) using the Statview Statistical Package (SAS Institute Inc., third edition). 
3.4.6 GSTpi expression 
For evaluation of GSTpi expression, a group of 5 mIce was treated with the same 
scheduled used for antitumour activity, that is with two cycles (each of 8 daily treatments) 
of zebularine 500mg/kg. 
The day after the last treatment with zebularine, mice were sacrificed, tumour fragments 
were excised and immediately frozen in dry ice and stored at -80°C for western blotting or 
fixed 24h in formalin (4% in PBS, Bio-Optica) for immunohistochemistry. 
3.4.6.1 Immunohistochemistry 
Immunohistochemistry on LNCaP tumors was kindly performed for me by Dr. Roberta 
Ceruti at Nerviano Medical Sciences (Nerviano, Milan, Italy). Formalin fixed tumours 
were embedded in paraffin. Slices (4Ilm) were put on super frost plus slides. Haematoxylin 
and eosin staining was performed for morphological evaluation. For 
immunohistochemistry, a Ventana Discovery autostainer was used. Briefly, standard CC 1 
(sCC 1) unmasking protocol was used, followed by GSTpi monoclonal antibody 
(Novocastra NeL-GST pi-438, dilution 1 :50 in D-PBS) incubation for 2h. The En-Vision 
labelled Polymer-HRP anti mouse (DAKO K4001) was used as secondary antibody: 
incubation was for 16 minutes. Standard diaminobenzidine (DAB) chromogen from 
Vent ana revealed the antibody binding. 
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3.5 WESTERN BLOTTING 
Western blotting analysis involves the separation of proteins according to molecular 
weight using sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS/P AGE), 
electrophoretically transferring them to a membrane and then using specific antibodies to 
detect the protein of interest. 
3.5.1 Protein extract preparation 
Total proteins were extracted from cells growing in culture by a lysis method. Basically 
cell cultures were washed twice with ice-cold PBS and then detached with a disposable 
scraper to 500 III ofPBS. The suspension was then centrifuged at 1,200rpm for 10 minutes 
at room temperature and after centrifugation, the pellet was re suspended in an amount of 
lysis buffer (Tris-Cl pH8 50mM, NaCl 150mM, EGTA ImM, NaF 100mM, glycerol 10%, 
MgCh ImM, Triton X-lOO 1% + protease inhibitor cocktail (Sigma) containing a mixture 
of protease inhibitors, in particular aprotinin, bestatin hydrochloride, EDT A, leupeptin, 
specifically inhibiting serine proteases, aminopeptidases, metalloproteases and cysteine 
proteases) dependent on the size of cell pellet (about 100111 for 5xlO6 pelletted cells) and 
incubated on ice for 30 minutes in an orbital shaker. Cellular debris .was pelleted by 
centrifugation at 12,000rpm at 4°C for 10min, and the supematant was recovered. 
Frozen tissue fragments were homogenized using a Polytron homogenizer in lysis buffer 
(ratio 1: 1 w/v). Insoluble material was pelletted at 12000rpm for 30 minutes at 4°C and the 
supernatant was recovered and placed in a fresh Eppendorftube (1.5 ml). 
An aliquot (2 Ill) of total proteins extracted from both cells and tumour fragments was used 
for determination of protein concentration. 
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3.5.2 Determination of protein concentration 
Before determining the protein concentration of the samples examined, a calibration curve 
was prepared. Solutions of bovine serum albumin (BSA) (ranging between I and 20llg/200 
Ill) were prepared from a stock solution of BSA obtained by dissolving powdered BSA 
(Sigma) in water. In a I.5ml tube, 200111 of each BSA solution were mixed with 600111 of 
distilled water and 200111 of BioRad protein assay dye (BioRad). In the blank sample 800111 
of distilled water was mixed with 200111 of BioRad protein assay dye. Samples were 
rapidly transferred into disposable cuvettes (PBI International, Milan-Italy) and the 
absorbance at 595nm was measured in the spectrophotometer. The absorbance value 
corresponding to the blank sample was subtracted from the values obtained in the BSA-
containing samples. Each calibration sample was run in triplicate. The calibration curve 
obtained in such a way, allows extrapolation of the exact absorbance value of Illg of 
proteins present in the solution. 
Protein concentration in the cellular or fragment extract was determined according to the 
Bradford protocol. In a I.5ml tube, 2111 of protein extract was mixed with 200111 of BioRad 
protein assay dye and distilled water to a final volume of Iml. The absorbance at 595nm 
was measured in the spectrophotometer and the sample concentration was calculated from 
the calibration curve previously determined. 
3.5.3 SDS-PAGE 
An aliquot (typically 30 - 60llg) of protein of each sample was mixed with the same 
volume of SDS loading buffer (lOOmM Tris-HCI pH 8.8, 200mM DTT, 4%w/v SDS, 
20%v/v glycerol and 0.2% bromophenol blue in sterile water). 
The mixture was heated at 95°C for 5 min and allowed to cool. Samples were SUbjected to 
SDS-PAGE. 
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Stacking (l25mM Tris-HCl pH 6.8, O.l%w/v SDS, 5%w/v acrylamide/bis 37.5:1, 0.05% 
w/v ammonium persulphate and 5 ~l TEMED to a final volume of 10ml with deionized 
water) and resolving (750mM Tris-HCl pH 8.8, 0.1 %w/v SDS, X %w/v acrylamide/bis 
37.5:1, 0.05% w/v ammonium persulphate and 7.5~1 TEMED to a final volume of 10 ml 
with deionized water) gels were prepared shortly before pouring. Ammonium persulphate 
catalyses polymerization and TEMED accelerates the reaction and so these two reagents 
were added last with through mixing before the addition. 
Proteins were resolved on a minigel apparatus (BioRad) and run for 2h at 100V in TGE 
buffer (25mM Tris base, 192mM glycine, 0.1 % w/v SDS to a final volume of 51 with 
deionized water. Stored at room temperature). 
The progress of the electrophoresis was monitored using pre-stained molecular weight 
markers (11-170 KDa, Page Ruler Prestained Protein Ladder, Fermentas). 
3.5.4 Protein transfer and detection 
The separated proteins were transferred onto a PVDF (polyvinylidene fluoride) membrane 
(Millipore), at 400mAmpere (corresponding to about 120V) for 45 minutes on ice, using a 
BioRad Mini transfer blot in transfer buffer (50mM Tris base, 100mM glycine, 0.01 % w/v 
SDS, 20% v/v methanol to a final volume of 41 with de ionized water. The solution was 
stored at room temperature). 
Filters were stained with Ponceau red solution (0.1 % w/v PonceauS in 5% v/v acetic acid, 
Sigma) to check sample loading and transfer and then washed in methanol. Blots were 
exposed for 2h at room temperature to the desired primary antibodies diluted to the optimal 
working solution in 5% non-fat dried milk dissolved in TBS-T 0.1 % (Tris base 20mM, 
NaCl 137mM, 0.1 % v/v Tween to a final volume of 11 with deionized water. The pH was 
adjusted to 7.6 with concentrated HCl and stored at 4°C). 
All the following procedures were carried out at room temperature on a shaker. After 
incubation, the blots were washed twice with TBS-T 0.1 % for 10-30 minutes and 
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incubated with the appropriate horseradish-peroxidase linked anti-mouse or anti-goat IgG 
secondary antibody (SantaCruz Biotechnology) for Ih using appropriate dilutions. Blots 
were washed again and detection was performed with an enhanced chemiluminescent 
detection system (ECL, GE Healthcare). Horseradish peroxidase acts as a catalyst for the 
oxidation of a luminol substrate, which subsequently emits small but sustained quantities 
of light. This chemiluminescence is specifically enhanced by chemical enhancers such as 
phenols. This has the effect of increasing the light output approximately 1000 fold and 
extending the time of light emission, allowing an image to be recorded on photographic 
film. The blots were exposed to film for different times ranging from 15 seconds to 3 
minutes and developed using an X-o graph compact x-2 developer with Kodak GBX 
developer and fixer. 
The antibodies used for Western blot analysis in this study were NCL-GSTpi 438 mouse 
monoclonal antibody for GSTpi (supplied by Novocastra) and, as actin was used as 
housekeeping gene, actin goat polyclonal antibody (SantaCruz Biotechnology). 
Stock solutions were stored at 4°C and working solutions were prepared by diluting the 
antibody 1 :500 in 5% non-fat dried milk dissolved in TBS-T 0.1 %. 
Horseradish peroxidase-coupled secondary antibodies (goat anti-mouse for GSTpi and 
donkey anti-goat for actin IgGs) were supplied by Santa Cruz and diluted 1 :3000 in 5% 
non-fat dried milk dissolved in TBS-TO.1 %. 
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3.6 Assay principle of total GST Enzymatic Activity 
In vitro enzymatic activity of total GST was measured according to the method of Habig 
and Jackoby (Habig and Jakoby, 1981). The reaction was initiated by the addition of 1-
chloro-2,4-dinitrobenzene (CDNB) and the velocity was determined by measuring the 
change in absorbance at 340 nm in 1 minute due to the 2,4-dinitrophenylglutathione 
formation and subtracting the rat~ of non-enzymatically-mediated conjugation (i.e. in the 
absence of enzyme). One unit of enzymatic activity is defmed as the amount of enzyme 
that catalyses the formation of 11lmol of S-2,4-dinitrophenylglutathione per min at 23 cC. 
Data are expressed as nanomoles of dinitrophenylglutathione formed Iminlmg of total 
protein using the extinction coefficient of9.6 mM-I cm-I. 
GS~ 0,1 GS 
-Cl' Q'N02 ... 
N02- J O2 
'nNH (H:\ lmplt'x 
2,4 dinitrophenylglutathione 
Figure 3.6.1 Reaction of GSH with CDNB catalyzed by GST family of enzymes 
The adclition of GSH to CDNB is a nucleofilic aromatic substitution reaction that occurs via an addition-
elimination sequence involving a short-lived a-complex intermediate and . leading to 2,4 
dinitrophenylglutathione formation (Annstrong, 1997). 
3.6.1 Total GST activity on cell LNCaP and Du145 cells 
Cells were washed twiCe with ice-cold PBS, harvested, lysed in sterile ice-cold water by 
sonication to destroy cellular membranes and centrifugated at 15000rpm, 4°C for 10 
minutes. The supernatant was transfered into a 1.5 ml Eppendorf tube, and an aliquot was 
used for protein quantitation, by the BioRad protocol. An aliquot (100111) of supernatant 
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was incubated with 100 J,tl of phosphate buffer (K2HP04 IM, KH2P04 IM to pH 6.5) and 1 
J,tmole of glutathione (GSH, 100J,tl of a solution of 10 mM GSH in water) in a final volume 
of 1ml with sterile water for 3 min at 25°C. At the end of the incubation, IJ,tmole of CD NB 
(20 J,tl of 50 mM CDNB solution in ethanol. CDNB is purchased as dry powder from 
Sigma) was added, the mixture was transferred to a lml microcuvette and the kinetics of 
CDNB conversion followed by spectrophotometer (UVIKON-860, Kontron Instruments). 
Data were normalised for the amount of protein present in each sample. 
3.6.2 KINETIC ASSAYS 
3.6.2.1 Inhibition o/the GST activity by brostallicin 
The effect of brostallicin as an inhibitor of GST was measured at 25°C in lml of O.lM 
potassium-phosphate buffer, pH 6.5, containing GSH and CDNB (at ImM or variable 
concentrations) as substrate. The activity was assayed spectrophotometrically by following 
the product of the reaction at 340nm. Initial velocity of the reaction of GST with GSH or 
CDNB was measured in the presence of different concentrations of brostallicin (0 - 50J,tM 
for GSTP 1 and 0 - 1 J,tM for GSTM). At each inhibitor concentration, either CDNB or 
GSH was varied from 0.25 to 2mM, while the co-substrate was maintened constant at 
1mM. Initial velocity data were reported as double reciprocal plots. 
Apparent inhibition constant (Ki) were calculated by re-plot analysis of the primary 
reciprocal plots. With GSTJ,t, the re-plot analysis, obtained when GSH was the varied 
substrate, gave a non-linear trend. In this case, the inhibition constant was obtained by a 
plot of 11 L\slope and 11 L\ intercept versus 1Iinhibitor concentration. L\slope and L\ intercept 
are the slope and the intercept obtained at a given brostallicin concentration sutracted of 
the slope or the intercept obtained in the absence of brostallicin. 
(Segel, I.H., (1975) New York: Wiley - Interscience). 
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3.6.2.2 GST activity with brostallicin 
OST activity, with OSH and brostallicin as substrates, was measured in 1 ml of 0.1 M 
potasium phosphate buffer, pH 6.5, using a spectrofluorometer (Perkin Elmer) with a 
sample holder set at 25°C. Excitation wavelength was 370nm and emission wavelenght 
was at 425nm. 
The dependence of initial velocity on substrate concentration was studied using 1 ~M 
OSTPl or OSTM and varying brostallicin concentration from l~M to lOO~M. The 
increase of fluorescence intensity was recorded in a time range of one minute (~F/min). 
Kinetic parameters were determined by fitting the Hill equation: 
V = Vmax . SAnH/1 + (KAnH/SAnH) 
to the experimental data, where nH is the Hill coefficient and K IS the substrate 
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The reversibility of the epigenetic modifications of DNA represents an opportunity in the 
therapeutic strategies against cancer: it offers the possibility to re-express molecular targets 
which exert a fundamental role in the antitumour activity of specific drugs. However, 
because methylation is being increasingly recognized as a means of acquisition of drug 
resistance, the combinations of cytotoxic molecules with agents reverting epigenetically 
silenced genes involved in the resistance mechanism should be considered as a novel 
treatment strategy. 
The choice of the "right" demethylating agents to use in drug combinations represents a 
very important step in in vitro studies, i.e. testing their capacity to induce the re-expression 
of the target genes prior defining the most effective schedule for combination with the 
cytotoxic drug considered. 
Prostate cancer has been widely investigated for epigenetic modifications of its genome, 
especially for the strong methylation affecting the GSTPl promoter (Li et aI., 2004; Millar 
et aI., 1999), starting from the first stages of tumour initiation. For this reason prostate 
cancer cell lines (which have been shown to retain the methylation of specific genes) have 
been extensively used in order to determine the capacity of nucleoside or non nucleoside 
inhibitors of methylation to re-express methylated genes. Among these, 'GSTPI has been 
one of the most frequently analyzed. GSTPl methylation presented the first suggestion of 
the possibility of combining demethylating drugs with the minor groove binder, 
brostallicin, a pro-drug that needs to be bound to GSH before exerting its cytotoxicity. 
Here, I will describe the different combinations of demethylating molecules and 
brostallicin on the LNCaP prostate cancer cell line, which retains the methylation of the 
GSTPl promoter found in primary prostatic tumours (Song et aI., 2002). 
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4.1.2 RESULTS 
4.1.2.1 Differential toxicity of brostallicin on LNCaP and DU145 prostatic cancer cell 
lines 
To evaluate the relationship between OST expression and antitumour activity of 
brostallicin on prostatic tumour models I used the two prostatic cancer cell lines, Dul45 
and LNCaP. LNCaP do not express OSTpi, Du145 cells do; thus, when the total OST 
activity was assessed using CDNB as substrate, 0.8nmol dinitrophenylglutathione was 
formed/minlmg protein in cytosolic extracts obtained from LNCaP cells and 3.2nmol 
dinitrophenylglutathione was formed/minlmg proteins in cytosolic extracts obtained from 
Du145 cells (fig. 4.1.1, A) respectively. This was confirmed by western blotting, using 
antibodies specific for OSTpi, which shows an easily detectable level of OSTpi expression 
in Du145 and no expression at all in LNCaP cells (fig. 4.1.5, first and second lanes). 
When the cytotoxicity of brostallicin was determined by using the MTT assay (fig.4.1.1, 
B), brostallicin was more active on Du145 cells (IC50~30ng/ml) than on LNCaP wild type 
cells (ICso> 150ng/ml), supporting the contribution of OST to brostallicin activity. 
In order to overcome the differences in the genetic background of these two cell lines, 
which prevent the evaluation of the specific contribution of OST alone to the antitumour 
activity of brostallicin, and to verify whether LNCaP cells can be sensitized to brostallicin 
by modulating only OST expression, LNCaP cells were transfected with a human OSTpi 
cDNA, subcloned in the pcDNA3 vector. The particular choice of the pi class was based 
on previous data obtained both in vitro and in vivo on the ovarian cancer cell line A2780, 
in which a strong correlation between the OSTpi levels and the antitumour activity of 
brostallicin was found (Oeroni et al., 2002). However it should be noted that, in human 
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Figure 4.1.1 Analyses ofLNCaP and Du145 cell lines 
(A) total GST activity of cytosolic extracts of LNCaP and Du145 cells, as determined by CDNB assay, The 
boxes show the average values of two independent experiments, each consisting of three replicates, ±SD 
(bars), 
(B) effect of increasing concentrations ofbrostallicn on growth ofLNCaP (pink line) and Du145 (blue line) 
cells as determined by MTT assay. The data shown are the mean of three independent experiments, each 
consisting of six replicates. Differences are statistically significant with p<O.05 (*) at 5nglml brostallicin and 
p<O.OO 1 (.) from 10nglml to 150nglmI brostallicin. Bars:SD. 
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Following growth of selected clones in antibiotic (G418), LNCaP-GSTpi clones 41 and 54 
showed a substantial increase in total GST activity (respectively, ::::::20 and ::::::63 
dinitrophenylglutathione formedimin/mg proteins, fig.4.1.2,A) compared to wild type cells 
and a corresponding detectable band of GSTpi protein by western blotting (fig.4.1.2,B). 
MTT assay (figA.1.2, C) also confirmed that brostallicin is more cytotoxic in clones 
overexpressing GST (clone 41 IC50::::::150ng/ml, clone 54 ICso::::::50ng/ml) than against 
LNCaPwt cells (lCso >200ng/ml). 
It is important to underline that even when expressing very high levels of GST enzymatic 
activity or protein (class pi) (fig.4.1.2, D), LNCaP cells are per se less sensitive than 
Du145 cells to the antitumour activity of brostallicin (figs 4.1.2, C versus 4.1.1, B). 
Furthermore doses higher than the ICso do not further increase its cytotoxic activity in 
LNCaP-GST cells. 
4.1.3.2 Evaluation of the activity of the combination of demethylating drugs with 
brostallicin on LNCaP eel/line. 
Since methylation is reversible by using DNMT inhibitors (see general introduction), the 
effects of in vitro combinations of demethylating agents and brostallicin were evaluated 
using LNCaP cells. 
The objective was to identify which molecule reverting DNA methylation was able to 
increase the activity ofbrostallicin on LNCaP cells. 
The most potent/effective demethylating drug known is the cytidine analog 5-aza-dC; as a 
consequence it was the first one I used in combination with brostallicin. 
LNCaP cells were pretreated with 0.051lM 5-aza-dC for 2 weeks (see Materials and 
Methods chapter, 3.1.4) and, after seeding in 6-well plates, treated with increasing 
concentrations of brostallicin for 72h. Initially I had used doses of 5-aza-dC currently 
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Figure 4.1.2 Characterization of LNCaP-GSTpi clones 
(A) total GST activity of cytosolic extracts of the selected LNCaP-GST clones, as determined by 
CDNB assay. The boxes show the average of three independent experiments an.d the bars, S.D. 
(B) western blotting analysis of two LNCaP-GSTpi transfected clones. 40/lg of total proteins were 
loaded on a polyacrylamide gel and GSTpi detected using a monoclonal antibody. Anti-actin 
antibody was used to assess consistency of the gel loading and transfer. 
(C) effect of increasing concentrations of brostallicin on LNCaPwt and LNCaP-GST clones as 
determined by MTT assay. The data are the mean of three independent experiments, each consisting 
of six replicates. Differences (for both clones versus controls) are statistically significant at 
brostallicin 50ng/ml (*, p<O.05) and brostallicin ~ lOOng/ml (e , p<O.OOl), as determined by the 
ANOVA test. 
(D) western blotting analysis for GSTpi on 40/lg of total proteins extracted by LNCaP-GST clone 54 
and Du145 cells. 
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was extremely toxic to the LNCaP cells and therefore did not allow the possible increased 
efficacy of brostallicin on LNCaP cells to be evaluated. I therefore progressively lowered 
5-aza-dC concentrations and extended the period of pre-treatment. Although a higher 
activity of brostallicin was seen with the combination (flg.4.1.3, plate on the right) 
compared to its activity on the controls (flgA.l.3, plate on the left), the cytotoxicity of 5-
aza-dC per se on LNCaP cells was not negligible (flgA.l.3, B). Moreover only a slight 
increase of GST total activity was evident in the treated cells (flgA.1.3, C). 
These results prompted me to assess the effectiveness of other DNMT inhibitors that might 
be used in combination with brostallicin. 
To assess other molecules reverting methylation, LNCaP cells were pre-treated with 
procainamide (100~M) or procaine (300~M) for 96h and then treated with increasing 
concentrations of brostallicin. As is evident in flgA.IA, panels A and B, pre-treatment with 
neither procaine nor procainamide, at any of the dose levels used, enhanced the 
cytotoxicity of brostallicin. This was also evident with longer exposure times and with 
higher concentrations of these non-nucleoside inhibitors of DNMTs (data not shown), so 
these combinations were not further considered. 
The cytidine deaminase inhibitor zebularine is known to be less toxic and more stable than 
5-aza-dC (Cheng et aI., 2003) and this allows prolonged treatments without replacing the 
drug daily. These characteristics make zebularine particularly practical for combinations 
with cytotoxic drugs. When zebularine was used to pretreat LNCaP cells (96h of 
continuous treatment) before brostallicin, it clearly sensitized them to the cytotoxic drug 
and with increasing dose of zebularine there was a greater effect of the combination 
(flgA.1.5, B). Although treatment with zebularine alone at 125~M showed detectable 
toxicity (flg.4.1.5, A), it produced the greatest enhancement of the cytotoxicity of 
brostallicin; the effects reached with 100~M and 125~M zebularine nearly reached those of 
brostallicin alone on LNCaP-GST clones. However, when I determined GSTpi expression, 
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Figure 4.1.3 Effects of 5-aza-dC on LNCaP cells 
(A) Effect of a 2 week pre-treatment with 5-aza-dC (O,05~M) on brostallicin cytotoxicity in LNCaP 
cells, Cristal Violet staining was performed 72h after treatment with increasing concentrations of 
brostallicin as shown, 
(B) 5-aza-dC toxicity after 2 week treatment, as assessed by MTT assay. Cells were treated with 5-aza-
dC in T-25 flasks before being seeded in 96 plates for the assay, Tha data shown are the mean of 
two independent experiments each consisting of six replicates. Difference between control and 
,,: I', 
treated cells is statistically significant with p<O.Ol (.). 
\, I ~ I ,. j H I (C) Total GST activity of cytosolic extracts of LNCaP treated for 2 weeks with 5-aza-dC, as determined 
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Figure 4.1.4 Effect of combination of procaine or procainamide and brostallicin on 
LNCaP cells 
Effect of 72h treatment with increasing concentrations of brostallicin on LNCaP cells pretreated with 
procaine, (pCA, A) or procainamide CB) for 96h, as determined by MTT assay. Differences between control 
and treated groups are not statistically significant. Bars, S.D. 
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no detectable signal was evident by western blotting at any zebularine concentration 
(fig.4.1.5, C). Furthermore, GST activity was only slightly increased and only after 
treatment with lOO/lM and 125/lM zebularine (fig.4.1.5, D). 
4.1.2.3 Effect of combination of zebularine and trichostatin A with brostallicin on 
LNCaPcells 
Because epigenetic silencing involves not only DNA methylation, but also chemical 
modifications of the histone proteins, I pretreated cells with zebularine and the HDACi 
Trichostatin A (TSA) before brostallicin. Zebularine concentrations higher than 50/lM 
were too toxic in combination with TSA. However greater toxicity was evident following 
simultaneous treatments of these two drugs, so TSA exposure was for 48h and zebularine 
for 24h (according to (Cameron et aI., 1999» before treatment with brostallicin. The 
growth inhibitory effect was substantially greater than that of zebularine or TSA alone 
(fig.4.1.6), but the previous results with zebularine alone were more satisfactory. Due to 
the difficulty of translating this combination to in vivo studies, no further analyses were 
performed on the re-expression of GSTpi. 
4.1.2.4 Effects of the zebularine-brostallicin combination on Du145 and LNCaP-GST 
cells 
In the experiments I am going to describe, I verified the possible effects of brostallicin 
treatment on cells already overexpressing GSTpi and pre-incubated with zebularine. 
In order to further characterize LNCaP-GST cells, their sensitivity to cDDP was assessed. 
GSTpi overexpression resulted, as expected, in a slight decrease in cDDP efficacy. Thus, 
in 5-10/lM range of cDDP concentrations, survival versus controls values were 32% in wt 
cells to 52% in LNCaP-GST. Increased resistance was also evident, although to a lesser 
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Figure 4.1.5 Effects of 96h treatment with zebularine on LNCaP cells 
(A) Effect of increasing concentrations of zebularine (96h treatment) on LNCaP cells, as determined by 
MTT assay. Growth inhibition by 125~ zebularine was significantly different versus controls C*, 
p<0.05, ANOV A test). Bars, S.D. 
(B) Effect of 72h treatment with increasing concentrations of brostallicin on LNCaP cells pretreated 
with zebularine for 96h, as determined by MTT assay. The graph is the mean of four independent 
experiments, each consisting of six replicates per group. Differences between treated groups versus 
controls are statistically different, according to the ANOVA test (_, p<O.Ol at each brostallicin 
concentration, starting from brostallicin 50ng/ml). Bars, S.D. 
CC) Western blotting against GSTpi on total proteins extracted by LNCaP treated or not with zebularine. 
LNCaP-GST clone 500 and clone 1000 are clones obtained by transfecting LNCaP with GSTpi 
cDNA and used as positive controls. Actin was used as housekeeping gene to detect the 
homogenous gel loading. 
(D) Total GST activity as determined by CDNB assay. The histogram is the mean ofthree independent 
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Figure 4.1.6 Effect of the combination of zebularine and TSA on brostallicin toxicity 
in LNCaP cells 
Effect of 72h treatment with increasing concentrations of brostallicin on LNCaP cells pretreated with 
zebularine (72h) and TSA (24h) alone or in combination as described in Results 4.1.2.3 (MTT assay). 
Differences between (TSA+zebularine) group versus control group are statistically significant according to 
tha ANOV A test (* , p<O.05). Bars, S.D. 
Pre-treatment of LNCaP wt cells with zebularine did not significantly affect their 
sensitivity to cDDP. 
In LNCaP-GST cells the efficacy of brostallicin was slightly increased when cells were 
pretreated with zebularine at 50llM for 8 days (fig.4.1.7, panel B), or at lOOIlM for 96h 
(fig.4.1.7, panel C) before brostallicin (Le. the same schedule adopted in LNCaPwt cells). 
On the contrary, zebularine had completely no effect on citotoxicity of brostallicin on 
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Figure 4.1.7 Effects of combination of zebularine and cDDP or brostallicin on GST 
expressing cells 
(A) Effect of cDDP treatment on LNCaP-GST cells (clone 54) compared to LNCaPwt cells treated or 
not with zebularine, as determined by MTT assay; differences result to be statistically significant 
between LNCaPwt and LNCaP-GST cells treated with 3~M (*, p<0.05), 6j.!M (e, p<O.OOl) and 
12j.!M (*, p<0.05) cisplatin, according to the ANOV A test. Differences between LNCaPwt and 
LNCaP+Zeb100j.!M are not statistically significant at each cDDP concentration used. 
(B) Effect of zebularine pretreatment (8days) on LNCaP-GST cell sensitivity to brostallicin; at 100 and 
200ng/rnl brostallicin, differences are statistically significant, with p<O.O 1 (_) according to the 
ANOVA test.(C) Effect of zebularine pretreatment (96h) on LNCaP-GST cell or Du145 cell (D) 
sensitivity to brostallicin. In (C) differences are statistically significant (* , p<O.05) at 50ng7ml and 
100ng/ml brostallicin, according to the ANOVA test, in (D) no statistically significant differences 
were found at each brostallicin concentrations used. In all cases, MTT assay was performed, each 
group consisting of sic replicates. Brostallicin and cDDP treatments took nh. 
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4.1.3 DISCUSSION 
The results described in this first chapter were aimed at showing that the effects obtained 
with the combination of demethylating agents and brostallicin strongly depend on the 
molecules considered, although data published in the literature could have been shown 
their efficacy as single agents in reverting the epigenetically silenced target (Lin et aI., 
2001a; Villar-Garea et aI., 2003). 
The in vitro studies undoubtedly offer the possibility to test several kinds of schedule of 
treatments, thus allowing to identify the most effective combination. 
In particular, zebularine was able to overcome the strong resistance of LNCaP cells to 
brostallicin treatment, through a not identified mechanism, and, even if I showed the 
results obtained with 96h zebularine pre-treatment, I had the opportunity to confirm the 
advantage of this combination with shorter or longer zebularine exposures. 
In general, the effects of the combination nearly resemble those of brostallicin alone on 
LNCaP-GST cells and this has been a very important goal in the project, although the 
specific re-expression of GSTpi has not been demonstrated. It cannot be neglected that 
there is an overall increase of the GST total enzymatic activity, that could explain the 
increased cytotoxicity of brostallicin. However, it is important to consider that the 
demethylating drugs do not specifically target an epigenetically silenced gene, but rather 
they exert a general activity on the genome, so it cannot be excluded that other genes could 
be affected by zebularine treatment, thus "helping" the brostallicin cytotoxicity; this could 
be suggested by its slight increase on LNCaP-GST cells pretreated with zebularine. 
The zebularine- brostallicin combination does not prevent the possibility of treatment with 
other cytotoxic drugs (such as cisplatin) which are usually detoxified by GST/GSH system, 
and this widens the therapeutic strategy against prostatic tumours. 
In summary all the experiments described gave me the opportunity to identify the best 
demethylating drug to combine with brostallicin: this goal could not be surely reached with 
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direct in vivo studies, both for ethical and economic reasons, because of the great number 
of animals needed. 
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CHAPTER 4.2 
IN VIVO COMBINATION OF THE DEMETHYLATING DRUG 




The capability of zebularine to increase the in vitro antitumour activity of brostallicin 
prompted me to test this combination in an in vivo model. 
In vivo studies are fundamental for testing of drugs, before evaluating their efficacy and 
safety in patients. In fact in vivo models allow not only the efficacy (i.e. effect on the 
tumour) of drugs or combinations to be evaluated, but also their toxicity (i.e. effect on 
normal tissues), although it is not practical to assess all possible schedules and 
concentrations used in the in vitro models. Moreover an in vivo system could change the in 
vitro activity of a drug, because of various mechanisms of detoxification and metabolism 
that may act within an organism. 
Few in vivo studies have analyzed the efficacy of zebularine as demethylating agent in 
solid tumours although it has been demonstrated to be able to revert p 16 promoter 
methylation in a model of bladder cancer (Cheng et aI., 2004a). The re-expression of this 
tumour suppressor gene was achieved through daily treatment (18 days) with high doses of 
zebularine (500mg/kg and 1000mg/kg, i.p. and per os), that did not show significant 
toxicity in balb-c nude mice. Based on this study, I planned to pre-treat mice with a similar 
schedule of zebularine, before administering brostallicin. 
4.2.2 RESULTS 
4.2.2.1 Antitumour activity of zebularine-brostallicin combination in LNCaP xenografts 
inSCIDmice 
The choice of this immunodeficient strain of mice (instead of the usually used less 
immunodeficient nude mice) depended on the weak tumorigenicity of LNCaP cells used 
as xenograft model. The first objective of this study was to evaluate the toxicity of daily 
administration of 500mg/kg or 1000mg/kg zebularine in SCID mice, a suitable host for the 
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growth of LNCaP cells as xenografts. Firstly untransplated mice were treated daily with 
zebularine Lp. and the body weights recorded. Zebularine 1000mg/kg was extremely toxic 
in SCID mice, starting from day 5 of administration (fig.4.2.1). This contrasts with the 
roughly total absence of toxicity recorded for balb-c mice (Cheng et aI., 2003). For this 
reason the zebularine dose was reduced to 750mg/kg, but this did not prevent a significant 
loss of body weight (>25%) by day 10 after beginning treatment, although no deaths 
occurred. 
In comparison, 500mg/kg zebularine was relatively well tolerated by these mice thus, 
although roughly 10% of weight loss could be observed, weight was rapidly regained after 
stopping treatment. Based on these results, zebularine at 500mg/kg was used in 









Figure 4.2.1 Toxicity of zebularine in untransplanted SCID mice 
Mice were treated with zebularine i.p.once a day for 18 days. The body weight was recorded daily. Each 
group ~as of 5 mice. D:ay O~ ftrst treatment Bars S.D. 
, I.' \. J 
The proposed schedule was that mice would to be treated for 18 days with zebularine and 
every 6 days with Lv. brostallicin at O.4mg/kg for three administrations. But after the first 
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combination treatment followed by 2 treatments with zebularine, mIce began to lose 
weight (figA.2.2, A) and therefore it was necessary to stop treatment. After a 6 day break 
for both drugs (during which body weight was partially restored), the schedule of the 
combination was resumed. 
Brostallicin or zebularine alone did not show any substantial antitumour activity, as 
expressed by the mean T/C% values respectively of 108 and 84 (table 4.2.1 , fig. 4.2.2,B). 
In contrast, the combination of the two drugs showed a mean T/C% value of 54, thus 
demonstrating that the zebularine-brostallicin combination had antitumour activity. As 
regards the toxicity (table 4.2.1), brostallicin and zebularine alone were well tolerated but 
for the combination, a 24% weight loss was recorded on the day of its nadir. This was 
partially restored by the end of the experiment, three weeks later. 
Treatment N° of mice 
Mean IC'o Weight loss Toxic 
(range) ('0) deaths 
Zebularine 7 84 (59-119) 6 017 
Brostallicin 7 108 (96-139) 11 0/7 
Combination 11 54 (37-71) 24 . 2/11 
Table 4.2.1 Parameters related to the in vivo treatments of the zebularine-brostallicin 
combination on LNCaP tumours 
Mean T/C% values calculated as described in Materials and Methods. In brackets are shown the highest and 
the lowest T/C% value reached one week after the last treatment.Toxicity expressed as toxic deaths (occurred 
on the 5th and 7th day after the flrst treatment with brostallicin respectively) and percentage of weight loss, 
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Figure 4.2.2 In vivo antitumour activity of zebularine-brostallicin .combination on 
LNCaP transplated mice 
(A) Relative body weight (calculated as described in Materials and Methods) curves. Body weight of 
each mouse was recorded on the same days of tumour measurements. 
(B) Tumour growth (expressed as relative tumour volume) curves of mice transplanted with LNCaP 
cells and treated with the combination zebularine-brostallicin. The horizontal brackets on X axis 
indicate the days of treatment. RTV values of the combination group are significantly (ANOVA 
test) reduced versus control group (p < 0.01), and versus brostallicin (p < 0.0001) and zebularine (p 
< 0.05) given alone, two days after the last treatment. 
Day 0= first treatment with zebularine; bars S.E. 
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When the LNCaP-GST (clone 54) xenografts were treated with brostallicin (O.4mg/kg, 
every 14 days, twice), their volumes attained 62% of the untreated controls (fig.4.2.3, table 
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Figure 4.2.3 Antitumour activity of brostallicin on LNCaP-GSTpi tumours 
Tumour growth curves of mice treated with brostallicin on day 6 and on day 20 (q14xd2), accordingly to the 
schedule ofbrostallicin treatment on LNCaPwt tumours. 
RTV values of the treated group were significantly (ANOV A test) reduced versus the control group 
(p < 0.05), two days after the last treatment with brostallicin. 
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It is also important to note that the doubling time of LNCaP-GST tumours was not 
affected by the overexpression of GSTpi (table 4.2.2,B), because it has no role as tumour 
suppressor, unlike p16 in bladder cancer, whose re-expression resulted in the inhibition of 
tumour growth (Cheng et aI., 2003). 
(A) 
Treatment N° of mice Mean T/CCYo Weight loss Toxic eyo) deaths 
Brostallicin 8 mice 62 (50-79) 11 017 
(B) 
Tumour LNCaP WT 16 ± 2 
Doubling Times 
(days) LNCaP -GSTpi 15 ± 4 
Table 4.2.2 LNCaP-GST tumour sensitivity to brostallicin 
Mean T/C% values (A) and DT (B) values calculated as described in Materials and Methods. In brackets (A) 
the highest and the lowest T /C% values attained a week after the last treatment with brostallicin are 
indicated; the highest weight loss % value was attained a week after the last treatment with brostallicin. 
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4.2.2.2 Assessment of re-expression of GSTp in LNCaP xenografts after zebularine 
treatment 
In order to establish if zebularine treatment affected the re-expression of GSTpi, which 
would correlate with the improvement of the antitumour activity of brostallicin, western 
blotting and immunohistochemistry were performed on tumour samples taken from mice 
sacrificed one day after the last treatment with zebularine. LNCaP tumour extracts did not 
show any expression of GSTpi (fig.4.2.4); although, it was very evident in LNCaP-GSTpi 







Figure 4.2.4 Western blotting for GSTpi expression in LNCaP tumour extracts 
Detection of GSTpi expression on protein extracts from tumours of mice treated' with two cycles of 
zebularine, excised one day after the last treatment, according to the schedule shown in figA.2.2,B . Proteins 
from LNCaP-GST tumours were used as positive controls. 
Actin was used to assess the homogeneously of gel loading. 
Because this technique does not allow an appreciation of any effects produced at an 
individual cell level and because a weak re-expression could be masked by the total protein 
amount derived from the homogenized tumours, an immunohistochemical examination of 
tumours was carried out. 
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The morphology of LNCaP and LNCaP-GST tumours, evaluated by hematoxylin and eosin 
staining on fixed tumour slices, showed no detectable differences among tumour types (i.e. 
LNCaPwt and LNCaP-GST tumours). Focal necrosis (20-60% of the mass) and abundant 
hemorrhagic areas were seen within the tumour masses (fig 4.2.5, A). 
As regards IRC, no positive GSTpi staining was detected in LNCaP tumours, treated or not 
with zebularine (table 4.2.3, fig 4.2.5, B). In contrast, a strong positivity was detected in 
LNCaP-GST tumours, and this was localized, as expected, in the nucleus and cytoplasm of 
the majority of tumour cells (fig.4.2 .5, C). 
stained slides protocol IHC result 
LNCaP wt/5 847-sCC1 negative 
LNCaP wt/6 847-sCC1 negative 
LNCaP wt/7 847-sCC1 negative 
LnCaP wtZEBU/5 847-sCC1 negative 
LnCaP wtZEBU/6 847-sCC1 negative 
LNCaPwtZE B U/7 847-sCC1 negative 
LNCaPwtZE B U/8 847-sCC1 negative 
LNCaPwtZE B U/9 847-sCC1 negative 
LNCaPwtZEBU/10 847-sCC1 negative 
LNCaP GST/6 847-sCC1 >90% 
LNCaP GST/7 847-sCC1 >90% 
LNCaP GST/8 847-sCC1 >90% 
Table 4.2.3 Summary of IHC detection of GSTpi in LNCaP tumours 
847-sCCl is the IHC protocol followed by Ventana discovery autostainer. 
Samples LNCaPwt ZEBU 5-7 derived from mice treated with one cycle of zebularine; samples 
LNCaPwtZEBU 8-10 derived from mice treated with two cycles ofzebularine (as indicated in fig 4.2.2, B) 
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(A) 
(B) LNCaP wt#7 LNCaPwtZEBU #9 
10X 
(C) 
Figure 4.2.5 Morphology and GSTpi expression in LNCaP tumours by IHC 
(A) Morphology ofLNCaPwt (left) and LNCaP-GST (right) tumours evaluated by Haematoxylin and 
Eosin staining (Hemorrhagic areas are indicated). 
(B) me analysis for GSTpi expression in LNeaPwt tumours treated (right) or not (left) with zebularine. 
Counterstaining was with hematoxylin. 
(C) mc analysis for GSTpi expression in LNCaP-GST tumours, showing the cytosolic and nuclear 
distribution of GSTpi. eounterstaining was with hematoxylin. 
10x of original magnification; in (e, right) 40x of original magnification. 
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4.2.2.3 Methylation analysis of the GSTpi promoter 
Methylation of the GSTPl promote was analyzed by methylation-specific PCR (MSP) and 
pyrosequencing (PSQ), which, respectively in a qualitative and quantitative way, 
determine the methylation status of DNA after bisulphite modification. The promoter 
region amplified by the primers chosen for MSP corresponds to the CpG island region with 
the highest observed versus expected CpG ratio, immediately upstream the transcription 
start site. The demethylation of this region could therefore affect the transcription of the 
gene. The region considered for PSQ was slightly downstream to that amplified by MSP 
(figure 4.2.6). 
By MSP (performed on the same mice tumours used for IHC), no change in the 
methylation status between controls and treated group samples was evident (figA.2.7). 
I used only primers for methylated cytosines, rather than both for methylated and 
unmethylated cytosines, because the reduction in methylation could be better demonstrated 
byPSQ. 
PSQ was used to analyze 14 CpG dinucleotides within the region amplified by PCR and 
the sequencing of this region provided the percentage of methylated cytosines for each of 
the CpG dinucleotides considered (fig 4.2.8,A). As could be evaluated from the scatter 
graph showing the % methylation change of treated samples versus controls, no differences 
in the GSTPl methylation level are evident, suggesting that the zebulaiine did not bring 
about the demethylation of the GSTPl promoter (fig.4.2.8, B). 
These data confirm, accurately and quantitatively, those obtained using MSP, and support 
the observation of the absence of GSTpi protein re-expression demonstrated by western 
blotting. 
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Human GSTP1-1 promoter 
CTGGGGACCTGGGAAAGAGGGAAAGGCTTCCCCGGCCAGCTGCGCGGCGACTCCGGGGACTCCAGGG 
: I I I I I I : : I I I I I I I I I I I I I I I I I : I I : : : ++ I : : I I : I I ++++ I ++ I : I : ++ I I I I : I : : I I I I 
TTGGGGATTTGGGAAAGAGGGAAAGGTTTTTTCGGTTAGTTGCGCGGCGATTTCGGGGATTTTAGGG 
CGCCCCTCTGCGGCCGACGCCCGGGGTGCAGCGGCCGCCGGGGCTGGGGCCGGCGGGAGTCCGCGCC 




I : : I I I I I I I ++ I : ++ I ++ : ++ I I I : I : I I : I : I I I I I ++ I I I ++ I I I ++ I I I : : I : : : I I I I I I I I 
TTTAGAAGAGCGGTCGGCGTCGTGATTTAGTATTGGGGCGGAGCGGGGCGGGATTATTTTTATAAGG 
CTCGGAGGCCGCGAGGCCTTCGCTGGAGTTTCGCCGCCGCAGTCTTCGCCACCAGTGAGTACGCGCG 
: I ++ I I I I : ++++ I I I : : I I ++: I I I I I I I I ++ : ++ : ++: I I I : I I ++ : : I : : I I I I I I I I ++++++ 
TTCGGAGGTCGCGAGGTTTTCGTTGGAGTTTCGTCGTCGTAGTTTTCGTTATTAGTGAGTACGCGCG 
GCCCGCGTCCCCGGGGATGGGGCTCAGAGCTCCCAGCATGGGGCCAACCCGCAGCATCAGGCCCGGG 
I : : ++++ I : : : ++ I I I I 1 I I I 1 : I : 1111 : I : : : I I : I I11 11 : : 11 : : ++: I I : I I : I I I : : ++ I I 
GTTCGCGTTTTCGGGGATGGGGTTTAGAGTTTTTAGTATGGGGTTAATTCGTAGTATTAGGTTCGGG 
CTCCCGGCAG 
: I : :++1: 11 
TTTTCGGTAG 
Figure 4.2.6 CpG island of the GSTPl promoter 
TSS 
Top: CpG island region identified by Methprimer software (Li and Dahiya, 2002), accordingly to Gardiner 
and Frommer criteria (Gardiner-Garden and Frommer, 1987). The region with the highest ObscpdExpCpG 
ratio is highlighted. 
Bottom: CpG island sequence, corresponding to the highlighted region in the top figure, for which primers 
for MSP (red) and PSQ (blue) were designed. The upper row of the sequence corresponds to unmodified 
DNA sequence, the lower row corresponds to bisulfite modified sequence. The arrow indicates the 
transcription start site, TSS (TATAA stretch of nu cl eo tides). 







M Ctrls Zebularine Autopsy N 50% IVM 
Figure 4.2.7 Agarose gel analysis of MSP of the GSTPl promoter 
Primers for methylate cytosines were used. The IVM, 50% and N are controls with respectively 100%, 50% 
and 0% methylation (IVM, In Vitro Methylated, N, normal). 
Calponin was used as control for homogeneous bisulfite modification. 
Ctrls indicate samples deriving from untreated mice, zebularine indicates samples taken one day after the last 
treatment with zebularine (corr.esponding to the.same material analyzed by western blotting and IRC), and 
autopsy indicates samples taken from animals sacrified at autopsy. 
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(A) 64 : lYGGAGGTYGYGAGG11TTYGTTGGAGTIlYGTYGTYGTAGTITTYGTTATTAGTGAGTAYGYGYGGTlYGYGTITTYGGGGA ~ I~I~ ~ I~I ~~ I~I ~~~~~~ 
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W " W ~ m ~ ~ 6 ~ ~ ~ ~ M ~ W ~ 
Mean Methylation value (%): 92 ± 11 
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Figure 4.2.8 Pyrosequencing of the GSTPl promoter 
I 
I 
(A) Pyrograms of 14 CpG dinucleotides comprised in the region amplified by PCR and analyzed using PSQ 
primers (see figure 4.2.6).The highlighted values indicate the percentage of methylation in each position 
considered. The upper sequence represents the sequence analyzed, the lower sequence represents the 
dispensation order of nucJetides; Y axis represents arbitrary units related to the PPi reaction. The 14 CpG 
analyzed are 332 bp upstream of exon 1 of the gene. The upper graph represents the analysis of a 
representative LNCaP control tumour, while the lower graph represents the analysis of a representative 
LNCaP tumour treated with zebularine. (B) Methylation changes at each CpG site, calculated as ratio of the 
% methylation of zebularine treated samples versus the % methylation of controls at the same CpG 
dinucleotide. Each point represents a treated mouse. 
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4.2.3 DISCUSSION 
The data shown in this chapter support the in vitro finding, that pre-treatment with 
zebularine significantly increases the antitumour activity of brostallicin. In fact we have to 
consider that brostallicin has no activity at all on LNCaP tumours (the tumour growth 
curves are superimposed to that of the controls), but when combined with zebularine, the 
tumour growth inhibition was apprximately 50%. Thus, in vivo, zebularine sensitizes 
LNCaP tumours to brostallicin. However zebularine did not elicit GSTpi expression (as 
shown by western blotting and IHC) and furthermore, there was no decrease in GSTPl 
methylation, which might have led to transcription of the gene. Therefore the relationship 
between GSTpi expression and cytotoxicity of brostallicin has not been verified in this 
model, even though it has been extensively studied and confirmed in other tumour cells 
lines (Geroni et aI., 2002). This concept was further strengthened by the data obtained for 
LNCaP-GST tumours, where, although the GSTpi protein levels were very high, as 
demonstrated by the strong immunostaining in IHC, the antitumour activity was similar to 
that obtained with the combination of zebularine plus brostallicin in LNCaP wt tumours. 
As I mentioned in the general introduction, GSTpi has not only a detoxification role in the 
cell, but, in its monomeric form, also a regulatory role by sequestering INK protein and 
preventing it exerting its apoptotic function on the cells in unstressed conditions. Thus we 
cannot exclude the possibility that very high GSTpi expression levels in LNCaP-GSTpi 
cells could have had the paradoxical effect of interfering with the apoptotic process, a 
means by which brostallicin can induce cell death. 
At the moment, I have not experimentally demonstrated this possible alternative role of 
GSTpi in reducing brostallicin cytotoxicity, which thus remains speculative. 
One hypothesis that seems to emerge from analyzing the in vivo data is that the enzymes 
involved in the intracellular activation of brostallicin in LNCaPwt (in combination) and 
LNCaP-GST may be different. 
153 
It was clear that LNCaP-GST cells are more sensitive to brostallicin than LNCaP cells and 
this is probably due to the expression of GSTpi. Thus the in vitro study showed that 
LNCaPwt cells not only have no detectable GSTpi protein expression, but also no activity 
on the CDNB substrate, which conversely became very high on the transfected cells. 
However, zebularine was not effective in GSTPI demethylation in LNCaP tumours, even 
though a sensitization to brostallicin was evident. 
It must be considered that many other epigenetically silenced genes may have had their 
methylation reverted after treatment. The absence of antitumour activity of zebularine 
alone might suggest that tumour suppressors do not undergo such re-expression. 
As described previously, the current perception is that demethylating agents have no a 
specific target of activity. However it is feasible that different levels of methylation in 
genes belonging to different pathways could determine a higher or lower sensitivity to 
being demethylated by treatments with these epigenetic drugs. 
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CHAPTER 4.3 
INVOLVEMENT OF GST ENZYMES IN THE ANTITUMOUR 
ACTIVITY OF BROSTALLICIN 
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4.3.1 INTRODUCTION 
I have above described the effects of the demethylating agent zebularine on the antitumour 
activity of brostallicin, which is clearly increased. This effect was expected to arise from 
the reversion of the methylation of the GSTPl gene promoter, but this has been shown not 
to be the case. 
As discussed in the previous chapter, the increased cytotoxic activity of brostallicin might, 
then, be explained by a non-specific effect of zebularine on some unidentified target. In my 
opinion, this does not detract from the results obtained, above all because I have shown 
activity in an in vivo system. Indeed it encourages further investigation of the possible 
consequences of zebularine treatment. 
A suggestion came from the in vitro data showing that LNCaP-GSTpi cells were more 
sensitive to brostallicin if pre-treated with zebularine (fig.4.1.7, B and C). This was 
different to that observed in Du 145 cells, whose sensitivity to brostallicin was not 
increased by zebularine (fig. 4.1.7, D). Moreover, another suggestion derived from the 
increased GST total activity detected by the CDNB assay, the results of which did not 
correspond to any signal evident by western blotting using an antibody recognizing 
specifically GSTpi: CDNB is a substrate for all classes of GST, so we cannot exclude the 
possibility that other promoter methylation silenced GST classes may have been 
reactivated by zebularine. 
In this chapter I will investigate the possible involvement of these classes of GST enzyme 
in the increased antitumour activity of brostallicin after treatment with zebularine. 
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4.3.2 RESULTS 
4.3.2.1 Role of different cytosolic classes of GST in the antitumour activity of brostallicin 
GSTPl methylation is not a peculiarity of the prostatic cancer cell line LNCaP alone, but 
has also been detected in the breast cancer cancer cell line MCF-7 (Jhaveri and Morrow, 
1998) and this correlates with the lack of GSTpi protein expression in these cells. 
However, the very low GST total activity, as determined by the CDNB assay (fig.4.3.1, 
(Tew et aI., 1996)), suggested that MCF-7 are deficient in this detoxification system and 
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Figure 4.3.1 CDNB assay on LNCaP wt and MCF -7 wt cells 
The CDNB assay was performed on cytosolic extracts of untreated cells, according to the method described. 
Bars, S.D. 
Clones of MCF-7 cells transfected with plasmid constructs containing the cDNA encoding 
for GSTu, GST~ and GST7t classes were available at Nerviano Medical Sciences (Milan, 
Italy), where their sensitivity to brostallicin were determined in parallel. 
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The results summarized in table 2 show that both GSTpi and mu made MCF-7 ten times 
more susceptible to the cytotoxicity of brostallicin than the empty vector, while GSTu 
overexpressing cells are only two times more sensitive to brostallicin. 
Cells 
MCF·7 MCF·7 MCF·7 MCF·7 
neo GST·1t GST·~ GST·u 
Brostallicin Average 
ICso ~M 0.55 0.06 0.06 0.24 
SD 0.10 0.001 0.001 0.01 
Table 4.3.1 Cytotoxicity of brostallicin in MCF -7 clones 
The table shows the ICso values of brostallicin on MCF -7 cells transfected with plasmid constructs of GST n, 
cr, and Il, compared to ICso value determined on MCF-7 cells transfected with the empty vector (MCF-7/ 
neo). The data in the table were kindly purchased by Nerviano Medical Sciences (Milan, Italy). 
4.3.2.2 Affinity studies of brostallicin for classes)l and 1r of GST 
Kinetic studies of the reaction between brostallicin and GSTmu and GSTpi were 
performed by Prof. Caccuri's group at the University of Tor Vergata in Rome. 
The results show that GSH is required for brostallicin binding to GSTpi protein and that 
brostallicin behaves as an uncompetitive inhibitor of GSH (fig.4.3.2,A). Moreover, 
brostallicin behaves as a non-competitive inhibitor of the co-substrate CDNB (fig. 4.3.2,C). 
, . '. , , • . 1 . ( I • .., . 
Both inhibition constants were in the micromolar range with Ki values of about 40llM 
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Figure 4.3.2 Inhibition properties of brostallicin towards GSTpi 
See the description in the text. 
When GST~ was considered (fig.4.3.3), brostallicin behaved like a mixed-type inhibitor in 
respect to both GSH and CDNB (fig.4.3.3, A and D) and the Ki values were about 1~M 
(the highest value was 1.6~M and the lowest 0.3~M, fig. 4.3.3 , E), about 40 times lower 
, ., 
than Ki found for GSTpi. 
These results suggest that GST~ has a binding site for brostallicin, that has higher affinity 
than that of GSTpi. 
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Figure 4.3.3 Inhibition properties of brostallicin towards GST" 
See the description in the text. 
When the effects of brostallicin concentration on the initial velocity of reaction catalyzed 
by GSTJ.L and pi were studied (fig.4.3.4), it was evident that the GSTJ.L reached maximum 
velocity at 5J.LM brostallicin (fig.4.3.4,A) and this depended on the high affinity of GSTJ.L 
for brostallicin. The GSTpi kinetics were characterized by a slow reaction rate at low 
brostallicin concentrations, followed by an exponential rate increase at higher 
concentrations up to a maximum velocity which was four times higher than that observed 
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with GST/l (fig. 4.3.4, B): in particular, at 5/lM brostallicin concentration, the velocity of 
reaction catalyzed by GSTpi was significantly lower than that catalyzed by GST/l. 
From the biological point of view, these data could suggest that in the presence of very low 
intracellular amount ofbrostallicin, the binding with GST/l is facilitated. Conversely, a low 
GST enzymatic activity could, in any case, ensure the reaction with brostallicin, because 
the high affinity, in particular for GST/l, would allow GST-brostallicin binding and, as a 
consequence, the intracellular activation of the drug. 
A 
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Figure 4.3.4 Effects of brostallicin concentration on the velocity of reaction with GST 
enzymes 
Valu~s obtained usipg increasing concentrations ofbrostallicin were plotted against GSTmu (upper graph) or 
, 
GSTpi (lower graph) activity (determined as described in Materials and Methods) expressed as ~t1uorescence 
I 
(F) recorded! minute. 
161 
4.3.2.3. GSTmu methylation analysis in LNCaP tumours 
The above data suggests that brostallicin can be activated intracellularly not only hy 
GSTpi, but also by GSTmu and that the higher affinity of this latter class for brostallicin 
can more easily allow its activation when low levels of the enzyme are present. 
Figure 4.3.5 shows that the GSTmu promoter contains a CpG island and, as a consequence, 
the same mechanism of silencing characterizing GSTPl gene could be relevant to GSTMl. 
Therefore, I examined the methylation status of the samples previously analyzed for 
GSTPl methylation, in particular those derived from the in vivo study, in which I could not 
detect any decrease in GSTPI promoter methylation. 
DNA was modified by bisulphite and then used in MSP: primers were specific for the 
GSTmu promoter containing the CpG island (fig.4.3.5,C), thus they were able to 
discriminate the methylated samples from the unmethylated ones. In this analysis, I used 
the touch down PCR with higher temperatures of primer annealing (Lodygin et aI., 2005) 
in order to avoid false positives. As is evident in the MSP results shown in fig. 4.3.6, in the 
three control samples, GSTmu promoter is totally methylated: no signal is associated with 
the pair of primers specific for the unmethylated promoter. Conversely, the three samples 
taken from mice treated with zebularine for two cycles (when the effects of zebularine on 
the antitumour activity of brostallicin were more evident) show a detectable signal 
corresponding to promoter demethylation in 2 of the 3 mice used in the analysis. 
This demethylation was reverted in samples taken from mice at autopsy. 
So it seems that zebularine treatment had no effect on GSTPI promoter methylation, but it 
demethylated at least partially the GSTmu promoter. Comparing the GSTPl CpG island 
(fig. 4.2.6) and the GSTMl CpG island (fig. 4.3.5, C), a lower density of CpG 
dinucleotides is evident in the latter, so I speculate that it could be easier to induce 
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TTGGGTAGGGAAGTTGGCGAGGTCGAGTTTCGTTTTGGGTTTTTGGGCGTTTTGATTTCG 
CTCCCGGAACCCTCGGGCCTGGGAGGCGGGAGGAAGTCTTACTGAGTGCAGCCCCAGGCG 
: I : : ++1 11::: 1++11 :: 1111111++111111111 : Ill : 111111 : 11 :::: 111++ 
TTTTCGGAATTTTCGGGTTTGGGAGGCGGGAGGAAGTTTTATTGAGTGTAGTTTTAGGCG 
CCCTCTCCCGGGCCTCCAGAATGGCGCCTTTCGGGTTGTGGCGGGCCGAGGGGCGGGGTC 
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TTTTTTTTCGGGTTTTTAGAATGGCGTTTTTCGGGTTGTGGCGGGTCGAGGGGCGGGGTC 
GCAGCAAGGCCCCGCCTGTCCCCTCTCCGGAGCTCTTATACTCTGAGCCCTGCTCGGTTT 
+ : 11 : 1111 :: : ++ :: Ill :::: I : I : ++111 : I : 11111 : I : 1111 ::: 11 : 1++ 1111 
GTAGTAAGGTTTCGTTTGTTTTTTTTTCGGAGTTTTTATATTTTGAGTTTTGTTCGGTTT 
AGGCCTGTCTGCGGAATCCGCACCAACCAGCACCATGCCCATGATACTGGGGTACTGGGA 
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TATTCGCGGGGTGAGCGAGGGTTCGTTGGACGGTGGGACGAGGGCGTAGGGGAGGGAAGT 
GCGAAGCAGCTGCGGGACGGACTCTAGGGACCGTTCCTCTTCAGGGCTGCCCGCCTCAGA 
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GCGAAGTAGTTGCGGGACGGATTTTAGGGATCGTTTTTTTTTAGGGTTGTTCGTTTTAGA 
Figure 4.3.5 CpG island of GSTMl promoter 
(A): CpG island designed by Methprimer software, accordingly to Gardiner and Frommer criteria. 
(C}: CpG island sequence on which primers for MSP (red) were designed. The upper row of the sequence 
corresponds to unmodified DNA sequence, the lower row corresponds to bisulfite modified sequence. The 
arrow cobnetting the' CpG islahtl and the sequence indicates the position of the first primer on the island 
Symbols + indicate the CpG dinucleotides. (B) The arrow indicates the position of the transcription start site 
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Figure 4.3.6 MSP on bisulfite modified GSTMl promoter 
(A) Primers for methylate (M) and unmethylated (U) cytosines were used. 
"Controls" indicate samples deriving from untreated mice, "zebularine" samples were taken one day after the 
last treatment with zebularine (corresponding to the same fragments analyzed by western blotting, mc and 
GSTPl methylation), and "autopsy" samples were taken from sacrified animals at autopsy. The arrows 
highlight the detection ofunmethylated cytosines in samples treated from the zebularine group. 




The data presented in this chapter may help in understanding the results obtained using the 
combinations of zebularine and brostallicin on the LNCaP cell line in vitro and in vivo. 
As I already mentioned, this cell line is a useful model for prostate cancer, because such 
tumours are also devoid of certain mechanisms of detoxification that protect the cells 
against dangerous molecules. 
The methylation of the GSTP1 promoter has been one of the most extensively investigated 
molecular characteristics of prostatic tumours, and many papers have been published that 
extensively examine the occurrence of this silencing in the different stages of the disease 
(Nelson et aI., 2003; Perry et aI., 2006; Meiers et aI., 2007). Very recently, there has been a 
shift towards the analysis of all classes of the GST family and this has revealed that GSTu 
and GST~ also display a significant reduction or loss of expression in prostatic tumours 
(Bostwick et al., 2007). In particular, silencing depending on promoter methylation has 
also been shown for GST~ and this methylation is retained by the LNCaP cell line 
(Lodygin et aI., 2005). 
This sheds new light on the data obtained, both in vitro and in vivo, with the combination 
of the demethylating agent zebularine and brostallicin. 
The data obtained for the transfected MCF -7 cells and the kinetic studies have 
demonstrated the ability of GST~ to catalyze the intracellular activation of brostallicin. 
Furthermore, at low concentrations, GST~ has shown a higher affinity for this drug than 
GSTpi, suggesting that it could be "easier" to capture brostallicin when there are low 
concentrations of both enzyme and drug in the cell. 
This is consistent with the mechanism related to methylation reversion by demethylating 
drugs: these do not totally'eliminate methyl groups from DNA: the level of demethylation 
depends (among other possible factors) on the percentage of methylated cytosines in the 
CpG island spanning the promoter analyzed. This could explain the different susceptibility 
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of different genes to treatment with demethylating drugs, as is clearly the case for GSTpi 
and mu. However their function is only temporarily restricted and so, differently from 
silencing that depends on a mutation or a chromosomal aberration, the decreased 
methylation may be reverted after stopping demethylating agent treatment, with kinetics 
that may also be specific for each gene. 
This may be the case for GST~ because no unmethylated signals were evident in the 
samples taken at autopsy, three weeks after the last treatment with zebularine. 
These data altogether indicate that zebularine is able to potentiate brostallicin antitumour 
activity through its demethylating activity not on GSTpi, as was originally hypothesised, 
but GSTmu. Admittedly, the level of demethylation was marginal, but I have also argued 
that even if this resulted in very small increases in GSTmu activity (which has yet to be 
demonstrated), because of the affinity of GSTmu for brostallicin, it may have been 
sufficient to cause the in vivo (and in vitro) sensitization. 
Essentially, the hypothesis generated, based on the mechanism of action of brostallicin, 
were therefore confinned in vitro and in vivo. 
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CHAPTER 4.4 
METHYLATION ANALYSIS OF THE MAGE lA GENE IN A PHASE 
I STUDY OF DECITABINE IN PATIENTS RECEIVING 
EPIRUBICIN, CISPLATIN AND 5-FU FOR ADVANCED GASTRIC 
OR OESOPHAGEAL CANCER 
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4.4.1 INTRODUCTION 
Following the discovery of the fundamental role of epigenetic aberrations in cancer 
development, new therapeutic prospects have arisen for several kind of cancer. This 
possibility has been further supported by the FDA approval of decitabine for the treatment 
of haematopoietic malignancies and many clinical studies have been designed to widen its 
application also to solid tumours. But in contrast to the encouraging results obtained for the 
blood cancers, no significant results have been obtained by treating solid tumours with 
decitabine as single agent. Nevertheless, as I mentioned in the general introduction, 
preclinical data have suggested the possibility of combining demethylating molecules with 
cytotoxic drugs, especially when the acquisition of drug resistance is related to the 
promoter methylation of genes involved in cellular responses to chemotherapy (Plumb et 
al., 2000). 
In order to establish the doses and the schedule of decitabine treatment that is able to 
induce DNA demethylation, a phase I clinical study has been conducted in patients 
affected by gastro-oesophageal tumours and receiving epirubicin, cisplatin and protracted 
venous infusional5-FU (ECF) as standard treatment. 
Gastro-oesophageal tumours are characterized by the epigenetic inactivation of several 
tumour suppressor genes and of genes involved in cell adhesion (CDHl), DNA repair 
(MGMT, GSTPl) and cell cycle control. Reversal of hypermethylation by treatment with 
decitabine may allow the reactivation of these genes and, hence, the possibility of 
circumventing drug resistance in cancer cell. 
Many studies have shown that low doses of decitabine are more effective than higher doses 
in inducing DNA hypomethylation with minimal toxicity. The first clinical studies attained 
this objective by a daily intravenous infusion of the drug (Schwartsmann et aI., 2000). 
Recently, a phase I study on solid tumours treated with decitabine in combination with 
carboplatin has shown that a single dose of decitabine, administrated before carboplatin, 
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can be enough to obtain the highest level of demethylation in tumours about 10 days after 
treatment for each dose used and that this demethylation is reverted by day 22 (Appleton 
et al., 2007). 
In this chapter I will describe the results of methylation analysis performed on tissue and 
blood taken 11 days after one decitabine treatment of patients with gastro-oesophageal 
cancer. The analyses have been carried out on the MAGE 1 A gene as marker of the effect 
of the demethylating treatment, because, as I mentioned in the general introduction, this 
gene is only expressed in the testis and is bi-allelically methylated and transcriptionally 
silenced in normal tissues. 
4.4.2 RESULTS 
4.4.2.1 Methylation analysis of MAGE lA gene 
The methylation analysis was conducted on tissue and blood samples from seven patients 
from those recruited to the clinical study. Biopsies of normal mucosa and of primary 
tumour sites have been taken at the time of diagnosis (day 0), together with peripheral 
blood samples, and the methylation level established at this time point represented the 
reference level for the analysis conducted on samples taken 11 days after one decitabine 
treatment administrated on day 1 with the starting dose of 30 mglm2• 
The methylation was analyzed at three different CpG sites in the MAGEIA promoter by 
pyrosequencing. 
In normal mucosa, the mean methylation value obtained for the three CpG sites was 90% 
for all patients on day 0 and this value was unchanged in samples taken 11 days later (fig. 
4.4.1, upper panel). This trend was also confirmed by the analysis of each CpG site, when 
the ratio between methylat~on valuqs. at day 11 versus the methylation values of the 
corresponding site on day 0 were calculated (fig. 4.4.1, lower panel). As is clearly shown, 
no methylation changes occured after treatment with decitabine. 
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The upper panel shows the average methylation percentage of the cytosines of the three different CpG sites 
analyzed at the time of diagnosis and 11 days after one treatment with decitabine; the lower panel shows the 
methylation changes at each CpG site, calculated as ratio of the % methylation on day 11 versus the % 
methylation of the same site at the time of diagnosis. 
, A total of seven patient~ "Yere analyzed and each ascribed a colour. 
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In blood samples, MAGE1A was methylated to the same extent as the normal mucosa, but 
methylation was more extensively affected than normal tissue by treatment with 
decitabine. However, this is not a general trend in each patient, because, while in two 
patients there is a decrease of methylation of about 10%, in the others there is a mean 
decrease of about 2-5%, distributed quite uniformly in the three CpG sites analyzed 
(fig.4.4.2). 
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Figure 4.4.2 Methylation analysis of blood samples by PSQ 
See previous figure for details. 
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In tumour biopsies (fig.4.4.3), the analysis showed a very different situation: the level of 
MAGE lA methylation was very variable in the untreated samples and this is in general 
associated to tumour transformation; in particular, except for three patients, the mean 
methylation level is equal or lower than 80% (fig.4.4.3 upper panel). The effects of 
decitabine treatment are generally more extensive than in the normal tissue and blood 
samples. Thus in three patients, the methylation decreased to ::::::50% or less, while two 
patients have an overall decrease of 2-5% and in two patients there was a slight increase in 
methylation. There were also slightly different hypomethylation levels for the three CpG 
positions considered. Nevertheless two patients show no significant changes in methylation 
level of MAGE lA gene, even when a small but appreciable decrease in methylation was 
seen in their blood samples. 
4.4.3 DISCUSSION 
The possibility of adopting a combination approach of demethylating agents and cytotoxic 
drugs is becoming increasingly considered for clinical trials. Confirmation of the 
underlying hypothesis obviously requires the analysis of the effects obtained on DNA 
methylation both as overall changes and at selected gene promoters and PSQ is able to 
quantify the methylation level at single cytosines in selected CpG islands (Tost and Gut, 
2007). In this chapter I have presented the PSQ analyses of tissue and blood samples of 
patients from a phase I clinical study of a combination of decitabine with an ECF regimen. 
Although only a few patients analyzed, some conclusions could be made. 
Overall, normal tissues showed consistent interindividual patterns which were generally 
not affected by demethylating treatment. In contrast blood but more extensively tumour 
samples show a clear general demethylation of the MAGE1A CpG sites. This could 
probably be related to a higher level of proliferation of blood and cancer cells compared to 
normal cells: decitabine exerts its demethylating function by incorporation into DNA of 
dividing cells and only in this way prevents the action of DNMTs. In contrast to what was 
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published in another phase I study (Appleton et aI. , 2007), I could see a much more 
extensive but extremely variable demethylation in tumour samples than in blood samples. 
In this context it is also important to consider the different kind of tumours recruited in the 
two different studies, which may explain the opposing results. In addition, a lesser effect 
on blood could also suggest a reduced haematological toxicity and this is would be an 
advantage rather than a disadvantage. 
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Figure 4.4.3 Methylation analysis of tumour samples I by PSQ 
See figure 4.4.1 for details. 
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It is important to emphasise that there are patients whose tumours are clearly unresponsive 
to decitabine treatment. The reasons for this could be different in different patients and we 
have to consider that there may be a number of parameters influencing the amount of the 
effective molecules being incorporated into DNA. Neverthless the responses in terms of 
modulating the levels of methylation (5/7) confirmed that one treatment with decitabine is 
able to exert its effects on MAGEIA promoter methylation in tumour cells. 
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5. GENERAL DISCUSSION 
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In the last few years there has been a sustained effort aimed at exploiting the increasing 
knowledge of the molecular mechanisms leading to tumour formation in order to adupt 
new therapeutic strategies that will be more specific for cancer cells. 
One of the most investigated fields of research has been the epigenomics of cancer, which 
in essence consists of several reversible chemical modifications affecting the chromatin 
components, DNA and histone proteins. Thus, molecules that can revert DNA methylation 
and histone deacetylation have been tested at both the preclinical and clinical level (Y 00 
and Jones, 2006). At the moment, the efficacy of the oldest DNA demethylating agent, 5-
aza-dC cannot be questioned. However characteristics, such as its chemical instability, 
toxicity and inactivation by cytidine deaminase heve prompted the search for and 
development of other molecules that are able to revert DNA methylation. 
In the scientific literature, what has emerged, from testing both nucleoside and non-
nucleoside analog DNA methylation inhibitors, is that their efficacy can depend on the cell 
line being investgated and the methylated promoter being considered (Chuang et aI., 2005; 
Stresemann et aI., 2006). 
I have shown that the choice of the right demethylating drug is a fundamental step in the 
preclinical evaluation of the feasibility of combining a DNMT inhibitor with brostallicin, 
not only for its capacity to induce brostallicin cytotoxicity in the cellular model chosen, but 
also for the inherent toxicity of the demethylating drug. In general, the use of non-
nucleoside analog demethylating molecules did not improve brostallicin activity, although 
no inherent toxicity was recorded at the concentrations and schedule used. However, 
because no methylation analysis was performed in this study, it is not possible to evaluate 
the capability of these molecules to demethylate the GSTP1 promoter or that of other 
genes. The data available in other studies are controversial. Thus, GSTPl methylation in 
LNCaP cells was reverted by a 1-2 week treatment with procainamide in vitro and by a 
weekly treatment for 7 weeks in vivo (Un et aI., 2001a). It is therefore possible that a 96h 
exposure of LNCaP cells to procainamide is not sufficient to cause demethylation nor, in 
176 
general, some other general effects that might improve brostallicin cytotoxicity. On the 
other hand, another study did not confirm the demethylating activity of procainamide on 
other genes, such as p16 and MAGEIA, and on LINE elements (Chuang et aI., 2005). 
Zebularine was already known as a cytidine deaminase inhibitor, but its demethylating 
properties have been investigated only recently (Cheng et aI., 2003). Studies showing its 
application for reverting DNA methylation, especially on solid tumours, have been very 
few until now and further data are necessary to understand its effects on different genes in 
different cancer cell types. The demethylating properties of zebularine were firstly 
demonstrated on the p 16 gene in the T24 bladder cancer cell line (both in vitro and in 
vivo), but not on the same gene in the prostatic cancer cell line PC3 and in the CALU-l 
lung carcinoma cells. However, zebularine was able to exert its demethylating activity at a 
single-copy gene level (including hMLHl and RASSFIA genes) and at repeated element 
level in A2780/ CP70 cells (a cisplatin-resistant ovarian cancer cell line) (Balch et aI., 
2005; Cheng et al., 2004b; Stresemann et aI., 2006). 
In contrast, data on methylation inhibition by 5-aza-dC are stronger and more 
homogeneous and this cytidine analog is usually used as reference molecule in studies 
characterizing new demethylating agents. 
It is important to underline that my project has not been a comparative study of the 
demethylating properties of different molecules, but rather the investigation of a new kind 
of therapeutic strategy against prostate cancer, for which few cytotoxic treatments are 
available. In this context, my study was mainly focused on the in vivo effect of the 
combination of zebularine with brostallicin, in order to establish the possibility of 
obtaining significant antitumour activity with null or acceptable toxicity. When zebularine 
and brostallicin were combined, toxicity was not negligible, even though the observed 
toxicity was rapidly reversed after stopping treatment. The schedule adopted was of 
prolonged treatments with zebularine in order to generate enhanced brostallicin toxicity in 
cells re-expressing GSTPl by constantly maintaining the demethylation induced in 
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transplanted LNCaP cells. Further studies are necessary to verify whether alternative 
treatment schedules or doses would have less toxicity while retaining the same efficacy. 
The effects of demethylating agents are not gene-specific, so the causes of the increased 
antitumor activity of the zebularine-brostallicin combination needed to be investigated, 
starting with the analysis of the expression of the GSTpi protein, which was considered to 
determine the intracellular activation of brostallicin. Although 5-aza-dC and non 
nucleoside analog demethylating molecules were tested in the past with the aim of 
reverting GSTPl methylation (Lin et aI., 2001a), no data were available until now about 
the effect of zebularine on this gene. The fact that no GSTpi protein was detected in the 
analyzed samples indicates that zebularine did not exert any demethylating activity on the 
GSTPl promoter (in LNCaP cells), thus leaving it in a closed and not-transcriptionally 
active form, even after prolonged treatments. This "negative" result was confirmed by both 
the qualitative and quantitative analyses performed. 
Actually, if I consider the peculiar mechanism of action of brostallicin, which is inactive as 
cytotoxic drug if not bound to GSH, it is not straightforward to sustain a general and not 
well identified role of zebularine in LNCaP sensitization to brostallicin. 
Brostallicin is cytotoxic in MCF-7 cells overexpressing GSTmu enzyme (data from 
Nerviano Medical Sciences, Milan, Italy. Personal communication) and GSTmu is 
promoter methylated in LNCaP cells (Lodygin et aI., 2005). These observations indicate 
the possible involvement of GSTmu rather than GSTpi in the antitumour activity of 
brostallicin in LNCaP tumours, after prolonged treatments with zebularine. 
Furthermore, it is also important to consider that a demethylating agent does not 
completely revert the methylation status of a promoter and, usually, the amount of the 
protein formed is not comparable to that synthesized when a promoter is completely 
unmethylated. The strong affinity of GSTmu enzyme for brostallicin versus GSTpi could 
ensure the catalysis of the reaction between GSH and brostallicin even when few GSTmu 
molecules are synthesized in the cell; in these partiCUlar conditions, the GSTmu catalysis 
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will be undoubtedly more favoured than the same reaction catalyzed by GSTpi or 
GSTalpha (which is the least efficient among the GST enzymes in the brostallicin 
activation). 
That GSTmu has its promoter methylation partially reverted after in vivo treatment with 
zebularine has been an unexpected finding of this project. For this to be relevant, future 
experiments will need to demonstrate that this demethylation results in GSTMl 
transcription and protein synthesis. At the moment, I have demonstrated that zebularine 
exerts its demethylating function on GSTMl rather than on GSTPl in an in vivo system, 
where factors such as the pharmacokinetics of the drug and the metabolism can affect the 
proper release of the demethylating drug to tumour cells. Differential demethylating 
activity may depend on the lower density of methylated cytosines in the GSTM 1 than the 
GSTPl promoter, thus making it relatively "easier" to revert methylation in GSTMl. 
In prostate cancer, only recently, has the analysis of GST expression been widened to other 
classes of cytosolic GST, such as GSTu and GST~ (Bostwick et aI., 2007). In human 
prostate cancer, GSTMl methylation, in a significant percentage of the patients analyzed in 
a clinical study (Lodygin et aI., 2005) and the low levels of expression, makes the results, I 
obtained in LNCaP cells, more interesting for future combination studies ofbrostallicin. 
This means that tumour transfonnation of the prostatic tissue is affected by the absence of 
those protecting systems preventing the DNA to be damaged by exogenous factors and 
strengthens the role of methylation as a mechanism of gene silencing in the first steps of 
tumours transfonnation. The precocity of this event may represent an advantage from the 
therapeutic point of view, because it could allow hitting the transfonned cells when they 
are still confined to the prostate (Meiers et aI., 2007). 
From a clinical perspective, zebularine offers the great advantage of being orally 
administrable (Cheng et aI., 2003), and this is a very important characteristic when 
prolonged treatments are needed. 
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The combinations of demethylating and cytotoxic drugs have recently become increasingly 
considered in cancer therapy and the data shown in the last chapter of the results clearly 
demonstrated the increasing potential for this approach not only in preclinical 
experimentation, but also in the clinical setting, both on haematological malignancies and 
on solid tumours (Appleton et al., 2007; Issa, 2007; Plimack et aI., 2007). 
To reiterate, this approach offers the potential advantage of reverting silencing of 
methylated promoters, which itself may be therapeutic, and killing cells by specifically 
expressing proteins that are required for the cytotoxic effects of certain drugs. In this way, 
the effects of methylation modulators and HDACi can be exploited and a high level of 
specificity can be achieved. Of course, it will be very important to determine when the 
lowest levels of methylation are reached, to properly design both preclinical and clinical 
schedules for combination treatments (Lyko and Brown, 2005) and hence maximize the 
effects of the administration of a cytotoxic drug. In this regard, my study represents an 
initial investigation aimed at verifying the feasibility of the combination of zebularine with 
brostallicin, based on which the schedule of treatment can now be optimized by assensing 
whether the same demethylating effects can be obtained by lowering zebularine 
concentration or by using fewer treatments, mainly to reduce the toxicity I have obtained in 
the schedule of treatment adopted. It is also important to underline that various factors, 
including DNA hypomethylation and cytotoxicity, may contribute to the complex effects 
observed after epigenetic drug treatment, and these cannot be neglected in the general 
evaluation of the effects of a drug combination. 
In conclusion my PhD project has demonstrated the feasibility of zebularine combination 
with a cytotoxic drug. That this combination approach enhances therapy in the model 
selected indicates that it might also be applied to other kind of tumours, such as the breast 
cancer cell line MCF~7, which shows the same GSTPI methylation silencing (Jhaveri and 
Morrow, 1998). 
180 
As knowledge increases on the epigenetic events in tumourigenesis~ therapies aimed 
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7. APPENDIX 
7.1 LIST OF ABBREVIATIONS 
aa aminoacid 
AHO Albright Hereditary Osteodystrophy 
ANOVA Analysis of Variance 
APC Adenomatosis Polyposis Coli 
APS Ammonium Persulphate 
AR Androgen Receptor 
ART Assisted Reproductive Technologies 
AS Angelmann Syndrome 
ASK Apoptosis Signal Regulating Kinase 1 
ASO Antisense 0 ligonucleotides 
ATP adenosine 5' triphospate 
5-azaCR 5-azacytidine 
5-aza-dC 5-aza-2' -deoxycytidine 
bp base pairs 
BPH Benign Prostatic Hyperplasia 
BSA bovine serum albumin 
BWS Beckwth-Wiedmann Syndrome 
CAGE Cancer Associated Gene 
cDNA complementary deoxyribonucleic acid 
cDDP cis-dichloro-diamine-platinum 
CDNB l-chloro-2,4-dinitrobenzene 
CDNK2A Cyclin-dependent kinase inhibitor 2A 
CIMP CpG island Methylator Phenotype 
DMBA Dimethylbenzanthracene 















































Extracellular signal RegUlating Kinase 
Endothelin - A 
fetal calf serum 
5-lipoxygenase activating protein 
Fragile X Syndrome 




Histone acetyl transferase 
Histone deacetylase 
High Grade Prostatic Intraepithelial Neoplasia 
Hypermethylated in Cancer 
Histone3 Lysine9 
Hormone Refractory Prostate Cancer 
Heat Shock Protein 
concentration inhibiting the growth by 50% 
Imprinting control region 




In Vitro Methylated 
c-Jun-N-terminal Kinase 









































Long Interspersed Nuclear Element 
Loss of Imprinting 
Long Range Epigenetic Silencing 
Leukotriene C4 Syntase 
Maleylacetoacetate Isomerase 
Melanoma Antigen Family lA 
Membrane Associated Proteins in Eicosanoid and 
Glutathione Metabolism 
Mitogen Activated Stress Kinase 
Methyl Binding Protein 
Multi Drug Resistance 
Minor Groove Binder 
06-methylguanine DNA methyltransferase 
Methylation Specific PCR 
messenger ribonucleic acid 
Non Small Cell Lung Cancer 
over night 
polyacrylamide gel electrophoresis 
phosphate buffered saline 
Prostate Cancer 
procaine 
polymerase chain reaction 
Platelet-derived Growth Factor receptor 
Prostaglandin E2 synthase 1 
Pseudohypoparathyroidism 
Proliferative Inflammatory Atrophy 
Urokinase Plasminogen Activator 
phenylmethylsulphonyl fluoride 
Prostate Specific Antigen 
Pyrosequencing 
Phosphate and Tensine homologue 
Polyvinylidene Fluoride 
Prader Willy Syndrome 
Retinoic Acid Receptor 
Retinoblastoma 
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RNA ribonucleic acid 
ROS Reactive oxygen species 
sc sub-cutaneously 
SD standard deviation 
SDS sodium dodecylsulphate 
SLE Systemic Lupus Erythematosus 
TAM tallimustine 
TBS tris buffered saline 
TEMED N' ,N,N' ,N' -tetramethylethylenediamine 
TI tumor growth inhibition 
TSA Trichostatin A 
TSS Transcription Start Site 
UV ultra violet 
UTR untranslated region 
V Volts 
VEGF Vascular Endothelial Growth Factor 
w/v weight/volume 
wt wild type 
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